{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "1e785137-20a1-449c-9b6f-8858a6f60018",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from dotenv import load_dotenv\n",
    "\n",
    "# Load environment variables from the .env file\n",
    "load_dotenv()\n",
    "\n",
    "# Ensure the environment variables are set\n",
    "langchain_api_key = os.getenv('LANGCHAIN_API_KEY')\n",
    "huggingface_api_key = os.getenv('HUGGINGFACE_API_KEY')\n",
    "\n",
    "if not langchain_api_key:\n",
    "    raise ValueError(\"LANGCHAIN_API_KEY is not set in the environment variables.\")\n",
    "if not huggingface_api_key:\n",
    "    raise ValueError(\"HUGGINGFACE_API_KEY is not set in the environment variables.\")\n",
    "\n",
    "# Set environment variables for the application\n",
    "os.environ['LANGCHAIN_TRACING_V2'] = 'true'\n",
    "os.environ['LANGCHAIN_API_KEY'] = langchain_api_key\n",
    "os.environ['HUGGINGFACE_API_KEY'] = huggingface_api_key"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "id": "dd3990bf-fcfc-4939-a639-2960a43ca270",
   "metadata": {},
   "outputs": [],
   "source": [
    "import bs4\n",
    "from langchain import hub\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain_community.document_loaders import PyPDFLoader\n",
    "from langchain_community.vectorstores import Chroma\n",
    "from langchain_core.output_parsers import StrOutputParser\n",
    "from langchain_core.runnables import RunnablePassthrough"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "id": "9e004f13-f241-4732-8a1a-5b06fc19dd87",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'DIABETES CARE \\nBADAS Guideline 2019 \\n          \\n  \\n   \\n  \\n   P|) \\nDAS GUELINE ON Man \\nDELIT IGEMEN \\n  \\nA Joint Initiative of \\nDiabetic Association of Bangladesh \\nNCDC Program, Directorate General of Health Services'"
      ]
     },
     "execution_count": 54,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Load Documents (use PyPDFLoader for PDF)\n",
    "file_path = r\"C:\\Users\\User\\Desktop\\NSU\\CSE299 Materials\\LLM\\Dataset\\Diabetes_Care_BADAS_guideline2019-3.pdf\"\n",
    "loader = PyPDFLoader(file_path)\n",
    "docs = loader.load()\n",
    "\n",
    "docs[0].page_content[:1000]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "id": "706ee92c-9055-4570-8e6f-f4199cd7e613",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Main Chunking Functions\n",
    "from chunking_evaluation.chunking import (\n",
    "    ClusterSemanticChunker,\n",
    "    LLMSemanticChunker,\n",
    "    FixedTokenChunker,\n",
    "    RecursiveTokenChunker,\n",
    "    KamradtModifiedChunker\n",
    ")\n",
    "# Additional Dependencies\n",
    "import tiktoken\n",
    "from chromadb.utils import embedding_functions\n",
    "import spacy\n",
    "import os"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "12fe344a-ffbb-4a96-949e-77435c5810df",
   "metadata": {},
   "source": [
    "# Helper Function for Analyzing Chunking"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "id": "688245ca-0eb8-4413-ac16-f07afc89e118",
   "metadata": {},
   "outputs": [],
   "source": [
    "def analyze_chunks(chunks, use_tokens=False):\n",
    "    # Print the chunks of interest\n",
    "    print(\"\\nNumber of Chunks:\", len(chunks))\n",
    "    print(\"\\n\", \"=\"*50, \"200th Chunk\", \"=\"*50,\"\\n\", chunks[199])\n",
    "    print(\"\\n\", \"=\"*50, \"201st Chunk\", \"=\"*50,\"\\n\", chunks[200])\n",
    "    \n",
    "    chunk1, chunk2 = chunks[199], chunks[200]\n",
    "    \n",
    "    if use_tokens:\n",
    "        encoding = tiktoken.get_encoding(\"cl100k_base\")\n",
    "        tokens1 = encoding.encode(chunk1)\n",
    "        tokens2 = encoding.encode(chunk2)\n",
    "        \n",
    "        # Find overlapping tokens\n",
    "        for i in range(len(tokens1), 0, -1):\n",
    "            if tokens1[-i:] == tokens2[:i]:\n",
    "                overlap = encoding.decode(tokens1[-i:])\n",
    "                print(\"\\n\", \"=\"*50, f\"\\nOverlapping text ({i} tokens):\", overlap)\n",
    "                return\n",
    "        print(\"\\nNo token overlap found\")\n",
    "    else:\n",
    "        # Find overlapping characters\n",
    "        for i in range(min(len(chunk1), len(chunk2)), 0, -1):\n",
    "            if chunk1[-i:] == chunk2[:i]:\n",
    "                print(\"\\n\", \"=\"*50, f\"\\nOverlapping text ({i} chars):\", chunk1[-i:])\n",
    "                return\n",
    "        print(\"\\nNo character overlap found\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c30aee96-9956-46ec-ac05-895515006ddb",
   "metadata": {},
   "source": [
    "# Character Text Splitting"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "283f7901-abfa-4db5-8678-ab89cfe26e84",
   "metadata": {},
   "outputs": [],
   "source": [
    "all_text = \" \".join([doc.page_content for doc in docs])\n",
    "\n",
    "def chunk_text(docs, chunk_size, overlap):\n",
    "    chunks = []\n",
    "    stride = chunk_size - overlap\n",
    "    current_idx = 0\n",
    "    \n",
    "    while current_idx < len(all_text):\n",
    "        # Take chunk_size characters starting from current_idx\n",
    "        chunk = docs[current_idx:current_idx + chunk_size]\n",
    "        if not chunk:  # Break if we're out of text\n",
    "            break\n",
    "        chunks.append(chunk)\n",
    "        current_idx += stride  # Move forward by stride\n",
    "    \n",
    "    return chunks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "id": "e14054b4-8a46-43ba-b2f0-a5153326970d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Number of Chunks: 296\n",
      "\n",
      " ================================================== 200th Chunk ================================================== \n",
      " t should be done annually with 75g 2h OGTT or \n",
      "A1C. If prediabetes, reassessment should be done 6 monthly and should be put \n",
      "on MNT or metformin should be followed by standard protocol. \n",
      "Low dose estrogen-progesterone can be offered for contraception. \n",
      "Progesterone only preparation increases risk of vascular complications. \n",
      "Screening for all components of metabolic syndrome should be offered. \n",
      "Throughout the period of breast feeding all types of insulins and metformin \n",
      "can be safely used in lactating women. Women with preprgnancy diabetes \n",
      "who are breastfeeding should continue to avoid any drugs for the treatment of \n",
      "diabetes complications that were discontinued for safety reasons in the \n",
      "pre-conception period. \n",
      "6.2 Diabetes in children \n",
      "Diabetes mellitus in childhood and adolescence is mo\n",
      "\n",
      " ================================================== 201st Chunk ================================================== \n",
      " oughout the period of breast feeding all types of insulins and metformin \n",
      "can be safely used in lactating women. Women with preprgnancy diabetes \n",
      "who are breastfeeding should continue to avoid any drugs for the treatment of \n",
      "diabetes complications that were discontinued for safety reasons in the \n",
      "pre-conception period. \n",
      "6.2 Diabetes in children \n",
      "Diabetes mellitus in childhood and adolescence is most often type 1 diabetes. \n",
      "But they have the chance of developing other specific types of diabetes. \n",
      "Now-a-days type 2 diabetes is developing in the young at a very high rate. \n",
      "Diagnostic and management issues in this group of population are a bit \n",
      "different from that of adult. \n",
      "Type 2 diabetes mellitus in children is relatively less common than in adult. But \n",
      "nowadays it is being reported more fr\n",
      "\n",
      " ================================================== \n",
      "Overlapping text (400 chars): oughout the period of breast feeding all types of insulins and metformin \n",
      "can be safely used in lactating women. Women with preprgnancy diabetes \n",
      "who are breastfeeding should continue to avoid any drugs for the treatment of \n",
      "diabetes complications that were discontinued for safety reasons in the \n",
      "pre-conception period. \n",
      "6.2 Diabetes in children \n",
      "Diabetes mellitus in childhood and adolescence is mo\n"
     ]
    }
   ],
   "source": [
    "character_overlap_chunks = chunk_text(all_text, chunk_size=800, overlap=400)\n",
    "\n",
    "analyze_chunks(character_overlap_chunks)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1b4efa63-2278-4208-bb87-6fb8c87452d7",
   "metadata": {},
   "source": [
    "# Token Text Splitting"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "d3ac6187-9142-4369-840c-8debb4e81a86",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Tokens: [22427, 16629]\n"
     ]
    }
   ],
   "source": [
    "import tiktoken\n",
    "\n",
    "# Loading cl100k_base tokenizer \n",
    "encoder = tiktoken.get_encoding(\"cl100k_base\")\n",
    "\n",
    "# Text Example\n",
    "text = \"Diabetes\"\n",
    "tokens = encoder.encode(text)\n",
    "\n",
    "print(\"Tokens:\", tokens)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "151711c8-898a-474d-8e0e-6329ef246d75",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Token 1: Di\n",
      "Token 2: abetes\n",
      "Full Decoding:  Diabetes\n"
     ]
    }
   ],
   "source": [
    "for i in range(len(tokens)):\n",
    "    print(f\"Token {i+1}:\", encoder.decode([tokens[i]]))\n",
    "\n",
    "print(\"Full Decoding: \", encoder.decode(tokens))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1b6a06ec-e205-4522-9c97-8d30cf5dca9c",
   "metadata": {},
   "source": [
    "# Helper Function for Counting Tokens"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "id": "781aea81-7ccc-4382-82f2-aa736c228f34",
   "metadata": {},
   "outputs": [],
   "source": [
    "def count_tokens(text, model=\"cl100k_base\"):\n",
    "    \"\"\"Count tokens in a text string using tiktoken\"\"\"\n",
    "    encoder = tiktoken.get_encoding(model)\n",
    "    return print(f\"Number of tokens: {len(encoder.encode(text))}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "aa6958f3-2b2f-49ed-81a6-d8ad80ed4184",
   "metadata": {},
   "source": [
    "# Character Text Splitting"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "id": "721c6f8c-e7c2-40d9-9326-30322f29cd5b",
   "metadata": {},
   "outputs": [],
   "source": [
    "all_text = \" \".join([doc.page_content for doc in docs])\n",
    "\n",
    "def chunk_text(docs, chunk_size, overlap):\n",
    "    chunks = []\n",
    "    stride = chunk_size - overlap\n",
    "    current_idx = 0\n",
    "    \n",
    "    while current_idx < len(all_text):\n",
    "        # Take chunk_size characters starting from current_idx\n",
    "        chunk = docs[current_idx:current_idx + chunk_size]\n",
    "        if not chunk:  # Break if we're out of text\n",
    "            break\n",
    "        chunks.append(chunk)\n",
    "        current_idx += stride  # Move forward by stride\n",
    "    \n",
    "    return chunks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "id": "a8c5495f-1945-4ac7-9ec1-467f76bd4543",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Number of Chunks: 296\n",
      "\n",
      " ================================================== 200th Chunk ================================================== \n",
      " t should be done annually with 75g 2h OGTT or \n",
      "A1C. If prediabetes, reassessment should be done 6 monthly and should be put \n",
      "on MNT or metformin should be followed by standard protocol. \n",
      "Low dose estrogen-progesterone can be offered for contraception. \n",
      "Progesterone only preparation increases risk of vascular complications. \n",
      "Screening for all components of metabolic syndrome should be offered. \n",
      "Throughout the period of breast feeding all types of insulins and metformin \n",
      "can be safely used in lactating women. Women with preprgnancy diabetes \n",
      "who are breastfeeding should continue to avoid any drugs for the treatment of \n",
      "diabetes complications that were discontinued for safety reasons in the \n",
      "pre-conception period. \n",
      "6.2 Diabetes in children \n",
      "Diabetes mellitus in childhood and adolescence is mo\n",
      "\n",
      " ================================================== 201st Chunk ================================================== \n",
      " oughout the period of breast feeding all types of insulins and metformin \n",
      "can be safely used in lactating women. Women with preprgnancy diabetes \n",
      "who are breastfeeding should continue to avoid any drugs for the treatment of \n",
      "diabetes complications that were discontinued for safety reasons in the \n",
      "pre-conception period. \n",
      "6.2 Diabetes in children \n",
      "Diabetes mellitus in childhood and adolescence is most often type 1 diabetes. \n",
      "But they have the chance of developing other specific types of diabetes. \n",
      "Now-a-days type 2 diabetes is developing in the young at a very high rate. \n",
      "Diagnostic and management issues in this group of population are a bit \n",
      "different from that of adult. \n",
      "Type 2 diabetes mellitus in children is relatively less common than in adult. But \n",
      "nowadays it is being reported more fr\n",
      "\n",
      " ================================================== \n",
      "Overlapping text (400 chars): oughout the period of breast feeding all types of insulins and metformin \n",
      "can be safely used in lactating women. Women with preprgnancy diabetes \n",
      "who are breastfeeding should continue to avoid any drugs for the treatment of \n",
      "diabetes complications that were discontinued for safety reasons in the \n",
      "pre-conception period. \n",
      "6.2 Diabetes in children \n",
      "Diabetes mellitus in childhood and adolescence is mo\n"
     ]
    }
   ],
   "source": [
    "character_overlap_chunks = chunk_text(all_text, chunk_size=800, overlap=400)\n",
    "\n",
    "analyze_chunks(character_overlap_chunks)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "0d36fe6d-c19a-49a2-8d15-7b0e97c3bd47",
   "metadata": {},
   "source": [
    "# Token Text Splitting"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "id": "58b68076-37a3-419e-98f7-94e9a8089d1b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Tokens: [8747, 16629]\n"
     ]
    }
   ],
   "source": [
    "import tiktoken\n",
    "\n",
    "# Loading cl100k_base tokenizer \n",
    "encoder = tiktoken.get_encoding(\"cl100k_base\")\n",
    "\n",
    "# Text Example\n",
    "text = \"diabetes\"\n",
    "tokens = encoder.encode(text)\n",
    "\n",
    "print(\"Tokens:\", tokens)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "id": "aee400e3-1386-4605-b2e5-d2e0a09a509c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Token 1: di\n",
      "Token 2: abetes\n",
      "Full Decoding:  diabetes\n"
     ]
    }
   ],
   "source": [
    "for i in range(len(tokens)):\n",
    "    print(f\"Token {i+1}:\", encoder.decode([tokens[i]]))\n",
    "\n",
    "print(\"Full Decoding: \", encoder.decode(tokens))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a8b0fc78-d8b7-47f6-9976-25613e2adc35",
   "metadata": {},
   "source": [
    "# Helper Function for Counting Tokens"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "id": "4f836e27-9f9f-4533-97b6-d7ad1b91308c",
   "metadata": {},
   "outputs": [],
   "source": [
    "def count_tokens(docs, model=\"cl100k_base\"):\n",
    "    \"\"\"Count tokens in a text string using tiktoken\"\"\"\n",
    "    encoder = tiktoken.get_encoding(model)\n",
    "    return print(f\"Number of tokens: {len(encoder.encode(all_text))}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "id": "e2961ee1-49ec-4ae9-b2c1-356a78f62207",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Number of Chunks: 203\n",
      "\n",
      " ================================================== 200th Chunk ================================================== \n",
      "  25.3 Kg/m2.He \n",
      "has presented with general weakness for last 2 months. There is nothing \n",
      "remarkable on physical examination. His OGTT was done 3 days back; report shows: \n",
      "FBG- 16.2 mmol/L; 2 hr post-glucose value- 24.1 mmol/L; HbA1c- 14.5%. There is \n",
      "nothing remarkable on other laboratory tests. What will be the management \n",
      "stratigy plan for him? \n",
      "  \n",
      "76 ‘158 Diabetes Care: BADAS Guideline 2019 Abbreviation \n",
      "ACR \n",
      "AGI \n",
      "ALA \n",
      "ALT \n",
      "ASCVD \n",
      "BG \n",
      "BMI \n",
      "BP \n",
      "BUN \n",
      "CAD \n",
      "CGM \n",
      "\n",
      "\n",
      " ================================================== 201st Chunk ================================================== \n",
      " CHF \n",
      "CKD \n",
      "CVD \n",
      "eGFR \n",
      "EPA \n",
      "DHA \n",
      "DM \n",
      "ESRD \n",
      "GAD \n",
      "hCG \n",
      "HbAic \n",
      "HDL \n",
      "HNF \n",
      "IHD \n",
      "ISPAD \n",
      "LAD \n",
      "LDL \n",
      "MDI \n",
      "MNT \n",
      "MODY \n",
      "NAFLD \n",
      "NPH \n",
      "PCI \n",
      "PCOS \n",
      "RBC \n",
      "SMBG \n",
      "TG \n",
      "UTI \n",
      "Albumin-to-creatinine ratio \n",
      "Alpha-glucosidase inhibitors \n",
      "a-Linolenic acid \n",
      "Alanine aminotransferase \n",
      "Atherosclerotic cardiovascular disease \n",
      "Blood glucose \n",
      "Body mass index \n",
      "Blood pressure \n",
      "Blood urea nitrogen \n",
      "Coronary artery disease \n",
      "Continuous glucose\n",
      "\n",
      "No token overlap found\n"
     ]
    }
   ],
   "source": [
    "all_text = \" \".join([doc.page_content for doc in docs])\n",
    "    \n",
    "fixed_token_chunker = FixedTokenChunker(\n",
    "    chunk_size=150, \n",
    "    chunk_overlap=0,\n",
    "    encoding_name=\"cl100k_base\"\n",
    ")\n",
    "\n",
    "token_chunks = fixed_token_chunker.split_text(all_text)\n",
    "\n",
    "analyze_chunks(token_chunks, use_tokens=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "id": "28d9e6e3-e8f1-44ab-8869-abf444c52204",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of tokens: 30370\n"
     ]
    }
   ],
   "source": [
    "count_tokens(token_chunks[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "id": "55820549-682e-4bac-9296-394028b9b4b4",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Number of Chunks: 304\n",
      "\n",
      " ================================================== 200th Chunk ================================================== \n",
      " Plasma Glucose values Treatment Change of treatment Treatment \n",
      "at onset if target not reviewed \n",
      "achieved in & continued \n",
      "FPG 292 to 109 NPT 2 week/1 week NPT+PT \n",
      "mg/dl mg/dl Uncomplicated/ \n",
      "(25.1 (6.0 complicated \n",
      "mmol/L) mmol/L) \n",
      "and/or \n",
      "2hPPG 2120 to <140 NPT 2 week/1 week NPT+PT \n",
      "mg/dl mg/dl Uncomplicated/ \n",
      "(26.7 (7.8 complicated \n",
      "mmol/L) mmol/L) \n",
      "FPG >110 to <126 NPT 1 week NPT+PT \n",
      "mg/dl\n",
      "\n",
      " ================================================== 201st Chunk ================================================== \n",
      " mg/dl mg/dl Uncomplicated/ \n",
      "(26.7 (7.8 complicated \n",
      "mmol/L) mmol/L) \n",
      "FPG >110 to <126 NPT 1 week NPT+PT \n",
      "mg/dl mg/dl \n",
      "(26.1 (7.0) \n",
      "mmol/L) mmol/L) \n",
      "and/or \n",
      "2hPPG 2140 to <200 NPT 1 week NPT+PT \n",
      "mg/dl mg/dl \n",
      "(27.8 (11.1 \n",
      "mmol/L) mmol/L) \n",
      "FPG 2=126 mg/dl NPT+PT x NPT+PT \n",
      "(27.0 mmol/L) \n",
      "and\n",
      "\n",
      " ================================================== \n",
      "Overlapping text (50 tokens): mg/dl mg/dl Uncomplicated/ \n",
      "(26.7 (7.8 complicated \n",
      "mmol/L) mmol/L) \n",
      "FPG >110 to <126 NPT 1 week NPT+PT \n",
      "mg/dl\n"
     ]
    }
   ],
   "source": [
    "fixed_token_chunker = FixedTokenChunker(\n",
    "    chunk_size=150, \n",
    "    chunk_overlap=50,\n",
    "    encoding_name=\"cl100k_base\"\n",
    ")\n",
    "\n",
    "token_overlap_chunks = fixed_token_chunker.split_text(all_text)\n",
    "\n",
    "analyze_chunks(token_overlap_chunks, use_tokens=True)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c5603d17-842b-444b-9e72-393f350224e1",
   "metadata": {},
   "source": [
    "# Recursive Character Text Splitter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "68c4470e-c6e6-40cb-921f-7d369d3ddb04",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Number of Chunks: 322\n",
      "\n",
      " ================================================== 200th Chunk ================================================== \n",
      " 25-35 (11.5-16.0) \n",
      "15-25 (7.0-11.5) \n",
      "11-20 (5-9.0) \n",
      "No recommendation \n",
      "37-54 (16.8-24.5) \n",
      "31-50 (14.1-22.7) \n",
      "25-42 (11.4-19.1) \n",
      "  \n",
      "52 IE Diabetes Care: BADAS Guideline 2019 Meal pattern \n",
      "Three meals and 3 snacks should be taken including one snack at bed time. This \n",
      "approach can be adopted where help of nutritionist service is not available. \n",
      "Recommended overall total caloric distribution\n",
      "\n",
      " ================================================== 201st Chunk ================================================== \n",
      " Carbohydrate: 33-40% with low glycemic index \n",
      "Protein: ~ 20% \n",
      "Fat: < 40%, saturated fat <7% and transfat<1% \n",
      "Plate model can be practiced \n",
      "Simple sugars should be avoided. Food containing complex carbohydrate \n",
      "intake is recommended \n",
      "High dietary fibre and whole grain containing foods should be encouraged. \n",
      "Non-calorie sweeteners (aspartame) may be used safely\n",
      "\n",
      "No character overlap found\n"
     ]
    }
   ],
   "source": [
    "recursive_character_chunker = RecursiveTokenChunker(\n",
    "    chunk_size=400,  # Character Length\n",
    "    chunk_overlap=0,  # Overlap\n",
    "    length_function=len,  # Character length with len()\n",
    "    separators=[\"\\n\\n\", \"\\n\", \".\", \"?\", \"!\", \" \", \"\"] # According to Research\n",
    ")\n",
    "\n",
    "recursive_character_chunks = recursive_character_chunker.split_text(all_text)\n",
    "analyze_chunks(recursive_character_chunks, use_tokens=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "02077953-5b31-48dc-b5b6-9e387db44406",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "391"
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(recursive_character_chunks[199]) # Chunk 200"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "432bf765-6c38-459e-aa0c-251309469b1f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Number of Chunks: 595\n",
      "\n",
      " ================================================== 200th Chunk ================================================== \n",
      " Empagliflozin 10 mg x 1,morning 25 mg (in 1 dose) eGFR <45- avoid \n",
      "eGFR <30- contraind \n",
      "Ertugliflozin 5 mg x 1,morning 15 mg (in 1 dose) eGFR <60-avoid \n",
      "eGFR <30-contraind         \n",
      "NB. ac- before meal; pc- after meal. \n",
      "eGFR ml/min/1.73 m2. \n",
      "  \n",
      "28 lll Diabetes Care: BADAS Guideline 2019 Classification of insulin \n",
      "Insulin type Onset TLC) PVE Li «:) \n",
      "  \n",
      "Bolus (prandial) insulins\n",
      "\n",
      " ================================================== 201st Chunk ================================================== \n",
      " NB. ac- before meal; pc- after meal. \n",
      "eGFR ml/min/1.73 m2. \n",
      "  \n",
      "28 lll Diabetes Care: BADAS Guideline 2019 Classification of insulin \n",
      "Insulin type Onset TLC) PVE Li «:) \n",
      "  \n",
      "Bolus (prandial) insulins \n",
      "Rapid-acting insulin analogues \n",
      "* Insulin Aspart \n",
      "* Insulin Glulisine \n",
      "* Insulin Lispro \n",
      "Short-acting (Regular) insulins \n",
      "Basal insulins \n",
      "Intermediate-acting (NPH) \n",
      "Long-acting insulin analogues\n",
      "\n",
      " ================================================== \n",
      "Overlapping text (197 chars): NB. ac- before meal; pc- after meal. \n",
      "eGFR ml/min/1.73 m2. \n",
      "  \n",
      "28 lll Diabetes Care: BADAS Guideline 2019 Classification of insulin \n",
      "Insulin type Onset TLC) PVE Li «:) \n",
      "  \n",
      "Bolus (prandial) insulins\n"
     ]
    }
   ],
   "source": [
    "recursive_character_chunker = RecursiveTokenChunker(\n",
    "    chunk_size=400,  # Character Length\n",
    "    chunk_overlap=200,  # Overlap\n",
    "    length_function=len,  # Character length with len()\n",
    "    separators=[\"\\n\\n\", \"\\n\", \".\", \"?\", \"!\", \" \", \"\"] # According to Research\n",
    ")\n",
    "\n",
    "recursive_character_overlap_chunks = recursive_character_chunker.split_text(all_text)\n",
    "analyze_chunks(recursive_character_overlap_chunks, use_tokens=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "640cea09-3eef-4255-9e10-afba9778b4b1",
   "metadata": {},
   "source": [
    "# Recursive Token Text Splitter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "id": "408c179d-a87d-4174-aa1a-e5a5a53425a7",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Count the number of tokens in each page_content\n",
    "def token_count(string: str) -> int:\n",
    "    \"\"\"Returns the number of tokens in a text string.\"\"\"\n",
    "    encoding = tiktoken.get_encoding(\"cl100k_base\")\n",
    "    num_tokens = len(encoding.encode(string, disallowed_special=()))\n",
    "    return num_tokens"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "id": "f9437f3b-27a6-42c6-9250-ffcc24e0f5a9",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Number of Chunks: 235\n",
      "\n",
      " ================================================== 200th Chunk ================================================== \n",
      " Pre-Ramadan dinner dose may be reduced by 20-50% \n",
      "for Suhoor (depending on prolonged fasting, carb \n",
      "content) and glycemic control \n",
      "  \n",
      "68 II Diabetes Care: BADAS Guideline 2019 SMBG \n",
      "Good to do: Pre Suhoor — before taking meal, early morning- 2 hrs after Suhoor, \n",
      "around 10 am, mid-day - 11 am to 2 pm, pre Iftar meal, 2 hrs after Iftar and at any \n",
      "time when there are symptoms of hypoglycemia / hyperglycemia or feeling unwell.\n",
      "\n",
      " ================================================== 201st Chunk ================================================== \n",
      " Must to do : Before Iftar, 2 hour after Iftar, Mid-day \n",
      "Frequency of SMBG should be daily for first 3 days, every 3rd day from next week \n",
      "onwards and every alternateday in the last week. \n",
      "6.7 Hajj and travel \n",
      "It could be estimated that Muslims with diabetes performing Hajj may exceed \n",
      "220000 per year. During Hajj duty, there may be major medical challenges for \n",
      "Muslims with diabetes and their healthcare providers. Risk stratification, medication \n",
      "adjustments, proper clinical assessment, and education before doing the Hajj are \n",
      "crucial. \n",
      "Changes during Hajj days\n",
      "\n",
      "No token overlap found\n"
     ]
    }
   ],
   "source": [
    "recursive_token_chunker = RecursiveTokenChunker(\n",
    "    chunk_size=150,  # Character Length\n",
    "    chunk_overlap=0,  # Overlap\n",
    "    length_function=token_count,\n",
    "    separators=[\"\\n\\n\", \"\\n\", \".\", \"?\", \"!\", \" \", \"\"] # According to Research\n",
    ")\n",
    "\n",
    "recursive_token_chunks = recursive_token_chunker.split_text(all_text)\n",
    "\n",
    "analyze_chunks(recursive_token_chunks, use_tokens=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "id": "1cce2ce2-7d49-4b46-8779-8ae0a4e1f2d7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Number of Chunks: 334\n",
      "\n",
      " ================================================== 200th Chunk ================================================== \n",
      " presence of ASCVD risk. \n",
      "<40 Yes High intensity statin; if LDL =>70 mg/dl despite \n",
      "of therapy consider combining with ezetimibe. \n",
      "240 No Moderate intensity statin or high intensity \n",
      "statin may be considered based on risk-benefit \n",
      "profile or presence of ASCVD risk. \n",
      "240 Yes High intensity statin; if LDL >70 mg/dl despite \n",
      "of therapy, consider combining with ezetimibe. \n",
      "    \n",
      "NB: Intensity of statin therapy may need to be adjusted according to individual \n",
      "patient response to medication (eg side effects, tolerability, LDL cholesterol \n",
      "levels, etc).\n",
      "\n",
      " ================================================== 201st Chunk ================================================== \n",
      " NB: Intensity of statin therapy may need to be adjusted according to individual \n",
      "patient response to medication (eg side effects, tolerability, LDL cholesterol \n",
      "levels, etc). \n",
      "Statin therapy is contraindicated during pregnancy. \n",
      "5.8 Use of antiplatelet agents \n",
      "Aspirin therapy (75-150 mg/day) as a secondary prevention strategy in those \n",
      "with diabetes and a history of atherosclerotic cardiovascular disease. \n",
      "Patients with atherosclerotic cardiovascular disease and documented aspirin \n",
      "allergy, clopidogrel (75 mg/day) should be used.\n",
      "\n",
      " ================================================== \n",
      "Overlapping text (36 tokens): NB: Intensity of statin therapy may need to be adjusted according to individual \n",
      "patient response to medication (eg side effects, tolerability, LDL cholesterol \n",
      "levels, etc).\n"
     ]
    }
   ],
   "source": [
    "recursive_token_chunker = RecursiveTokenChunker(\n",
    "    chunk_size=150,  # Character Length\n",
    "    chunk_overlap=50,  # Overlap\n",
    "    length_function=token_count,\n",
    "    separators=[\"\\n\\n\", \"\\n\", \".\", \"?\", \"!\", \" \", \"\"] # According to Research\n",
    ")\n",
    "\n",
    "recursive_token_overlap_chunks = recursive_token_chunker.split_text(all_text)\n",
    "\n",
    "analyze_chunks(recursive_token_overlap_chunks, use_tokens=True)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "291ed475-888b-445d-adda-3385489512f0",
   "metadata": {},
   "source": [
    "# Semantic Chunker"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "id": "e0bb1d71-db69-4564-b40f-37a803cd6317",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Helper Function from the Repo that Returns Embeddings\n",
    "embedding_function = embedding_functions.HuggingFaceEmbeddingFunction(api_key=os.environ[\"HUGGINGFACE_API_KEY\"], model_name=\"sentence-transformers/paraphrase-MiniLM-L6-v2\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "id": "674a4675-81b6-4d95-81c6-84a91bd6ca50",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_experimental.text_splitter import SemanticChunker\n",
    "from langchain_huggingface.embeddings import HuggingFaceEmbeddings\n",
    "\n",
    "lc_semantic_chunker = SemanticChunker(HuggingFaceEmbeddings())\n",
    "\n",
    "lc_semantic_chunks = lc_semantic_chunker.create_documents([all_text])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "id": "95e62bd9-f150-4c6d-bd60-6414c6bc6e64",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "# of Chunks: 41 \n",
      "\n",
      "eGFR ml/min/1.73 m2. 28 lll Diabetes Care: BADAS Guideline 2019 Classification of insulin \n",
      "Insulin type Onset TLC) PVE Li «:) \n",
      "  \n",
      "Bolus (prandial) insulins \n",
      "Rapid-acting insulin analogues \n",
      "* Insulin Aspart \n",
      "* Insulin Glulisine \n",
      "* Insulin Lispro \n",
      "Short-acting (Regular) insulins \n",
      "Basal insulins \n",
      "Intermediate-acting (NPH) \n",
      "Long-acting insulin analogues \n",
      "* Insulin Detemir \n",
      "* Insulin Glargine \n",
      "* Insulin Degludec \n",
      "Premix insulins \n",
      "* Biphasic Human Insulin \n",
      "* Biphasic Insulin Aspart \n",
      "* Insulin Lispro + Insulin Lispro \n",
      "Protamine \n",
      "Coformulation \n",
      "* Insulin Degludec + \n",
      "Insulin Aspart   \n",
      "of action \n",
      "10-15 min \n",
      "10-15 min \n",
      "10-15 min \n",
      "30 min \n",
      "1-3 hours \n",
      "90 min \n",
      "90 min \n",
      "30 mins \n",
      "10-20 mins \n",
      "10-20 mins \n",
      "30-90 mins \n",
      "10-20 min \n",
      "NB. Inhaled rapid acting insulin is also available \n",
      "Insulin regimens \n",
      "  \n",
      "1-1.5 hour \n",
      "1-1.5 hour \n",
      "1-2 hour \n",
      "2-3 hours \n",
      "5-8 hours \n",
      "N/A \n",
      "N/A \n",
      "2-8 hours \n",
      "1-4 hours \n",
      "1-4 hours \n",
      "NA \n",
      "40-90 min   \n",
      "of action \n",
      "3-5 hours \n",
      "3-5 hours \n",
      "3.5-4.75 hours \n",
      "6.5 hours \n",
      "Upto 18 hours \n",
      "24 hours \n",
      "24 hours \n",
      "42 hours \n",
      "Upto 24 hours \n",
      "Upto 24 hours \n",
      "Upto 24 hours \n",
      "Beyond 24 hours \n",
      "  \n",
      "Clear \n",
      "Clear \n",
      "Clear \n",
      "Clear \n",
      "Cloudy \n",
      "Clear \n",
      "Clear \n",
      "Clear \n",
      "Cloudy \n",
      "Cloudy \n",
      "Cloudy \n",
      "Clear \n",
      "Regimen pre ttt) \n",
      "NPH or basal analogue Once daily \n",
      "Twice daily \n",
      "* Premixed \n",
      "* Coformulation \n",
      "* Split-mixed \n",
      "Multiple daily injections \n",
      "+ Basal Plus \n",
      "* Basal bolus \n",
      "Continuous subcutaneous \n",
      "insulin infusion   \n",
      "Less mealtime flexibility \n",
      "Offers more mealtimeflexibility \n",
      "One long acting analogue at bedtime, plus one injection of \n",
      "rapid acting analogue with the largest meal \n",
      "One long acting analogue at bedtime, plus two or three \n",
      "injections of rapid acting analogue with meal \n",
      "Insulin pump \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI! 29 Continuous subcutaneous insulin infusion (CSII) \n",
      "An insulin pump is an alternative to treatment with MDI.The pump is worn at waist \n",
      "or other convenient places, and insulin is delivered through tube into \n",
      "subcutaneous needle placed over abdomen. Basal insulin is delivered continuously, \n",
      "and the bolus dose is person-activated. Rapid acting insulin analogues are usually \n",
      "used in these devices, both as basal as well as bolus dose. Sensor-augmented pumps are provided with CGM system. Newer generation \n",
      "pumps automatically shut-off to prevent hypoglycemia when the sensor has fallen \n",
      "below a preset threshold. The newer smart pumps can automatically calculate meal \n",
      "or correction boluses based on_ insulin-to-carbohydrate ratios and_ insulin \n",
      "sensitivity factors. rear Ei Cm um (eel Crliiimelrlraiels (ie) \n",
      "  \n",
      "GLP-1 agonists Exenatide | Type 2 DM; weight-friendly; 10 ug (in 2 doses) ac within 1 hr of \n",
      "meal; increase dose after 4 weeks (max. 20 ug/day) \n",
      "  \n",
      "Liraglutide} Type 2 DM;weight-friendly; 0.6 mg daily, increase to 1.2 mg after \n",
      "1 week; max. dose 1.8 mg \n",
      "  \n",
      "Albiglutide, dulaglutide, lixisenatide, semaglutide are available. Combinations of long acting insulin analogue and GLP-1RA are also available. Amylin analogues | Pramlintide) Weight-friendly; use with insulin; immediate ac. Type 1 DM: 15 ug x 3; increase dose after 7 days (max. 60 x 3) \n",
      "Type 2 DM:60 ug x 3; increase dose after 7 days (max. 120 x 3)     \n",
      "NB. ac- before meal \n",
      "Monitoring and changing treatment regimen \n",
      "Blood glucose testing \n",
      "Self monitoring of blood glucose (SMBG) by glucometer is to be done frequently \n",
      "(covering pre-meal, post-meal and critical periods) in persons who are on multiple \n",
      "dose insulin regimen or insulin pump, specially in type 1 diabetes and pregnancy. For others it is to be done as required according to clinical situations. Continuous \n",
      "glucose monitoring (CGM) can be used in selected persons. Blood glucose \n",
      "monitoring guide to the changes of the doses of drugs. This education should be \n",
      "given to the patient for self-management. 30 I Diabetes Care: BADAS Guideline 2019 HbA1c \n",
      "Glycated hemoglobins are formed by non-enzymatic condensation of glucose \n",
      "with globin component of hemoglobin. This generally reflects glycemic status over \n",
      "the preceding 2-3 months. RBC turnover (blood loss, hemolysis, blood transfusion, \n",
      "pregnancy etc.) and hemoglobin variants must be considered while testing HbA1c. HbA1c guides change in therapeutic regimen. A1C test should be done at least two times a year in patients who are meeting \n",
      "treatment goals (and who have stable glycemic control). A1C test is to be done quarterly in patients whose therapy has changed or \n",
      "who are not meeting glycemic goals. More stringent A1C goals may be set for selected individuals if this can be \n",
      "achieved without significant hypoglycemia or other adverse effects of \n",
      "treatment (i.e. polypharmacy), e.g. those with short duration of diabetes, type \n",
      "2 diabetes treated with lifestyle or metformin only, long life expectancy, or no \n",
      "significant cardiovascular disease. Less stringent A1C goals may be appropriate for persons with history of \n",
      "severe or repeated hypoglycemia, hypoglycemia unawareness, limited life \n",
      "expectancy, advanced microvascular or macrovascular complications, \n",
      "extensive comorbid conditions, or long-standing diabetes in whom the goal is \n",
      "difficult to achieve despite diabetes self-management education, appropriate \n",
      "glucose monitoring, and effective doses of multiple glucose-lowering agents \n",
      "including insulin. References \n",
      "Diabetes Mellitus, Distance Learning Program, 5th edition, BADAS, 2018.\n",
      "\n",
      "\n",
      " ================================================== \n",
      "\n",
      "\n",
      "Standards of Medical care in Diabetes, ADA (American Diabetes Association), 2019. Comprehensive Type 2 Diabetes Management Algorithm, AACE (American \n",
      "Association of Clinical Endocrinologists) Task Force, 2019. Global Guideline for Type 2 Diabetes, Clinical Guidelines Task Force, IDF \n",
      "(International Diabetes Federation), 2012. Diabetes Care: BADAS Guideline 2019 HEI!) 31 Chapter 4 \n",
      "Acute Complications of Diabetes Mellitus \n",
      "4.1 Hypoglycemia \n",
      "It is defined biochemically with blood glucose level below 3.9 mmol/L (70 mg/dl) \n",
      "with clinical features of autonomic over activity and neuroglycopenia. Some diabetics, especially those with persistent high blood glucose, may develop \n",
      "clinical features (particularly autonomic) of hypoglycemia at a higher blood \n",
      "glucose level. It occurs more in Type 1 than Type 2 diabetes. Levels of hypoglycemia \n",
      "Level 1: blood glucose <3.9 mmol/L - 3.0 mmol/L \n",
      "Level 2: blood glucose <3.0 mmol/L \n",
      "Level 3: A severe event characterized by altered mental and/or physical status \n",
      "requiring assistance \n",
      "Causes of hypoglycemia \n",
      "* Taking excess dose of insulin \n",
      "* Excess intake of anti-diabetic medications, specially insulin secretagogues \n",
      "* Delay, omission or undue reduction of a meal \n",
      "* Unusual exercise \n",
      "* Over intake of alcohol \n",
      "* Severe renal or hepatic impairment \n",
      "Consequences of hypoglycemia \n",
      "* Recurrent hypoglycemia may cause behavioral change and cognitive \n",
      "impairment \n",
      "* In Type 2 diabetes - increased incidence of life-threatening cardiovascular \n",
      "events and mortality (cardiovascular and all cause) \n",
      "* InType 1 diabetes - increased mortality (4-10% of deaths) \n",
      "Hypoglycemia unawareness \n",
      "Occurs in individuals with long standing type 1 diabetes, autonomic neuropathy, \n",
      "medications (like non-selective beta-blockers), or very tight glycemic control. Nocturnal hypoglycemia occurs at night, usually between 11pm and 5 am. 32 (IIE Diabetes Care: BADAS Guideline 2019 Clinical features of hypoglycemia \n",
      "Clinical features of hypoglycemia according to severity \n",
      "Types of features Severity of hypoglycemia \n",
      "Mild to moderate Severe \n",
      "Level 1 Level 2,3 \n",
      "Autonomic Sweating, palpitation, tremor, \n",
      "irritability, hunger. Neuroglycopenic Headache, visual disturbance Confusion, drowsiness, \n",
      "behavioral abnormality \n",
      "convulsion, coma \n",
      "Treatment of hypoglycemia \n",
      "Level 1: Mild to moderate hypoglycemia \n",
      "* Treated by the patient him/herself or by a family member \n",
      "* — It is usually relieved by 15 gm glucose or equivalent food, e.g. a glass of soft \n",
      "drink or fruit juice or snacks or meal (if it is due). These measures are usually \n",
      "adequate to raise blood glucose to reasonably safe limit (5.5 mmol/L). * The food/drink is repeated every 15 minutes until the patient is stable. * If recurrent hypoglycemia follows, hospitalization should be considered. * Modification in ongoing treatment should be considered. Level 2,3: Severe hypoglycemia \n",
      "* 100 ml of 25% dextrose is given intravenously under medical supervision. * — If hypoglycemia is due to longer acting anti-diabetic medications then 10% \n",
      "dextrose infusion should be started to prevent recurrent hypoglycemia. * Ongoing activity of the anti-diabetic medication may lead to recurrence of \n",
      "hypoglycemia.Hence, food ingestion is to be ensured after initial recovery. * — If recovery does not occur, addressing additional causes and modification in \n",
      "treatment should be done. * In person with type 1 diabetes, glucagon 1 mg intramuscularly or subcutane- \n",
      "ously can be given. * Patient with severe hypoglycemia may need to keep under supervission in \n",
      "hospital. Diabetes Care: BADAS Guideline 2019 HE 33 Hypoglycemia unawareness \n",
      "* Frequent blood glucose should be monitored to prevent hypoglycemia. * Each patient with hypoglycemia should be evaluated and provided with \n",
      "appropriate education to prevent and manage future episodes. Nocturnal hypoglycemia \n",
      "* Reduction of evening dose of insulin \n",
      "* Changing time of evening insulin dose with dinner time \n",
      "* Taking bed time snacks may be considered \n",
      "* These adjustments are made in conjunction with blood glucose monitoring \n",
      "4.2 Diabetic ketoacidosis (DKA) \n",
      "Diabetic ketoacidosis (DKA) is a medical emergency in diabetic patients. It is \n",
      "commonly found in type1 diabetes but it also occurs in other types of diabetes \n",
      "during stressful situations. It results from lack of insulin and an increase in \n",
      "counter-regulatory hormones that lead to hyperglycemia and subsequent lipolysis. Precipitating factors \n",
      "Common precipitating factors \n",
      "* — Intercurrent Infection \n",
      "* Discontinuation of insulin therapy \n",
      "* Inadequate insulin therapy \n",
      "* Pancreatitis, myocardial infarction, cerebrovascular accident, pulmonary \n",
      "embolism \n",
      "* Stressful conditions like trauma, pregnancy \n",
      "* New-onset type 1 diabetes \n",
      "Clinical features \n",
      "* Develops rapidly (hours to days) \n",
      "* Symptoms of uncontrolled diabetes precedes \n",
      "* Dehydration is the most obvious clinical feature with dry skin and tongue, low \n",
      "BP, rapid weak pulse \n",
      "* Acidotic breathing is characteristic; there may be acetone smell in breath \n",
      "* Weakness, vomiting, impairment of level of consciousness, acute abdomen are \n",
      "also found \n",
      "  \n",
      "34 (IIB Diabetes Care: BADAS Guideline 2019 4.3 Hyperglycemic hyperosmolar state (HHS) \n",
      "HHS is a combination of severe degree of hyperglycemia, dehydration and \n",
      "hyperosmolality without significant ketonuria, usually seen as complication of \n",
      "elderly type 2 diabetes patients. Here residual insulin reserve prevents ketosis. Precipitating factors of HHS: Similar as DKA. Others are \n",
      "* Compromised fluid intake \n",
      "* Drugs, eg glucocorticoids, diuretics etc \n",
      "Clinical features \n",
      "* Develops slowly (days to weeks) \n",
      "* Symptoms of uncontrolled diabetes precede \n",
      "* Dehydration is profound \n",
      "* Impairment of consciousness is common \n",
      "  \n",
      "Diagnostic criteria for DKA and HHS \n",
      "Mild Moderate Severe \n",
      "BG >13.8 mmol/L >13.8 mmol/L >13.8 mmol/L >33.3 mmol/L \n",
      "Arterial PH 7.25-7.30 7.00-<7.24 <7.00 >7.30 \n",
      "S. bicarbonate mEq/L 15-18 10-<15 <10 >18 \n",
      "Urine ketone Positive Positive Positive Small \n",
      "Effective serum Variable Variable Variable >320 mOsm/kg \n",
      "osmolality \n",
      "Anion gap >10 >12 >12 Variable \n",
      "Mental status Alert Alert/ drowsy Stupor/coma Stupor/coma \n",
      "        \n",
      "NB: Effective serum osmolality: 2 [measured Nat (mEq/L) + Glucose (mmol/L); Anion Gap: (Na*) \n",
      "-[Cl + HCO3 (mEq/L)] \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI 35 Protocol for management of adult person with DKA or HHS. Initial Evaluation \n",
      "* Check blood glucose/capillary glucose, serum/urine ketones: to confirm \n",
      "hyperglycemia and ketonemia/ketonuria. * Obtain blood for metabolic profile. * Start IV fluids: As per protocol. IV Fluid Protocol \n",
      "WATT Ey \n",
      "Phen \n",
      "  \n",
      "Severe hypovolemia Mild dehydration Cardiogenic shock \n",
      "Administer 0.9% NaCl Corrected serum Na Hemodynamic monitor \n",
      "1.0 L/ hr Use of pressors \n",
      "Serum Na high / Serum Na normal Serum Na low \n",
      "0.45% NaCl (250-500 ml/hr)As per hydration status 0.9% NaCl (250 -500 ml/hr) \n",
      "| As per hydration status \n",
      "When serum glucose is 11.1 mmol/L (DKA) or 16.7 mmol/L (HHS), change to 5% dextrose \n",
      "with 0.45% NaCl at 150-250 ml/hr \n",
      "N.B.: Corrected Na for hyperglycemia= measured Na + [1.6 (Glucose in mg/dl— 100) / 100] \n",
      "  \n",
      "36 ll Diabetes Care: BADAS Guideline 2019 Potassium & bicarbonate \n",
      "eee ia) \n",
      "Establish adequate renal function \n",
      "(urine output around 50 ml/hr) \n",
      "  \n",
      "K+<3.3 mEq/L K+ = 3.3- 5.2mEq/L Kt>5.2mEq/L \n",
      "4 4 4 \n",
      "Hold insulin and Administer 20-30 Administer 20-30 mEqKineach — Do not give K*, check K* every \n",
      "mEq/hr K* until Kt>3.3 mEq/L litre of IV fluids. 2 hourly. Target K*= 4-5 mEq/L \n",
      "Bicarbonate \n",
      "pH 26.9 pH <6.9 \n",
      "No HCOs 100 mmol in 400 ml H20 + 20 mEq \n",
      "KCL, infuse for 2 hours \n",
      "Repeat every 2 hours until pH = \n",
      "7.Monitor K every 2 hrs \n",
      "Insulin protocol \n",
      "PE Lara atte mre ace eh egal bY) \n",
      "0.1 U/kg. B.Wt. as IV bolus 0.14 U/kg. B.Wt./hr as IV continuous insulin infusion \n",
      "g \n",
      "0.1 U/kg. B.Wt/hr IV continuous insulin \n",
      "If serum glucose does not fall by at least 10% in first hour, give 0.14 U/kg as IV bolus, then continue \n",
      "J previous treatment. y \n",
      "DKA HHS \n",
      "When serum glucose reaches 11.1 mmol/L, reduce When serum glucose reaches 16.7 mmol/L, \n",
      "infusion rate to 0.02-0.05 U/kg/hr IV. Target BG is in reduce infusion rate to 0.02-0.05 U/kg/hr IV. between 8.33-11.1 mmol/L until resolution of DKA. Target BG is in between 11.1- 16.7 mmol/L until \n",
      "patient is mentally alert. Diabetes Care: BADAS Guideline 2019 HE) 37 Other evaluations \n",
      "Serum electrolyte, BUN, venous pH, creatinine and glucose should be \n",
      "checked 2 hourly until resolution of the crisis. After resolution of DKA/HHS and person is able to eat, SC multidose insulin \n",
      "should be initiated. Subcutaneous insulin should be started at least 1-2 hour \n",
      "before stopping IV insulin. Precipitating cause should be addressed. Criteria for improvement of DKA \n",
      "Ay FF YN \n",
      "No dehydration \n",
      "No vomiting \n",
      "Able to take food \n",
      "No ketone in urine \n",
      "Anion gap normal \n",
      "Patient is well oriented, hemodynamically stable \n",
      "References \n",
      "1. American Diabetes Association’s Standards of Medical Care in Diabetes-2019. Diabetes Care 2018; 42(Suppl. 1):S1-S194. Bangladesh Endocrine Society Insulin guideline 2018. http://bes-org.net/ \n",
      "wp-content/ uploads/2019/03/Insulin%20Guideline.pdf \n",
      "Diabetes Mellitus. Diabetic Association of Bangladesh. 5th ed 2018.\n",
      "\n",
      "\n",
      " ================================================== \n",
      "\n",
      "\n",
      "Number of tokens: 30370\n",
      "Number of tokens: 30370\n"
     ]
    }
   ],
   "source": [
    "print(\"# of Chunks:\", len(lc_semantic_chunks), \"\\n\")\n",
    "print(lc_semantic_chunks[19].page_content)\n",
    "print(\"\\n\\n\", \"=\"*50, \"\\n\\n\")\n",
    "print(lc_semantic_chunks[20].page_content)\n",
    "print(\"\\n\\n\", \"=\"*50, \"\\n\\n\")\n",
    "\n",
    "count_tokens(lc_semantic_chunks[19].page_content)\n",
    "count_tokens(lc_semantic_chunks[20].page_content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "id": "2ec1c949-0fd8-40c0-8651-3c8cd2a331ff",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Number of Chunks: 451\n",
      "\n",
      " ================================================== 200th Chunk ================================================== \n",
      " Anion gap >10 >12 >12 Variable \n",
      "Mental status Alert Alert/ drowsy Stupor/coma Stupor/coma\n",
      "\n",
      " ================================================== 201st Chunk ================================================== \n",
      " NB: Effective serum osmolality: 2 [measured Nat (mEq/L) + Glucose (mmol/L); Anion Gap: (Na*) \n",
      "-[Cl + HCO3 (mEq/L)]\n",
      "\n",
      "No token overlap found\n"
     ]
    }
   ],
   "source": [
    "cluster_chunker = ClusterSemanticChunker(\n",
    "    embedding_function=embedding_function, \n",
    "    max_chunk_size=100, \n",
    "    length_function=token_count\n",
    ")\n",
    "\n",
    "cluster_chunker_chunks = cluster_chunker.split_text(all_text)\n",
    "\n",
    "analyze_chunks(cluster_chunker_chunks, use_tokens=True)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "3cbfc33e-27b3-4dc0-a82f-2926b85a2bbc",
   "metadata": {},
   "source": [
    "# LLM Semantic Chunker"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 101,
   "id": "47a65fe6-f7e0-4891-85d0-b04a86b8c2f6",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Chunk 1: DIABETES CARE \n",
      "BADAS Guideline 2019 \n",
      "          \n",
      "  \n",
      "   \n",
      "  \n",
      "   P|) \n",
      "DAS GUELINE ON Man \n",
      "DELIT IGEMEN \n",
      "  \n",
      "A Joint Initiative of \n",
      "Diabetic Association of Bangladesh \n",
      "NCDC Program, Directorate General of Health Services DIABETES CARE \n",
      "BADAS Guideline 2019 \n",
      "  \n",
      "A Joint Initiative of \n",
      "Diabetic Association of Bangladesh \n",
      "NCDC Program, Directorate General of Health Services \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI! 1 DIABETES CARE: BADAS GUIDELINE 2019 \n",
      "Convener: Prof A K Azad Khan \n",
      "Chairman: Prof Hajera Mahtab \n",
      "Members of the steering committee \n",
      "Prof Dr AHM Enayet Hossain \n",
      "Prof Akhtar Hussain \n",
      "Prof Zafar Anmed Latif \n",
      "Prof Tofail Ahmed \n",
      "Prof Laique Ahmed Khan \n",
      "Prof Nazrul Islam Siddiqui \n",
      "Prof Md Hafizur Rahman \n",
      "Prof Abdus Saleque Mollah \n",
      "Prof Md Farid Uddin \n",
      "Prof M A Jalil Ansary \n",
      "Prof Dr MA Samad \n",
      "Prof SM Ashrafuzzaman \n",
      "Prof MA Hasnat \n",
      "Dr Kazi Ali Hassan \n",
      "Dr Abdul Mannan Sarker \n",
      "Members of the Task Force \n",
      "Prof Md Faruque Pathan \n",
      "Dr Tareen Ahmed \n",
      "Dr Md Feroz Amin \n",
      "Dr Faria Afsana \n",
      "Dr Bishwajit Bhowmik \n",
      "Dr Nazmul Kabir Qureshi \n",
      "Dr Indrajit Prasad \n",
      "Dr Tanjina Hossain \n",
      "Dr Shahjada Selim \n",
      "Dr M Saifuddin \n",
      "Dr Tasnima Siddiquee \n",
      "Dr Abdul Alim \n",
      "Published \n",
      "November 2019 \n",
      "Correspondence \n",
      "Diabetic Association of Bangladesh \n",
      "122 Kazi Nazrul Islam Avenue, Dhaka 1000, Bangladesh \n",
      "Design and layout \n",
      "Liason Office,122 Kazi Nazrul Islam avenue, Shabag, Dhaka \n",
      "Printing \n",
      "BADAS-RVTC Printing Press \n",
      "477 Medical Road, Jurain, Dhaka 1204, Bangladesh \n",
      "  \n",
      "Unrestricted Educational Grant from Novo Nordisk (Pvt) Limited \n",
      "  \n",
      "2 \\l§8 Diabetes Care: BADAS Guideline 2019 President \n",
      "  \n",
      "Diabetic Association of Bangladesh \n",
      "Message \n",
      "It gives me immense pleasure to know that BADAS is publishing country’s first \n",
      "diabetes care guideline\n",
      "\n",
      "Chunk 2: | express my heartfelt thanks to all the members of the \n",
      "taskforce team and expert committee for putting their effort to develop the guide- \n",
      "line\n",
      "\n",
      "Chunk 3: \n",
      "World is suffering from an epidemic of diabetes and this epidemic is rising faster in \n",
      "developing countries like Bangladesh; hence number of increasing patients need \n",
      "to get access to quality care for getting optimal control\n",
      "\n",
      "Chunk 4: It is well known that to \n",
      "ensure quality care competence building of physician is an utmost need\n",
      "\n",
      "Chunk 5: | believe \n",
      "this guideline will help the physician to choose the right regimen for treating the \n",
      "diabetic patients properly\n",
      "\n",
      "Chunk 6: In this regard | like to thank NCDC Program, Directorate \n",
      "General of Health Services for their support in developing this guideline\n",
      "\n",
      "Chunk 7: \n",
      "Based on this guideline we are also developing an app-based treatment approach \n",
      "named Diabetes Journey\n",
      "\n",
      "Chunk 8: We believe these initiatives will expand the specialist \n",
      "physicians base and will empower the physicians to enhance the treatment of \n",
      "diabetes ensuring quality care\n",
      "\n",
      "Chunk 9: \n",
      "| look forward to the success of this guideline\n",
      "\n",
      "Chunk 10: \n",
      "Greyet VYUST TNO \n",
      "Professor AK Azad Khan \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI) 3 Secretary General \n",
      "  \n",
      "Diabetic Association of Bangladesh \n",
      "Message \n",
      "It is a proud moment for BADAS to launch the Diabetes Care Guideline and \n",
      "Diabetes Journey app which is a simple mobile decision support application for \n",
      "diagnosis and treatment of diabetes, \n",
      "BADAS is fortunate to have forward-thinking medical, scientific, educational and \n",
      "executive professionals, who strategically lead and focus efforts to ensure the \n",
      "establishment of this “Diabetes Care Guideline’ \n",
      "We are also privileged to have Novo Nordisk as partner on launching of Diabetes \n",
      "Journey app\n",
      "\n",
      "Chunk 11: The app is developed as a supporting tool for healthcare providers \n",
      "and empowers them to select the best treatment for a particular patient aligning \n",
      "with Diabetes Care Guideline\n",
      "\n",
      "Chunk 12: \n",
      "We look forward for your gracious support to these and make it a grand success\n",
      "\n",
      "Chunk 13: \n",
      "* \n",
      "Bua \n",
      "Md Sayef Uddin \n",
      "  \n",
      "4 ‘ll Diabetes Care: BADAS Guideline 2019 Secretary \n",
      "Health Care Division \n",
      "Ministry of Health & Family Welfare \n",
      "The Peoples’ Republic of Bangladesh \n",
      "  \n",
      "Message \n",
      "| am immensely delighted to know that BADAS is publishing country’s first \n",
      "diabetes care guideline and launching an app-based treatment approach called \n",
      "Diabetes journey\n",
      "\n",
      "Chunk 14: | like to take this moment to express my heartfelt gratitude to all \n",
      "members who worked relentlessly to develop the guideline and the app\n",
      "\n",
      "Chunk 15: \n",
      "The number of diabetic patients is increasing worldwide and also in Bangladesh at \n",
      "an alarming rate\n",
      "\n",
      "Chunk 16: As a result, increased number of patients need to get access to \n",
      "quality care for achieving optimal control\n",
      "\n",
      "Chunk 17: Improving capacity of the physicians is \n",
      "also a demand of the time\n",
      "\n",
      "Chunk 18: \n",
      "| believe these initiatives will expand the specialist physicians base and will \n",
      "empower the physicians and will help to progress further towards fulfilling the \n",
      "vision to creating digital Bangladesh\n",
      "\n",
      "Chunk 19: \n",
      "| look forward to witnessing the wide utilization of this guideline and the app\n",
      "\n",
      "Chunk 20: \n",
      "= ee a \n",
      "Md Ashadul Islam \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HE 5 Directorate General \n",
      "Directorate General of Health Services \n",
      "Ministry of Health & Family Welfare \n",
      "  \n",
      "Message \n",
      "Across the world diabetes is a common burden\n",
      "\n",
      "Chunk 21: We are facing same challenges in \n",
      "Bangladesh\n",
      "\n",
      "Chunk 22: About 6.9 million people in Bangladesh have diabetes\n",
      "\n",
      "Chunk 23: This figure \n",
      "would be just doubled by 2045\n",
      "\n",
      "Chunk 24: We are struggling to provide quality care to the \n",
      "diabetic due to limited number of diabetes specialists.| believe this diabetes guide- \n",
      "line from Diabetic Association of Bangladesh will guide a physician to select appro- \n",
      "priate therapy to manage diabetes as well as boost up the treatment knowledge of \n",
      "physicians and ensure better treatment in individualized care\n",
      "\n",
      "Chunk 25: \n",
      "This guideline is directly aligning with the objective of non-communicable disease \n",
      "program of the Govt\n",
      "\n",
      "Chunk 26: We are happy to see such type of initiative of BADAS and \n",
      "appreciate their effort to publish this guideline\n",
      "\n",
      "Chunk 27: \n",
      "We look forward to the success of this and believe it would be a widely used guide- \n",
      "line among the physician\n",
      "\n",
      "Chunk 28: \n",
      "> \n",
      "Professor Dr Abul Kalam Azad \n",
      "  \n",
      "6 ‘IIB Diabetes Care: BADAS Guideline 2019 Additional Director General \n",
      "(Planning & Development) \n",
      "Ministry of Health & Family Welfare \n",
      "  \n",
      "Message \n",
      "Diabetes mellitus is running in an epidemic scale almost all over the world, \n",
      "Bangladesh is no exception\n",
      "\n",
      "Chunk 29: Day by day number of patients are increasing and they \n",
      "are more prone to be affected by different types of comorbid conditions\n",
      "\n",
      "Chunk 30: Physicians \n",
      "are playing important role to ensure better care\n",
      "\n",
      "Chunk 31: But they face problems to \n",
      "individualize the treatment\n",
      "\n",
      "Chunk 32: | am happy to learn that BADAS has developed a \n",
      "guideline on diabetes care based on treatment algorithm for disease management\n",
      "\n",
      "Chunk 33: \n",
      "This will help and guide a physician for making a decision towards treatment in \n",
      "addition to enriching their knowledge in current treatment approach\n",
      "\n",
      "Chunk 34: \n",
      "From the Government side, we want to maintain a collaboration with BADAS to \n",
      "take such type of initiative in future which is in line with non-communicable \n",
      "disease control program of the Government\n",
      "\n",
      "Chunk 35: \n",
      "| sincerely hope this guideline will be helpful to physicians and will serve useful \n",
      "purpose in daily practice\n",
      "\n",
      "Chunk 36: \n",
      "i = = = \n",
      "Prof Dr AHM Enayet Hossain \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI) 7 Chairpersion \n",
      "Diabetes Care BADAS Guideline 2019 \n",
      "  \n",
      "Message \n",
      "| express my heartiest thanks to all the members of task force and the expert \n",
      "committee of Diabetes Care BADAS Guideline 2019 for their brilliant contribution \n",
      "to publish this guideline\n",
      "\n",
      "Chunk 37: \n",
      "Diabetes is a chronic lifelong disease\n",
      "\n",
      "Chunk 38: If undetected or uncontrolled, it can lead to \n",
      "life-threating acute emergencies and long-term chronic complications leading to \n",
      "blindness, end-stage renal failure, neurological complications, and cardiovascular \n",
      "disease\n",
      "\n",
      "Chunk 39: Research has proved that all these complications are largely preventable \n",
      "by early detectionand with good control of diabetes\n",
      "\n",
      "Chunk 40: | believe this guideline will \n",
      "guide our physicians to choose the appropriate treatment regimen for the man- \n",
      "agement of their patients properly\n",
      "\n",
      "Chunk 41: \n",
      "| look forward to the success of this guideline\n",
      "\n",
      "Chunk 42: \n",
      "PojerR tfoblel \n",
      "Professor Hajera Mahtab \n",
      "  \n",
      "8 ‘IIE Diabetes Care: BADAS Guideline 2019 Content \n",
      "Page \n",
      "CHAPTER 1 \n",
      "Overview, Pathophysiology and Epidemiology of Diabetes mellitus 11 \n",
      "Chapter 2 \n",
      "Screening and Diagnosis of Diabetes Mellitus 17 \n",
      "Chapter 3 \n",
      "Treatment of Diabetes Mellitus 21 \n",
      "Chapter 4 \n",
      "Acute Complications Diabetes Mellitus 32 \n",
      "Chapter 5 \n",
      "Chronic Complications Diabetes Mellitus 39 \n",
      "Chapter 6 \n",
      "Special Situations in Diabetes Mellitus 51 \n",
      "Chapter 7 \n",
      "Prevention of Diabetes Mellitus 72 \n",
      "Appendix 74 \n",
      "Case History 75 \n",
      "Abbreviation 77 \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 BE) 9 10 ‘lI Diabetes Care: BADAS Guideline 2019 CHAPTER 1 \n",
      "Overview, Pathophysiology and Epidemiology \n",
      "of Diabetes mellitus \n",
      "1.1 Overview \n",
      "Diabetes mellitus (DM) is a chronic/persistent hyperglycemia, due to different \n",
      "degrees of deficiency of insulin secretion, and/or of insulin action\n",
      "\n",
      "Chunk 43: At recent time \n",
      "several other pathological pathways are recognized, specially in type 2 diabetes\n",
      "\n",
      "Chunk 44: \n",
      "Diabetes mellitus is classified on the basis of etiology into four types: \n",
      "1\n",
      "\n",
      "Chunk 45: Type 1 diabetes mellitus \n",
      "2. Type 2 diabetes mellitus \n",
      "3\n",
      "\n",
      "Chunk 46: Other specific types \n",
      "4\n",
      "\n",
      "Chunk 47: Gestational diabetes mellitus (GDM) \n",
      "Type 1 diabetes mellitus tends to occur usually in the young, although it can occur \n",
      "at any age\n",
      "\n",
      "Chunk 48: They are found to be lean\n",
      "\n",
      "Chunk 49: Onset of symptoms is often rapid\n",
      "\n",
      "Chunk 50: It is mostly \n",
      "caused by autoimmune destruction of the beta-cells in the pancreas, resulting in \n",
      "severe reduction of insulin production\n",
      "\n",
      "Chunk 51: Although there does not appear to be a \n",
      "strong genetic link, there is genetic susceptibility to the disease\n",
      "\n",
      "Chunk 52: Environmental \n",
      "factors have also been implicated\n",
      "\n",
      "Chunk 53: Persons with type 1 diabetes are dependent on \n",
      "insulin to survive\n",
      "\n",
      "Chunk 54: \n",
      "Type 2 diabetes mellitus occurs more often in older age group of people who are \n",
      "overweight/obese and lead sedentary lifestyles\n",
      "\n",
      "Chunk 55: Onset of symptoms is slower, and \n",
      "the disease may go undiagnosed for many years\n",
      "\n",
      "Chunk 56: It is associated with both \n",
      "impairment of insulin secretion and resistance to insulin action\n",
      "\n",
      "Chunk 57: Type 2 diabetes is \n",
      "often associated with a strong genetic predisposition\n",
      "\n",
      "Chunk 58: Lifestyle measures, \n",
      "non-insulin agents and also insulin can be used to control diabetes\n",
      "\n",
      "Chunk 59: \n",
      "Other specific types cover a group of diabetes where cause of hyperglycemia can \n",
      "be attributed to factors such as drug, endocrine, pancreatic disease or genetic \n",
      "syndrome etc\n",
      "\n",
      "Chunk 60: Clinically these groups of cases will posses features of both diabetes \n",
      "and the underlying causal factors\n",
      "\n",
      "Chunk 61: \n",
      "Gestational diabetes mellitus (GDM) is glucose intolerance detected in a pregnant \n",
      "woman who was not known to have this abnormality prior to conception\n",
      "\n",
      "Chunk 62: Most of \n",
      "the GDM cases become normal afterwards\n",
      "\n",
      "Chunk 63: But the mother has increased risk of \n",
      "developing GDM in subsequent pregnancies, and permanent diabetes later in life\n",
      "\n",
      "Chunk 64: \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HE! 11 Classification of diabetes mellitus \n",
      "Peete \n",
      "A\n",
      "\n",
      "Chunk 65: Autoimmune \n",
      "B\n",
      "\n",
      "Chunk 66: Idiopathic \n",
      "2\n",
      "\n",
      "Chunk 67: Type 2 diabetes mellitus \n",
      "A\n",
      "\n",
      "Chunk 68: Insulin resistance predominates over the relative defects in hormone secretion \n",
      "B\n",
      "\n",
      "Chunk 69: Defects in insulin secretion predominate over the presence of insulin resistance \n",
      "RPM Otet Taam embry \n",
      "A\n",
      "\n",
      "Chunk 70: Genetic defects in B-cell function \n",
      "1\n",
      "\n",
      "Chunk 71: Chromosome 12, HNF-1a (MODY 3) \n",
      "Chromosome 7, glycosidase (MODY 2) \n",
      "Chromosome 20, HNF-4a (MODY 1) \n",
      "Mitochondrial DNA \n",
      "\n",
      "\n",
      "Chunk 72: Others \n",
      "B\n",
      "\n",
      "Chunk 73: Genetic defects in insulin action \n",
      "1\n",
      "\n",
      "Chunk 74: Type A insulin resistance \n",
      "2\n",
      "\n",
      "Chunk 75: Leprechaunism \n",
      "3\n",
      "\n",
      "Chunk 76: Rabson-Mendenhall syndrome \n",
      "4\n",
      "\n",
      "Chunk 77: Lipotrophic diabetes \n",
      "5\n",
      "\n",
      "Chunk 78: Others \n",
      "C\n",
      "\n",
      "Chunk 79: Disease of exocrine pancreas \n",
      "Pancreatitis \n",
      "Pancreatectomy/trauma \n",
      "Neoplasia \n",
      "Cystic fibrosis \n",
      "Hemochromatosis \n",
      "Fibrocalcific pancreatopathy \n",
      "\n",
      "\n",
      "Chunk 80: Others \n",
      "D\n",
      "\n",
      "Chunk 81: Endocrinopathies \n",
      "Acromegaly \n",
      "Cushing syndrome \n",
      "Glucagonoma \n",
      "Pheochromocytoma \n",
      "Hyperthyroidism \n",
      "Somatostatinoma \n",
      "Aldosteronoma \n",
      "\n",
      "\n",
      "Chunk 82: Other \n",
      "E\n",
      "\n",
      "Chunk 83: Pharmacologically of chemically induced \n",
      "Vacor \n",
      "Pentamidine \n",
      "Nicotinic acid \n",
      "Glucocorticoids \n",
      "Thyroid hormones \n",
      "wbwn NOM PWNS OPNANARWN wWPWwns \n",
      "  \n",
      "12 ‘IIB Diabetes Care: BADAS Guideline 2019 Diazoxide \n",
      "B-adrenergic agonists \n",
      "Tiazides \n",
      "Dilantin \n",
      "ainterferon \n",
      "\n",
      "\n",
      "Chunk 84: Others \n",
      "F\n",
      "\n",
      "Chunk 85: Infections \n",
      "1\n",
      "\n",
      "Chunk 86: \n",
      "2\n",
      "\n",
      "Chunk 87: \n",
      "3\n",
      "\n",
      "Chunk 88: \n",
      "Congenital rubella \n",
      "Cytomegalovirus \n",
      "Others \n",
      "G\n",
      "\n",
      "Chunk 89: Infrequent forms of autoimmune diabetes \n",
      "1\n",
      "\n",
      "Chunk 90: \n",
      "2\n",
      "\n",
      "Chunk 91: \n",
      "3\n",
      "\n",
      "Chunk 92: \n",
      "Stiff-man syndrome \n",
      "Antibodies against insulin receptors \n",
      "Others \n",
      "H\n",
      "\n",
      "Chunk 93: Other syndromes occasionally associated with diabetes \n",
      "1 \n",
      "2 \n",
      "3 \n",
      "4\n",
      "\n",
      "Chunk 94: \n",
      "5\n",
      "\n",
      "Chunk 95: \n",
      "6 \n",
      "7\n",
      "\n",
      "Chunk 96: \n",
      "8\n",
      "\n",
      "Chunk 97: \n",
      "9 \n",
      "10\n",
      "\n",
      "Chunk 98: \n",
      "11\n",
      "\n",
      "Chunk 99: \n",
      "Down syndrome \n",
      "Klinefelter syndrome \n",
      "Turner syndrome \n",
      "Wolfram syndrome \n",
      "Friedreich ataxia \n",
      "Huntington’s chorea \n",
      "Lawrence-Moon-Biedel syndrome \n",
      "Myotonic dystrophy \n",
      "Porphyria \n",
      "Prader-Willi syndrome \n",
      "Others \n",
      "4\n",
      "\n",
      "Chunk 100: Gestational diabetes mellitus (GDM) \n",
      "MODY: maturity onset diabetes of the young \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI) 13 Prediabetes \n",
      "IGT (impaired glucose tolerance) and IFG (impaired fasting glucose) are referred as \n",
      "‘Prediabetes: Persons with prediabetes have high risk of development of diabetes \n",
      "(25% IFG and 30% IGT cases become diabetic over time) and cardiovascular \n",
      "diseases\n",
      "\n",
      "Chunk 101: Any type of diabetes can pass through the stages of prediabetes, but it is \n",
      "most obvious in type 2 diabetes\n",
      "\n",
      "Chunk 102: These persons are treated by lifestyle \n",
      "modifications; drugs may be used where indicated\n",
      "\n",
      "Chunk 103: About 40% of IFG and 30% of \n",
      "IGT cases may revert to normal if proper intervention can be given\n",
      "\n",
      "Chunk 104: \n",
      "Clinical presentation \n",
      "The spectrum of presentation ranges from asymptomatic to typical features\n",
      "\n",
      "Chunk 105: \n",
      "Asymptomatic cases are diagnosed by biochemical test only\n",
      "\n",
      "Chunk 106: A vast majority of \n",
      "type 2 diabetes and other types remain asymptomatic over a prolonged period\n",
      "\n",
      "Chunk 107: \n",
      "Routine check-up usually picks up this form of diabetes\n",
      "\n",
      "Chunk 108: Type 1 diabetes is always \n",
      "symptomatic and shows classical features of hyperglycemia\n",
      "\n",
      "Chunk 109: \n",
      "Typical features of diabetes mellitus start with glycosuria, which begins after the \n",
      "blood glucose level has gone above individual's renal threshold for glucose\n",
      "\n",
      "Chunk 110: \n",
      "Features include polyuria, polydipsia, polyphagia, weight loss and general \n",
      "weakness\n",
      "\n",
      "Chunk 111: These are mostly seen at presentation of type 1 diabetes, though not so \n",
      "common in other types\n",
      "\n",
      "Chunk 112: \n",
      "Atypical manifestations are non-specific, which include non-healing infection, \n",
      "infertility or repeated pregnancy loss, pruritus vulvae, undue fatigability etc\n",
      "\n",
      "Chunk 113: This is \n",
      "a common mode of presentation in type 2 diabetes\n",
      "\n",
      "Chunk 114: \n",
      "Specific complications of diabetes may be present at the time of diagnosis\n",
      "\n",
      "Chunk 115: In type \n",
      "2 diabetes and other forms of diabetes mellitus, presentations may remain \n",
      "asymptomatic for quite a long period resulting in late diagnosis and intervention\n",
      "\n",
      "Chunk 116: \n",
      "So significant proportion of type 2 diabetes cases present with one or more chronic \n",
      "complications\n",
      "\n",
      "Chunk 117: All type 1 diabetes cases are usually diagnosed before development \n",
      "of chronic complications\n",
      "\n",
      "Chunk 118: \n",
      "Diabetic complications \n",
      "Long term complications are mediated by microvascular (nephropathy, \n",
      "retinopathy, neuropathy) and macrovascular (coronary artery disease, \n",
      "cerebrovascular disease, peripheral vascular disease) changes\n",
      "\n",
      "Chunk 119: A diabetic person is \n",
      "at risk of developing these complications many times more than a non-diabetic \n",
      "person\n",
      "\n",
      "Chunk 120: Children with uncontrolled diabetes may have problem in growth\n",
      "\n",
      "Chunk 121: \n",
      "Pregnancy in women with diabetes threatens both expectant mother and foetus\n",
      "\n",
      "Chunk 122: \n",
      "Acute metabolic derangement may lead to life threatening diabetic comas, such as \n",
      "diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state (HHS), lactic \n",
      "acidosis, including hypoglycemia\n",
      "\n",
      "Chunk 123: \n",
      "  \n",
      "14 ‘IIE\n",
      "\n",
      "Chunk 124: GDM: SAFES RECOMMENDATIONS and ACTION PLAN 1.2 Pathophysiology \n",
      "Type 1 diabetes: Marked impairment of insulin production due to cellular- \n",
      "mediated autoimmune destruction of beta cells is the hall mark\n",
      "\n",
      "Chunk 125: Some of type 1 \n",
      "diabetes cases are of idiopathic in nature\n",
      "\n",
      "Chunk 126: \n",
      "Type 2 diabetes: Insulin resistance and 6-cell failure represent the main \n",
      "pathophysiologic defects in type 2 diabetes\n",
      "\n",
      "Chunk 127: Subjects with type 2 are maximally \n",
      "insulin resistant and have lost over approximately 80% of their B-cell function\n",
      "\n",
      "Chunk 128: In \n",
      "addition, muscle (impaired glucose disposal), liver (increased glucose production), \n",
      "and B-cell (reduced insulin production), the fat cell (accelerated lipolysis), \n",
      "gastrointestinal tract (incretin deficiency/resistance), a-cell (hyperglucagonemia), \n",
      "kidney (increased glucose reabsorption), and brain (insulin resistance)- all play \n",
      "important roles in the development of glucose intolerance in type 2 diabetic \n",
      "individuals\n",
      "\n",
      "Chunk 129: Collectively, these eight pathways comprise the ominous octet\n",
      "\n",
      "Chunk 130: \n",
      "Other specific types: Pathophysiological process depends on the etiology of the \n",
      "particular type of diabetes\n",
      "\n",
      "Chunk 131: \n",
      "Gestational diabetes mellitus: This type of diabetes is caused by placental \n",
      "hormones, namely beta HCG, human placental lactogen, estrogen, progesterone \n",
      "etc\n",
      "\n",
      "Chunk 132: antagonizing the action of insulin\n",
      "\n",
      "Chunk 133: \n",
      "1.3 Epidemiology \n",
      "Global trend \n",
      "Diabetes mellitus is now one of the most common non-communicable diseases \n",
      "globally\n",
      "\n",
      "Chunk 134: It is epidemic in many developing and industrializing countries, At Present \n",
      "total number of diabetic person globally is nearly 425 millions with a prevalence of \n",
      "8.8% in adult population (20 to 79 years)\n",
      "\n",
      "Chunk 135: China and India hold the 1st and 2nd \n",
      "position respectively having 114.4 and 72.9 million of total cases of diabetes\n",
      "\n",
      "Chunk 136: \n",
      "In addition to diabetes, prediabetes also constitutes a major public health problem \n",
      "because of its association with increased risk of diabetes and cardiovascular \n",
      "diseases\n",
      "\n",
      "Chunk 137: \n",
      "Type 2 diabetes constitutes about 85 to 95% of all diabetes\n",
      "\n",
      "Chunk 138: The increasing trend of \n",
      "type 2 diabetes is associated with changing lifestyle such as dietary changes, \n",
      "reduced physical activity due to rapid economic transition and increasing \n",
      "urbanization along with population aging\n",
      "\n",
      "Chunk 139: \n",
      "Type 1 diabetes usually accounts for only a minority of the total burden of diabetes \n",
      "though it is also increasing\n",
      "\n",
      "Chunk 140: Total number is above 1.1 million in population under \n",
      "19 years of age\n",
      "\n",
      "Chunk 141: Though predominant diabetes in the younger age is type 1, type 2 \n",
      "diabetes is on the rise in this population\n",
      "\n",
      "Chunk 142: \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 MHI 15 Bangladesh trend \n",
      "Magnitude of diabetes mellitus in Bangladesh is also increasing\n",
      "\n",
      "Chunk 143: At present the \n",
      "total number of diabetic person is nearly 7 million, with prevalence being 8.4% in \n",
      "adult population (20 to 79 years)\n",
      "\n",
      "Chunk 144: Almost all are type 2 diabetes\n",
      "\n",
      "Chunk 145: \n",
      "Morbidity and mortality \n",
      "About 50% of mortality is due to CVD resulting from damage of large blood vessels\n",
      "\n",
      "Chunk 146: \n",
      "Diabetes is one of the major causes of premature illness and death in most \n",
      "countries\n",
      "\n",
      "Chunk 147: Cardiovascular diseases, resulting from damage to large blood vessels, \n",
      "cause death of 50% or more of people with diabetes depending on the population\n",
      "\n",
      "Chunk 148: \n",
      "At least one complication usually present in 50% of newly detected diabetes cases\n",
      "\n",
      "Chunk 149: \n",
      "An estimated 4 million adults die from diabetes-related causes globally, accounting \n",
      "for 10.7% of all deaths in the 20-79 years age group\n",
      "\n",
      "Chunk 150: \n",
      "In Bangladesh total number of diabetes related death is nearly one hundred \n",
      "thousand death in 2017\n",
      "\n",
      "Chunk 151: \n",
      "References \n",
      "* Diabetes Mellitus, Distance Learning Program, 5th edition, BADAS, 2018\n",
      "\n",
      "Chunk 152: \n",
      "* Standards of Medical care in Diabetes, ADA (American Diabetes Association), 2019\n",
      "\n",
      "Chunk 153: \n",
      "* Diabetes Atlas, 8th edition, IDF (International Diabetes Federation), 2017\n",
      "\n",
      "Chunk 154: \n",
      "* Ralph A\n",
      "\n",
      "Chunk 155: DeFronzo\n",
      "\n",
      "Chunk 156: From the Triumvirate to the Ominous Octet: a New Paradigm for \n",
      "the Treatment of Type 2 Diabetes Mellitus\n",
      "\n",
      "Chunk 157: Diabetes 2009; 58(4): 773-795\n",
      "\n",
      "Chunk 158: \n",
      "  \n",
      "16 ‘lI Diabetes Care: BADAS Guideline 2019 Chapter 2 \n",
      "Screening and Diagnosis of Diabetes Mellitus \n",
      "2.1 Screening for prediabetes and diabetes \n",
      "Screening for prediabetes and type 2 diabetes in adults \n",
      "Testing for prediabetes/type 2 diabetes in asymptomatic people should be \n",
      "considered in adults of any age who are overweight/obese (BMI > 23 kg/m? in \n",
      "Asians) and who have one or more of the following risk factors: \n",
      "*  First-degree relative with diabetes \n",
      "* High-risk race/ethnicity, like Bangladeshies \n",
      "* History of CVD with Hypertension (2140/90 mmHg or on therapy for \n",
      "hypertension) \n",
      "* HDL cholesterol level <35 mg/dL and/or a triglyceride level >250 mg/dL \n",
      "* Women with polycystic ovary syndrome (PCOS) \n",
      "* Physical inactivity \n",
      "* Other clinical conditions associated with insulin resistance (e.g., severe \n",
      "obesity, acanthosis nigricans (PCOS) \n",
      "For all other people (even if without risk factors), testing should begin at age 40 \n",
      "years\n",
      "\n",
      "Chunk 159: \n",
      "If results are normal, testing should be repeated at 1-3-year intervals, with \n",
      "consideration of more frequent testing depending on initial results and risk \n",
      "status\n",
      "\n",
      "Chunk 160: Patients with prediabetes (A1C >5.7%, IGT, or IFG) should be tested \n",
      "yearly\n",
      "\n",
      "Chunk 161: Women who were diagnosed with GDM should have lifelong testing at \n",
      "least every 1-3 years\n",
      "\n",
      "Chunk 162: \n",
      "Immediate testing is required in symptomatic cases\n",
      "\n",
      "Chunk 163: \n",
      "Screening for prediabetes and type 2 diabetes in children \n",
      "Should be considered after the onset of puberty or after 10 years of age, \n",
      "whichever occurs earlier, in asymptomatic children and adolescents who are \n",
      "overweight (BMI >85th percentile) or obese (BMI >95th percentile) and who \n",
      "have additional risk factors for diabetes: \n",
      "* Maternal history of diabetes or GDM during the child's gestation \n",
      "* Family history of type 2 diabetes in first- or second-degree relative \n",
      "* Race/ethnicity, e.g\n",
      "\n",
      "Chunk 164: Asians \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI! 17 * — Signs of insulin resistance or conditions associated with insulin resistance \n",
      "(acanthosis nigricans, hypertension, dyslipidemia, PCOS, or small-for- \n",
      "gestational-age birth weight) \n",
      "If tests are normal, repeat testing at a minimum of 3-year intervals, or more \n",
      "frequently if BMI is increasing, is recommended\n",
      "\n",
      "Chunk 165: \n",
      "Immediate testing is required in symptomatic cases\n",
      "\n",
      "Chunk 166: \n",
      "Screening for type 1 diabetes \n",
      "Plasma blood glucose rather than A1C should be used to diagnose the acute \n",
      "onset of type 1 diabetes in individuals with symptoms of hyperglycemia\n",
      "\n",
      "Chunk 167: \n",
      "Screening for type 1 diabetes risk with a panel of autoantibodies \n",
      "(autoantibodies to islet cell, insulin, GAD, tyrosine phosphatases, and ZnT8) is \n",
      "currently recommended only in the setting of a research trial or in first-degree \n",
      "family members of a proband with type 1 diabetes\n",
      "\n",
      "Chunk 168: \n",
      "Persistence of two or more autoantibodies predicts clinical diabetes and may \n",
      "serve as an indication for intervention in the setting of a clinical trial\n",
      "\n",
      "Chunk 169: \n",
      "2.2 Diagnosis of prediabetes and diabetes \n",
      "Diagnosis is based on documentation of glucose intolerance in the individual\n",
      "\n",
      "Chunk 170: \n",
      "Procedures for documenting glucose intolerance include: \n",
      "1\n",
      "\n",
      "Chunk 171: \n",
      "2 \n",
      "3\n",
      "\n",
      "Chunk 172: \n",
      "A \n",
      "OGTT \n",
      "Fasting plasma glucose (FPG) \n",
      "HbAic \n",
      "Random plasma glucose (RPG) \n",
      "OGTT (Oral glucose tolerance test) \n",
      "Plasma glucose level is determined by fasting and 2 hours after 75 grams of oral \n",
      "glucose drink\n",
      "\n",
      "Chunk 173: It classifies a person as a diabetic, IGT (impaired glucose tolerance), \n",
      "IFG (impaired fasting glucose), or normal\n",
      "\n",
      "Chunk 174: \n",
      "Fasting plasma glucose (FPG) \n",
      "By fasting plasma glucose level,a person can be labeled as a diabetic, IFG or normal\n",
      "\n",
      "Chunk 175: \n",
      "Persons with normal glucose or IFG, if subjected to OGTT, may be found as a \n",
      "diabetic or IGT\n",
      "\n",
      "Chunk 176: \n",
      "  \n",
      "18 l§N Diabetes Care: BADAS Guideline 2019 HbA1c \n",
      "Hbatc is now increasingly being used in diagnosis of diabetes\n",
      "\n",
      "Chunk 177: The test must be \n",
      "highly standardized for using it in this purpose\n",
      "\n",
      "Chunk 178: \n",
      "Random plasma glucose (RPG) \n",
      "No preparation is required for this procedure\n",
      "\n",
      "Chunk 179: Plasma glucose levels are estimated \n",
      "from a sample irrespective of last meal\n",
      "\n",
      "Chunk 180: RPG, in presence of classical symptoms of \n",
      "hyperglycemia or hyperglycemic crisis, can confirm diabetes\n",
      "\n",
      "Chunk 181: \n",
      "PTF emery \n",
      "FPG >7.0 mmol/L*, &/or \n",
      "2-hr PG at OGTT 211.1 mmol/L*, &/ or \n",
      "HbA1c 26.5%*, &/or \n",
      "RPG (in presence of classical symptoms of hyperglycemia or hyperglycemic \n",
      "crisis) >11.1 mmol/L \n",
      "*(in absence of unequivocal hyperglycemia, at least 2 abnormal test results are \n",
      "required) \n",
      "Impaired glucose tolerance (IGT) \n",
      "2-hr PG at OGTT 7.8-<11.1 mmol/L \n",
      "[FPG should be <7.0 mmol/L] \n",
      "Impaired fasting glucose (IFG) \n",
      "FPG 6.1-<7.0 mmol/L \n",
      "[2-hr PG at OGTT should be <7.8 mmol/L] \n",
      "eC CMe acme (Cle) \n",
      "FPG >5.1 mmol/L, &/or \n",
      "1-hr PG at OGTT 210.0 mmol/L, &/or \n",
      "2-hr PG at OGTT 28.5 mmol/L \n",
      "Pre-pregnancy/overt diabetes \n",
      "FPG >7.0 mmol/L, &/or \n",
      "2-hr PG at OGTT 211.1 mmol/L, &/or \n",
      "HbA1c 26.5%, &/or \n",
      "RPG (in presence of classical symptoms of hyperglycemia or hyperglycemic \n",
      "crisis) >11.1 mmol/L \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 BE 19 OGTT procedure \n",
      "¢ Person should take unrestricted diet containing at least 150 grams of \n",
      "carbohydrate daily for at least previous 3 days\n",
      "\n",
      "Chunk 182: \n",
      "* The test should be in the morning after 8-14 hours of overnight fast (preferably \n",
      "before 9 am)\n",
      "\n",
      "Chunk 183: \n",
      "* A fasting blood sample prior to glucose drink is collected\n",
      "\n",
      "Chunk 184: \n",
      "* An oral glucose load of 75 gram for adult (1.75 gram/kg body weight, up to \n",
      "maximum 75 gram for child) is given in 250-300 ml of water.The drink must be \n",
      "completed within 5 minutes\n",
      "\n",
      "Chunk 185: \n",
      "* Asecond blood sample is collected at 120th minute after the glucose drink\n",
      "\n",
      "Chunk 186: \n",
      "* If glucose is not estimated immediately then the blood sample may be \n",
      "preserved with sodium fluoride (6 mg/ml whole blood)\n",
      "\n",
      "Chunk 187: Blood should be \n",
      "centrifuged, and plasma separated and frozen until estimation\n",
      "\n",
      "Chunk 188: \n",
      "* Smoking, tea or physical stress is not allowed during the test\n",
      "\n",
      "Chunk 189: \n",
      "References \n",
      "* Diabetes Mellitus, Distance Learning Program, 5th edition, BADAS, 2018\n",
      "\n",
      "Chunk 190: \n",
      "* Standards of Medical care in Diabetes, ADA (American Diabetes Association), 2019\n",
      "\n",
      "Chunk 191: \n",
      "* Definition and Diagnosis of Diabetes Mellitus and Intermediate hyperglycemia, a \n",
      "Report of a WHO (World Health Organization) Consultation, 2011\n",
      "\n",
      "Chunk 192: \n",
      "¢ Global Guideline for Type 2 Diabetes, Clinical Guidelines Task Force, IDF \n",
      "(International Diabetes Federation), 2012\n",
      "\n",
      "Chunk 193: \n",
      "  \n",
      "20 ‘IN Diabetes Care: BADAS Guideline 2019 Chapter 3 \n",
      "Treatment of Diabetes Mellitus \n",
      "3.1 Diagnosis, patient factors and goal setting \n",
      "Confirmation of diagnosis is described in Chapter 2\n",
      "\n",
      "Chunk 194: \n",
      "Following patient factors should be considered \n",
      "* Type of DM \n",
      "* Age of the person \n",
      "* Body weight \n",
      "* Associated conditions, e.g\n",
      "\n",
      "Chunk 195: acute/chronic \n",
      "complications/ illnesses, pregnancy/ lacta- \n",
      "tion, major surgery, life expectancy etc\n",
      "\n",
      "Chunk 196: \n",
      "* — Lifestyle of the person \n",
      "Targets of treatment \n",
      "Degree of hyperglycemia \n",
      "Job and occupation \n",
      "Previous anti-diabetic agents (if on any) \n",
      "Socio-economic condition, care-giver \n",
      "support \n",
      "Target of diabetes management \n",
      "Blood (plasma) glucose \n",
      "HbA1c \n",
      "Blood lipids \n",
      "BP \n",
      "BMI \n",
      "Waist circumference (WC) \n",
      "o \n",
      "o \n",
      "Fasting/pre-meal <7.0 mmol/L \n",
      "Post-meal <10.0 mmol/L \n",
      "<7% \n",
      "Oo \n",
      "Oo \n",
      "Oo \n",
      "o \n",
      "o \n",
      "o \n",
      "Oo \n",
      "LDL cholesterol <100 mg/dl \n",
      "HDL cholesterol >40 mg/dl (male) \n",
      ">50 mg/dl (female) \n",
      "Triglyceride <150 mg/dl \n",
      "Systolic <130 mm of Hg \n",
      "Diastolic <80 mm of Hg \n",
      "BMI <23 kg/m2 \n",
      "WC <90cm (male) \n",
      "<80 cm (female) \n",
      "* Target of glycemic control may be individualized considering above patient factors \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HE 21 3.2 Treatment regimen and monitoring \n",
      "Selection and initiation of a treatment regimen \n",
      "Life style modification \n",
      "Medical nutrition therapy \n",
      "An individualized medical nutrition therapy preferably by a registered dietitian, is \n",
      "recommended for all people with diabetes and prediabetes\n",
      "\n",
      "Chunk 197: There is no single ideal \n",
      "dietary distribution of calories among carbohydrates, fats, and proteins for people \n",
      "with diabetes; therefore, meal plans should be individualized while keeping total \n",
      "calorie and metabolic goals in mind\n",
      "\n",
      "Chunk 198: \n",
      "Weight loss (>5-10%) by combination of reduction of calorie intake and increased \n",
      "physical activity, benefits overweight or obese adults with type 2 diabetes and \n",
      "prediabetes\n",
      "\n",
      "Chunk 199: \n",
      "Nutrient-dense carbohydrate sources that are high in fiber, including vegetables, \n",
      "fruits, legumes, whole grains, as well as dairy products should be emphasized who \n",
      "are on insulin therapy\n",
      "\n",
      "Chunk 200: Education on carbohydrate counting should be given\n",
      "\n",
      "Chunk 201: \n",
      "People with diabetes and those at risk are advised to avoid sugar-sweetened \n",
      "beverages (including fruit juices) in order to control glycemia, weight\n",
      "\n",
      "Chunk 202: It also \n",
      "reduces their risk for cardiovascular disease and fatty liver\n",
      "\n",
      "Chunk 203: \n",
      "Diet should contain sufficient protein from animal and plant sources\n",
      "\n",
      "Chunk 204: \n",
      "Dietary fat: Diet rich in monounsaturated and polyunsaturated fats may be \n",
      "considered to improve glucose metabolism and lower cardiovascular disease risk\n",
      "\n",
      "Chunk 205: \n",
      "Foods rich in long-chain n-3 fatty acids, such as fatty fish (EPA and DHA) and nuts \n",
      "and seeds (ALA) are recommended to prevent or treat cardiovascular disease\n",
      "\n",
      "Chunk 206: \n",
      "There is no clear evidence that dietary supplementation with vitamins, minerals \n",
      "(such as chromium and vitamin D), herbs, or spices (such as cinnamon or aloe vera) \n",
      "can improve outcomes in people with diabetes\n",
      "\n",
      "Chunk 207: \n",
      "Adults with diabetes who drink alcohol should do so in moderation (no more than \n",
      "one drink per day for adult women and no more than two drinks per day for adult \n",
      "men) it is better to stop alcohol drinking\n",
      "\n",
      "Chunk 208: \n",
      "As for the general population, people with diabetes should limit salt consumption \n",
      "to 6 gm/day\n",
      "\n",
      "Chunk 209: \n",
      "Nonnutritive sweeteners can reduce overall calorie and carbohydrate intake but \n",
      "overall, people are encouraged to decrease both sweetened and non-nutritive \n",
      "sweetened beverages and to use other alternatives, with an emphasis on water \n",
      "intake\n",
      "\n",
      "Chunk 210: \n",
      "  \n",
      "22 ‘iI Diabetes Care: BADAS Guideline 2019 Physical activity \n",
      "Adults with diabetes should perform in 150 min or more of moderate intensity \n",
      "aerobic activity per week, spread over at least 5 days/week, with no more than 2 \n",
      "consecutive days without activity\n",
      "\n",
      "Chunk 211: Shorter durations (minimum 75 min/week) of \n",
      "moderate intensity or interval training may be sufficient for younger and more \n",
      "physically fit individuals\n",
      "\n",
      "Chunk 212: Adults with diabetes should engage in 2-3 sessions/week \n",
      "of resistance exercise on nonconsecutive days\n",
      "\n",
      "Chunk 213: All adults, and particularly those \n",
      "with type 2 diabetes, should decrease the amount of time spent in daily sedentary \n",
      "behavior, prolonged sitting should be interrupted every 30 min\n",
      "\n",
      "Chunk 214: Physical activity or \n",
      "exercise is encouraged to do same time in a day\n",
      "\n",
      "Chunk 215: \n",
      "Flexibility training and balance training are recommended 2-3 times/week for \n",
      "older adults with diabetes\n",
      "\n",
      "Chunk 216: Yoga and tai chi may be included based on individual \n",
      "preferences to increase flexibility, muscular strength, and balance\n",
      "\n",
      "Chunk 217: \n",
      "Some practical points on exercise \n",
      "* Exercise recommendation for persons with diabetes is the same, as for persons \n",
      "without diabetes, where an exercise programme includes a proper warm-up and \n",
      "cool-down period\n",
      "\n",
      "Chunk 218: A warm-up should consist of 5-10 minutes of aerobic activity \n",
      "(eg\n",
      "\n",
      "Chunk 219: walking) at a low-intensity level; it prepares the heart for exercise\n",
      "\n",
      "Chunk 220: After a short \n",
      "warm-up, muscles should be gently stretched for another 5-10 minutes for prepar- \n",
      "ing the muscle and preventing muscle injury\n",
      "\n",
      "Chunk 221: A cool down period of 5-10 minutes \n",
      "should follow the main activity session\n",
      "\n",
      "Chunk 222: It gradually brings the heart rate down to \n",
      "pre-exercise level\n",
      "\n",
      "Chunk 223: \n",
      "¢ Persons with diabetes who do not have complications and have good blood \n",
      "glucose control, can do all levels of exercise, including leisure activities, recreational \n",
      "sports and competitive professional performances\n",
      "\n",
      "Chunk 224: The emphasis must be given on \n",
      "adjusting the therapeutic regimen with the level of exercise and diet, and avoiding \n",
      "hypoglycemia\n",
      "\n",
      "Chunk 225: \n",
      "* — Inchildren, extra attention needs to be paid to balance glycemic control with activ- \n",
      "ity level and for this the support of parents, teachers and trainers may be necessary\n",
      "\n",
      "Chunk 226: \n",
      "Their meal and activity in school are important\n",
      "\n",
      "Chunk 227: \n",
      "* Persons with diabetes must view exercise as a vital component for the manage- \n",
      "ment\n",
      "\n",
      "Chunk 228: Exercise along with a reduced calorie intake may enhance weight loss\n",
      "\n",
      "Chunk 229: The \n",
      "combination of diet, exercise and behavioural modification is the most effective \n",
      "approach to weight control\n",
      "\n",
      "Chunk 230: Normally low to moderate intensity long duration \n",
      "exercise is recommended for weight loss\n",
      "\n",
      "Chunk 231: \n",
      "¢ The diabetic patient with peripheral neuropathy, loss of protective sensation, and \n",
      "osteoarthritis of back and knee should not engage in repetitive weight bearing \n",
      "exercises, eg\n",
      "\n",
      "Chunk 232: prolonged walking, treadmill, jogging etc\n",
      "\n",
      "Chunk 233: as these activities may \n",
      "result in blistering, ulceration and fracture\n",
      "\n",
      "Chunk 234: Non-weight-bearing exercises, eg\n",
      "\n",
      "Chunk 235: swim- \n",
      "ming, cycling, rowing, etc\n",
      "\n",
      "Chunk 236: may be better\n",
      "\n",
      "Chunk 237: \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HHI! 23 Persons with severe Charcot's joint should avoid weight-bearing exercises, as it can \n",
      "result in multiple fractures and dislocation of the ankles and feet even without the \n",
      "patient being aware of it\n",
      "\n",
      "Chunk 238: \n",
      "In patients who have proliferative and moderate to severe non-proliferative \n",
      "diabetic retinopathy, strenuous activity may precipitate vitreous haemorrhage or \n",
      "tractional retinal detachment\n",
      "\n",
      "Chunk 239: These individuals should avoid anaerobic exercise \n",
      "and physical activity that involves straining, jarring or Valsalva-like maneuvers (eg\n",
      "\n",
      "Chunk 240: \n",
      "weight lifting, boxing, heavy competitive sports etc)\n",
      "\n",
      "Chunk 241: In these persons low impact \n",
      "exercises like swimming (but not diving), walking or stationary cycling may be \n",
      "recommended\n",
      "\n",
      "Chunk 242: \n",
      "Patients with stable coronary heart disease should perform exercise of moderate \n",
      "intensity\n",
      "\n",
      "Chunk 243: Persons with uncontrolled hypertension should withhold exercise until \n",
      "control of blood pressure\n",
      "\n",
      "Chunk 244: \n",
      "If the person develops symptomatic hyperglycemia or ketosis exercise should be \n",
      "postponed\n",
      "\n",
      "Chunk 245: If blood glucose goes below 5.5 mmol/L the person should take extra \n",
      "15-30 grams carbohydrate before exercise\n",
      "\n",
      "Chunk 246: \n",
      "One should not do exercise during any significant acute illness or uncompensated \n",
      "major chronic illnesses\n",
      "\n",
      "Chunk 247: \n",
      "During pregnancy moderate exercise (eg\n",
      "\n",
      "Chunk 248: walking at moderate speed for 30 \n",
      "minutes a day at a time or in divided fashion) is advised\n",
      "\n",
      "Chunk 249: Vigorous exercise or \n",
      "exercises causing pressure in the abdomen should be avoided\n",
      "\n",
      "Chunk 250: \n",
      "  \n",
      "24 ‘88 Diabetes Care: BADAS Guideline 2019 Target of glycemic status should be individualized \n",
      "v v \n",
      "Asymptomatic \n",
      "Symptomatic \n",
      "y \n",
      "v \n",
      "LS+Metformin \n",
      "LS \n",
      "+ \n",
      "Metformin+Sulphonylurea \n",
      "LS \n",
      "+ \n",
      "Insulin \n",
      "LS \n",
      "+ \n",
      "Insulin \n",
      "or \n",
      "other \n",
      "agents \n",
      "(Premix/Basal/Split- \n",
      "(Premix/Basal/Split- \n",
      "mix)t \n",
      "Metformin \n",
      "mix)t \n",
      "Metformin \n",
      "v \n",
      "¥ \n",
      "& & \n",
      "If HbA1c 27% on treatment \n",
      "PUL ryew nT] \n",
      "  \n",
      "4 \n",
      "v \n",
      "SF \n",
      "Add \n",
      "2\" \n",
      "oral \n",
      "agent \n",
      "Add \n",
      "3\" \n",
      "oral \n",
      "agent \n",
      "of \n",
      "Titration \n",
      "and \n",
      "optimization \n",
      "different \n",
      "action \n",
      "different \n",
      "action \n",
      "y \n",
      "Vv \n",
      "y \n",
      "eal Were a ema lag \n",
      "Diabetes Care \n",
      "  \n",
      "y v v \n",
      "© Add \n",
      "3™ \n",
      "oral \n",
      "agent \n",
      "of \n",
      "different \n",
      "action» \n",
      "Add \n",
      "4“ \n",
      "oral \n",
      "agent \n",
      "of \n",
      "different \n",
      "action \n",
      "e \n",
      "Intensification \n",
      "of \n",
      "e \n",
      "Insulin \n",
      "is \n",
      "the \n",
      "best \n",
      "option \n",
      "to \n",
      "add \n",
      "e \n",
      "Insulin \n",
      "is \n",
      "the \n",
      "best \n",
      "option \n",
      "to \n",
      "add \n",
      "Insulin \n",
      "regimen \n",
      "(Premix/ \n",
      "Basal/Split-mix): \n",
      "omit \n",
      "SU \n",
      "(Premix/ \n",
      "Basal/Split-mix): \n",
      "omit \n",
      "SU \n",
      "PUI TITF Yo eP a Lam te] Con \n",
      "If \n",
      "HbA1c \n",
      "29% \n",
      "3 \n",
      "months \n",
      "after \n",
      "initiation \n",
      "of \n",
      "treatment \n",
      "(at \n",
      "any \n",
      "point)- \n",
      "add/start \n",
      "Insulin \n",
      "  *LS— \n",
      "Lifestyle; \n",
      "SU- \n",
      "Sulphonylurea \n",
      "After \n",
      "adding \n",
      "any \n",
      "OAD, \n",
      "uptitrate \n",
      "the \n",
      "dose \n",
      "by \n",
      "1-2-week \n",
      "interval \n",
      "with \n",
      "SMBG \n",
      "Source: Study findings of Changing Diabetes Barometer (CDB), an ongoing research program of BADAS   \n",
      "BADAS Guideline 2019 HEI 25 \n",
      "  \n",
      "  \n",
      "Diabetes management algorithm in uncomplicated, non-pregnant adults with type 2 diabetes (based on glycemic status) \n",
      "FBG \n",
      "<10.0 \n",
      "mmol/I \n",
      "and \n",
      "/or \n",
      "HbA1c \n",
      "FBG \n",
      "10-<14 \n",
      "mmol/| \n",
      "and \n",
      "/or \n",
      "HbA1c \n",
      "8.5- \n",
      "<10 \n",
      "% \n",
      "and \n",
      "FBG \n",
      "214 \n",
      "mmol/l \n",
      "and \n",
      "/or \n",
      "HbAlc \n",
      "210% \n",
      "and \n",
      "/or \n",
      "<8.5%and/or \n",
      "RBG \n",
      "<12mmol/I \n",
      "acme \n",
      "eee \n",
      "nhl \n",
      "RBG \n",
      "218 \n",
      "mmol/l \n",
      "with \n",
      "or \n",
      "without \n",
      "symptoms \n",
      "  \n",
      "Target \n",
      "FBG/ Premeal <7.0 mmol/L \n",
      "2hABF/Post meal <10.0 mmol/L \n",
      "HbAic <7 % \n",
      "| Consider \n",
      "ty \n",
      "[store WANT \n",
      "  \n",
      "Drug treatment fe PEST icles eer\n",
      "\n",
      "Chunk 251: VPLS] \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "      \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "    \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "Class Name Duration of action (hr) | Mode of excretion \n",
      "A\n",
      "\n",
      "Chunk 252: Secretagogues \n",
      "15* generation (Not in use at present) \n",
      "Tolbutamide 6-12 Mostly urine \n",
      "Chlorpropamide 24-72 Urine \n",
      "Sulphonylureas 2\"4 generation \n",
      "Glibenclamide 24 Urine & faeces \n",
      "Glipizide 8-12 Mostly urine \n",
      "Gliclazide 8-12 Urine & faeces \n",
      "Glimepiride 24 Urine & faeces \n",
      "Meglitinide analogue \n",
      "Non-sulphonylureas Repaglinide | 45 | Mostly faeces \n",
      "d-phenylalanine derivative \n",
      "Nateglinide | 45 | Mostly urine \n",
      "B\n",
      "\n",
      "Chunk 253: Insulin sensitizers \n",
      "Biguanides Metformin 8-12 Mostly urine \n",
      "Thiazolidinediones Pioglitazone 24 Urine & faeces \n",
      "Rosiglitazone 24 Urine & faeces \n",
      "C\n",
      "\n",
      "Chunk 254: Alpha-glucosidase inhibitors \n",
      "Acarbose 4 Faeces & urine \n",
      "Miglitol 4 Urine \n",
      "Voglibose NA Mostly faeces \n",
      "D.DPP-4 inhibitors \n",
      "Sitagliptin 24 Mostly urine \n",
      "Vildagliptin 24 Mostly urine \n",
      "Linagliptin 24 Mostly faeces \n",
      "Saxagliptin 24 Urine & faeces \n",
      "Alogliptin 24 Mostly urine \n",
      "E\n",
      "\n",
      "Chunk 255: SGLT-2 inhibitors \n",
      "Dapagliflozin 24 Mostly urine \n",
      "Canagliflozin 24 Mostly faeces \n",
      "Empagliflozin 24 Urine & faeces \n",
      "Ertugliflozin 24 Urine & faeces \n",
      "F\n",
      "\n",
      "Chunk 256: Other agents \n",
      "Dopamine-2 agonists | Bromocriptine 24 Mostly faeces \n",
      "Bile acid sequestrants | Colesevelam 24 Faeces       \n",
      "NB\n",
      "\n",
      "Chunk 257: Various combination preparations are also available\n",
      "\n",
      "Chunk 258: \n",
      "  \n",
      "26 ‘lI Diabetes Care: BADAS Guideline 2019 Selection issues of an oral agent \n",
      "Tay: | \n",
      "Sulphonylureas \n",
      "Advantage \n",
      "Potent; reduce pre- & \n",
      "post-prandial BG \n",
      "Non-sulphonylureas Less hypoglycaemia; \n",
      "reduce post-prandial BG \n",
      "Improve insulin sensitivity; \n",
      "weight friendly ; reduce \n",
      "pre- (mostly) & post- \n",
      "prandial BG; favourable \n",
      "effect on lipid & NAFLD \n",
      "Biguanides \n",
      "Thiazolidinediones Improve insulin sensitivity; \n",
      "reduce pre- (mostly) & post- \n",
      "prandial BG; favourable \n",
      "effect on lipid (pioglitazone) \n",
      "& NAFLD \n",
      "Alpha-glucosidase Weight friendly; reduce \n",
      "inhibitors post-prandial BG \n",
      "DPP-4 inhibitors Weight friendly; reduce \n",
      "pre- & post-prandial \n",
      "(mostly) BG \n",
      "SGLT-2 inhibitors Weight-friendly; reduce \n",
      "pre- & post-prandial BG \n",
      "Weight-friendly; reduce \n",
      "pre- & post-prandial BG; \n",
      "reduce LDL \n",
      "Bile acid sequestrants \n",
      "Weight-friendly; reduce \n",
      "pre- & post-prandial BG; \n",
      "reduce TG \n",
      "Dopamine-2 agonists \n",
      "  \n",
      "NB\n",
      "\n",
      "Chunk 259: NAFLD- Non-alcoholic fatty liver disease \n",
      "eGFR ml/min/1.73m2 \n",
      "  \n",
      "Hazard \n",
      "Hypoglycemia; \n",
      "weight gain \n",
      "Weight gain \n",
      "Gl upset; lactic \n",
      "acidosis \n",
      "Weight gain; fluid \n",
      "retention; IHD & \n",
      "raise LDL \n",
      "(rosiglitazone) \n",
      "Gl upset \n",
      "Gl upset; upper \n",
      "RT|; pancreatitis \n",
      "UTI; genital fungal \n",
      "infection \n",
      "Constipation; \n",
      "increase TG \n",
      "Dizziness; syncope \n",
      "  \n",
      "Ate iiteda) \n",
      "Impaired hepatic, \n",
      "renal function \n",
      "Impaired hepatic, \n",
      "renal function \n",
      "Impaired hepatic \n",
      "function; \n",
      "eGFR <45- avoid; \n",
      "eGFR <30- contraind\n",
      "\n",
      "Chunk 260: \n",
      "ALT > 2.5 times; heart \n",
      "failure \n",
      "Impaired hepatic \n",
      "function; eGFR <30 (excpt \n",
      "voglibose); inflam\n",
      "\n",
      "Chunk 261: bowel \n",
      "disease; malabsorption \n",
      "states \n",
      "Impaired renal \n",
      "function (except \n",
      "linagliptin) \n",
      "Impaired renal \n",
      "function \n",
      "Interfere with \n",
      "absorption of \n",
      "other drugs \n",
      "Impaired hepatic, \n",
      "renal function \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI! 27 Initiation and dose titration of OADs may be done using following table \n",
      "Sea lipases Maximum daily dose Pe ras \n",
      "  \n",
      "Glibenclamide | 1.25-2.5 mg x 1;30 \n",
      "min ac \n",
      "20 mg (in 1-2 doses) \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "Glipizide 2.5 mg x 1;30 min ac 40 mg (in 1-2 doses) Increase by smallest \n",
      "Gliclazide 40 mg x 1;30 min ac 320 mg (in 1-2 doses) dose every 2 weeks \n",
      "MR/ExR-120 mg (in 1 dose) \n",
      "Glimepiride 1mgx1 8 mg (in 1 dose) \n",
      "Repaglinide 0.5 mg x 3;15 min ac 12 mg (in 3 doses) Increase by smallest \n",
      "dose every 1-2 weeks \n",
      "Nateglinide 60 mg x 3;15 min ac 360 mg (in 3 doses) \n",
      "Metformin 500 mg x 1; pc; build 2500 mg (in 2-3 doses) Increase (on the built- \n",
      "up dose weekly ExR-2000 mg (in 1 dose) up) by smallest dose \n",
      "every 4 weeks \n",
      "Pioglitazone 15 mg x 1,morning 45 mg (in 1 dose) Increase by smallest \n",
      "  \n",
      "Rosiglitazone 4mg x1(or 2 mg x 2) 8 mg (in 1-2 doses) \n",
      "dose every 4-6 weeks \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "Acarbose 25-50 mg x 1-3; 300 mg (in 3 doses) Increase (on the built- \n",
      "Miglitol within meal; build up up) by smallest \n",
      "dose weekly dose every 6 week \n",
      "Voglibose 0.2 mg x 1-3; pc 0.9 mg (in 3 doses) \n",
      "Sitagliptin 100 mg x 1,morning 100 mg (in 1 dose) eGFR <50- 50 mg/day \n",
      "eGFR <30- 25 mg/day \n",
      "Vildagliptin 50mg x2 100 mg (in 2 doses) eGFR <50- 50 mg/day \n",
      "Linagliptin 5 mg x 1,morning 5 mg (in 1 dose) Full dose in renal \n",
      "impairment \n",
      "Saxagliptin 2.5 mg x 1,morning 5 mg (in 1 dose) eGFR <50- 2.5 mg/day \n",
      "Alogliptin 25mg x 1,morning 25 mg (in 1 dose) eGFR <60- 12.5 mg/day \n",
      "eGFR<30- 6.25 mg/day \n",
      "Dapagliflozin 5 mg x 1,morning 10 mg (in 1 dose) eGFR <60- avoid \n",
      "eGFR <30- contraind \n",
      "Canagliflozin 100 mg x 1, morning 300 mg (in 1 dose) eGFR <60- 100 mg \n",
      "eGFR <45- avoid \n",
      "eGFR <30- contraind \n",
      "Empagliflozin 10 mg x 1,morning 25 mg (in 1 dose) eGFR <45- avoid \n",
      "eGFR <30- contraind \n",
      "Ertugliflozin 5 mg x 1,morning 15 mg (in 1 dose) eGFR <60-avoid \n",
      "eGFR <30-contraind         \n",
      "NB\n",
      "\n",
      "Chunk 262: ac- before meal; pc- after meal\n",
      "\n",
      "Chunk 263: \n",
      "eGFR ml/min/1.73 m2\n",
      "\n",
      "Chunk 264: \n",
      "  \n",
      "28 lll Diabetes Care: BADAS Guideline 2019 Classification of insulin \n",
      "Insulin type Onset TLC) PVE Li «:) \n",
      "  \n",
      "Bolus (prandial) insulins \n",
      "Rapid-acting insulin analogues \n",
      "* Insulin Aspart \n",
      "* Insulin Glulisine \n",
      "* Insulin Lispro \n",
      "Short-acting (Regular) insulins \n",
      "Basal insulins \n",
      "Intermediate-acting (NPH) \n",
      "Long-acting insulin analogues \n",
      "* Insulin Detemir \n",
      "* Insulin Glargine \n",
      "* Insulin Degludec \n",
      "Premix insulins \n",
      "* Biphasic Human Insulin \n",
      "* Biphasic Insulin Aspart \n",
      "* Insulin Lispro + Insulin Lispro \n",
      "Protamine \n",
      "Coformulation \n",
      "* Insulin Degludec + \n",
      "Insulin Aspart   \n",
      "of action \n",
      "10-15 min \n",
      "10-15 min \n",
      "10-15 min \n",
      "30 min \n",
      "1-3 hours \n",
      "90 min \n",
      "90 min \n",
      "30 mins \n",
      "10-20 mins \n",
      "10-20 mins \n",
      "30-90 mins \n",
      "10-20 min \n",
      "NB\n",
      "\n",
      "Chunk 265: Inhaled rapid acting insulin is also available \n",
      "Insulin regimens \n",
      "  \n",
      "1-1.5 hour \n",
      "1-1.5 hour \n",
      "1-2 hour \n",
      "2-3 hours \n",
      "5-8 hours \n",
      "N/A \n",
      "N/A \n",
      "2-8 hours \n",
      "1-4 hours \n",
      "1-4 hours \n",
      "NA \n",
      "40-90 min   \n",
      "of action \n",
      "3-5 hours \n",
      "3-5 hours \n",
      "3.5-4.75 hours \n",
      "6.5 hours \n",
      "Upto 18 hours \n",
      "24 hours \n",
      "24 hours \n",
      "42 hours \n",
      "Upto 24 hours \n",
      "Upto 24 hours \n",
      "Upto 24 hours \n",
      "Beyond 24 hours \n",
      "  \n",
      "Clear \n",
      "Clear \n",
      "Clear \n",
      "Clear \n",
      "Cloudy \n",
      "Clear \n",
      "Clear \n",
      "Clear \n",
      "Cloudy \n",
      "Cloudy \n",
      "Cloudy \n",
      "Clear \n",
      "Regimen pre ttt) \n",
      "NPH or basal analogue Once daily \n",
      "Twice daily \n",
      "* Premixed \n",
      "* Coformulation \n",
      "* Split-mixed \n",
      "Multiple daily injections \n",
      "+ Basal Plus \n",
      "* Basal bolus \n",
      "Continuous subcutaneous \n",
      "insulin infusion   \n",
      "Less mealtime flexibility \n",
      "Offers more mealtimeflexibility \n",
      "One long acting analogue at bedtime, plus one injection of \n",
      "rapid acting analogue with the largest meal \n",
      "One long acting analogue at bedtime, plus two or three \n",
      "injections of rapid acting analogue with meal \n",
      "Insulin pump \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI! 29 Continuous subcutaneous insulin infusion (CSII) \n",
      "An insulin pump is an alternative to treatment with MDI.The pump is worn at waist \n",
      "or other convenient places, and insulin is delivered through tube into \n",
      "subcutaneous needle placed over abdomen\n",
      "\n",
      "Chunk 266: Basal insulin is delivered continuously, \n",
      "and the bolus dose is person-activated\n",
      "\n",
      "Chunk 267: Rapid acting insulin analogues are usually \n",
      "used in these devices, both as basal as well as bolus dose\n",
      "\n",
      "Chunk 268: \n",
      "Sensor-augmented pumps are provided with CGM system\n",
      "\n",
      "Chunk 269: Newer generation \n",
      "pumps automatically shut-off to prevent hypoglycemia when the sensor has fallen \n",
      "below a preset threshold\n",
      "\n",
      "Chunk 270: The newer smart pumps can automatically calculate meal \n",
      "or correction boluses based on_ insulin-to-carbohydrate ratios and_ insulin \n",
      "sensitivity factors\n",
      "\n",
      "Chunk 271: \n",
      "rear Ei Cm um (eel Crliiimelrlraiels (ie) \n",
      "  \n",
      "GLP-1 agonists Exenatide | Type 2 DM; weight-friendly; 10 ug (in 2 doses) ac within 1 hr of \n",
      "meal; increase dose after 4 weeks (max\n",
      "\n",
      "Chunk 272: 20 ug/day) \n",
      "  \n",
      "Liraglutide} Type 2 DM;weight-friendly; 0.6 mg daily, increase to 1.2 mg after \n",
      "1 week; max\n",
      "\n",
      "Chunk 273: dose 1.8 mg \n",
      "  \n",
      "Albiglutide, dulaglutide, lixisenatide, semaglutide are available\n",
      "\n",
      "Chunk 274: \n",
      "Combinations of long acting insulin analogue and GLP-1RA are also available\n",
      "\n",
      "Chunk 275: \n",
      "  \n",
      "Amylin analogues | Pramlintide) Weight-friendly; use with insulin; immediate ac\n",
      "\n",
      "Chunk 276: \n",
      "Type 1 DM: 15 ug x 3; increase dose after 7 days (max. 60 x 3) \n",
      "Type 2 DM:60 ug x 3; increase dose after 7 days (max\n",
      "\n",
      "Chunk 277: 120 x 3)     \n",
      "NB\n",
      "\n",
      "Chunk 278: ac- before meal \n",
      "Monitoring and changing treatment regimen \n",
      "Blood glucose testing \n",
      "Self monitoring of blood glucose (SMBG) by glucometer is to be done frequently \n",
      "(covering pre-meal, post-meal and critical periods) in persons who are on multiple \n",
      "dose insulin regimen or insulin pump, specially in type 1 diabetes and pregnancy\n",
      "\n",
      "Chunk 279: \n",
      "For others it is to be done as required according to clinical situations\n",
      "\n",
      "Chunk 280: Continuous \n",
      "glucose monitoring (CGM) can be used in selected persons\n",
      "\n",
      "Chunk 281: Blood glucose \n",
      "monitoring guide to the changes of the doses of drugs\n",
      "\n",
      "Chunk 282: This education should be \n",
      "given to the patient for self-management\n",
      "\n",
      "Chunk 283: \n",
      "  \n",
      "30 I Diabetes Care: BADAS Guideline 2019 HbA1c \n",
      "Glycated hemoglobins are formed by non-enzymatic condensation of glucose \n",
      "with globin component of hemoglobin\n",
      "\n",
      "Chunk 284: This generally reflects glycemic status over \n",
      "the preceding 2-3 months\n",
      "\n",
      "Chunk 285: RBC turnover (blood loss, hemolysis, blood transfusion, \n",
      "pregnancy etc.) and hemoglobin variants must be considered while testing HbA1c\n",
      "\n",
      "Chunk 286: \n",
      "HbA1c guides change in therapeutic regimen\n",
      "\n",
      "Chunk 287: \n",
      "A1C test should be done at least two times a year in patients who are meeting \n",
      "treatment goals (and who have stable glycemic control). \n",
      "A1C test is to be done quarterly in patients whose therapy has changed or \n",
      "who are not meeting glycemic goals\n",
      "\n",
      "Chunk 288: \n",
      "More stringent A1C goals may be set for selected individuals if this can be \n",
      "achieved without significant hypoglycemia or other adverse effects of \n",
      "treatment (i.e\n",
      "\n",
      "Chunk 289: polypharmacy), e.g\n",
      "\n",
      "Chunk 290: those with short duration of diabetes, type \n",
      "2 diabetes treated with lifestyle or metformin only, long life expectancy, or no \n",
      "significant cardiovascular disease\n",
      "\n",
      "Chunk 291: \n",
      "Less stringent A1C goals may be appropriate for persons with history of \n",
      "severe or repeated hypoglycemia, hypoglycemia unawareness, limited life \n",
      "expectancy, advanced microvascular or macrovascular complications, \n",
      "extensive comorbid conditions, or long-standing diabetes in whom the goal is \n",
      "difficult to achieve despite diabetes self-management education, appropriate \n",
      "glucose monitoring, and effective doses of multiple glucose-lowering agents \n",
      "including insulin\n",
      "\n",
      "Chunk 292: \n",
      "References \n",
      "Diabetes Mellitus, Distance Learning Program, 5th edition, BADAS, 2018\n",
      "\n",
      "Chunk 293: \n",
      "Standards of Medical care in Diabetes, ADA (American Diabetes Association), 2019\n",
      "\n",
      "Chunk 294: \n",
      "Comprehensive Type 2 Diabetes Management Algorithm, AACE (American \n",
      "Association of Clinical Endocrinologists) Task Force, 2019\n",
      "\n",
      "Chunk 295: \n",
      "Global Guideline for Type 2 Diabetes, Clinical Guidelines Task Force, IDF \n",
      "(International Diabetes Federation), 2012\n",
      "\n",
      "Chunk 296: \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI!) 31 Chapter 4 \n",
      "Acute Complications of Diabetes Mellitus \n",
      "4.1 Hypoglycemia \n",
      "It is defined biochemically with blood glucose level below 3.9 mmol/L (70 mg/dl) \n",
      "with clinical features of autonomic over activity and neuroglycopenia\n",
      "\n",
      "Chunk 297: \n",
      "Some diabetics, especially those with persistent high blood glucose, may develop \n",
      "clinical features (particularly autonomic) of hypoglycemia at a higher blood \n",
      "glucose level\n",
      "\n",
      "Chunk 298: It occurs more in Type 1 than Type 2 diabetes\n",
      "\n",
      "Chunk 299: \n",
      "Levels of hypoglycemia \n",
      "Level 1: blood glucose <3.9 mmol/L - 3.0 mmol/L \n",
      "Level 2: blood glucose <3.0 mmol/L \n",
      "Level 3: A severe event characterized by altered mental and/or physical status \n",
      "requiring assistance \n",
      "Causes of hypoglycemia \n",
      "* Taking excess dose of insulin \n",
      "* Excess intake of anti-diabetic medications, specially insulin secretagogues \n",
      "* Delay, omission or undue reduction of a meal \n",
      "* Unusual exercise \n",
      "* Over intake of alcohol \n",
      "* Severe renal or hepatic impairment \n",
      "Consequences of hypoglycemia \n",
      "* Recurrent hypoglycemia may cause behavioral change and cognitive \n",
      "impairment \n",
      "* In Type 2 diabetes - increased incidence of life-threatening cardiovascular \n",
      "events and mortality (cardiovascular and all cause) \n",
      "* InType 1 diabetes - increased mortality (4-10% of deaths) \n",
      "Hypoglycemia unawareness \n",
      "Occurs in individuals with long standing type 1 diabetes, autonomic neuropathy, \n",
      "medications (like non-selective beta-blockers), or very tight glycemic control\n",
      "\n",
      "Chunk 300: \n",
      "Nocturnal hypoglycemia occurs at night, usually between 11pm and 5 am\n",
      "\n",
      "Chunk 301: \n",
      "32 (IIE Diabetes Care: BADAS Guideline 2019 Clinical features of hypoglycemia \n",
      "Clinical features of hypoglycemia according to severity \n",
      "Types of features Severity of hypoglycemia \n",
      "Mild to moderate Severe \n",
      "Level 1 Level 2,3 \n",
      "Autonomic Sweating, palpitation, tremor, \n",
      "irritability, hunger\n",
      "\n",
      "Chunk 302: \n",
      "Neuroglycopenic Headache, visual disturbance Confusion, drowsiness, \n",
      "behavioral abnormality \n",
      "convulsion, coma \n",
      "Treatment of hypoglycemia \n",
      "Level 1: Mild to moderate hypoglycemia \n",
      "* Treated by the patient him/herself or by a family member \n",
      "* — It is usually relieved by 15 gm glucose or equivalent food, e.g\n",
      "\n",
      "Chunk 303: a glass of soft \n",
      "drink or fruit juice or snacks or meal (if it is due)\n",
      "\n",
      "Chunk 304: These measures are usually \n",
      "adequate to raise blood glucose to reasonably safe limit (5.5 mmol/L)\n",
      "\n",
      "Chunk 305: \n",
      "* The food/drink is repeated every 15 minutes until the patient is stable\n",
      "\n",
      "Chunk 306: \n",
      "* If recurrent hypoglycemia follows, hospitalization should be considered\n",
      "\n",
      "Chunk 307: \n",
      "* Modification in ongoing treatment should be considered\n",
      "\n",
      "Chunk 308: \n",
      "Level 2,3: Severe hypoglycemia \n",
      "* 100 ml of 25% dextrose is given intravenously under medical supervision\n",
      "\n",
      "Chunk 309: \n",
      "* — If hypoglycemia is due to longer acting anti-diabetic medications then 10% \n",
      "dextrose infusion should be started to prevent recurrent hypoglycemia\n",
      "\n",
      "Chunk 310: \n",
      "* Ongoing activity of the anti-diabetic medication may lead to recurrence of \n",
      "hypoglycemia.Hence, food ingestion is to be ensured after initial recovery\n",
      "\n",
      "Chunk 311: \n",
      "* — If recovery does not occur, addressing additional causes and modification in \n",
      "treatment should be done\n",
      "\n",
      "Chunk 312: \n",
      "* In person with type 1 diabetes, glucagon 1 mg intramuscularly or subcutane- \n",
      "ously can be given\n",
      "\n",
      "Chunk 313: \n",
      "* Patient with severe hypoglycemia may need to keep under supervission in \n",
      "hospital\n",
      "\n",
      "Chunk 314: \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HE 33 Hypoglycemia unawareness \n",
      "* Frequent blood glucose should be monitored to prevent hypoglycemia\n",
      "\n",
      "Chunk 315: \n",
      "* Each patient with hypoglycemia should be evaluated and provided with \n",
      "appropriate education to prevent and manage future episodes\n",
      "\n",
      "Chunk 316: \n",
      "Nocturnal hypoglycemia \n",
      "* Reduction of evening dose of insulin \n",
      "* Changing time of evening insulin dose with dinner time \n",
      "* Taking bed time snacks may be considered \n",
      "* These adjustments are made in conjunction with blood glucose monitoring \n",
      "4.2 Diabetic ketoacidosis (DKA) \n",
      "Diabetic ketoacidosis (DKA) is a medical emergency in diabetic patients\n",
      "\n",
      "Chunk 317: It is \n",
      "commonly found in type1 diabetes but it also occurs in other types of diabetes \n",
      "during stressful situations\n",
      "\n",
      "Chunk 318: It results from lack of insulin and an increase in \n",
      "counter-regulatory hormones that lead to hyperglycemia and subsequent lipolysis\n",
      "\n",
      "Chunk 319: \n",
      "Precipitating factors \n",
      "Common precipitating factors \n",
      "* — Intercurrent Infection \n",
      "* Discontinuation of insulin therapy \n",
      "* Inadequate insulin therapy \n",
      "* Pancreatitis, myocardial infarction, cerebrovascular accident, pulmonary \n",
      "embolism \n",
      "* Stressful conditions like trauma, pregnancy \n",
      "* New-onset type 1 diabetes \n",
      "Clinical features \n",
      "* Develops rapidly (hours to days) \n",
      "* Symptoms of uncontrolled diabetes precedes \n",
      "* Dehydration is the most obvious clinical feature with dry skin and tongue, low \n",
      "BP, rapid weak pulse \n",
      "* Acidotic breathing is characteristic; there may be acetone smell in breath \n",
      "* Weakness, vomiting, impairment of level of consciousness, acute abdomen are \n",
      "also found \n",
      "  \n",
      "34 (IIB Diabetes Care: BADAS Guideline 2019 4.3 Hyperglycemic hyperosmolar state (HHS) \n",
      "HHS is a combination of severe degree of hyperglycemia, dehydration and \n",
      "hyperosmolality without significant ketonuria, usually seen as complication of \n",
      "elderly type 2 diabetes patients\n",
      "\n",
      "Chunk 320: Here residual insulin reserve prevents ketosis\n",
      "\n",
      "Chunk 321: \n",
      "Precipitating factors of HHS: Similar as DKA\n",
      "\n",
      "Chunk 322: \n",
      "Others are \n",
      "* Compromised fluid intake \n",
      "* Drugs, eg glucocorticoids, diuretics etc \n",
      "Clinical features \n",
      "* Develops slowly (days to weeks) \n",
      "* Symptoms of uncontrolled diabetes precede \n",
      "* Dehydration is profound \n",
      "* Impairment of consciousness is common \n",
      "  \n",
      "Diagnostic criteria for DKA and HHS \n",
      "Mild Moderate Severe \n",
      "BG >13.8 mmol/L >13.8 mmol/L >13.8 mmol/L >33.3 mmol/L \n",
      "Arterial PH 7.25-7.30 7.00-<7.24 <7.00 >7.30 \n",
      "S\n",
      "\n",
      "Chunk 323: bicarbonate mEq/L 15-18 10-<15 <10 >18 \n",
      "Urine ketone Positive Positive Positive Small \n",
      "Effective serum Variable Variable Variable >320 mOsm/kg \n",
      "osmolality \n",
      "Anion gap >10 >12 >12 Variable \n",
      "Mental status Alert Alert/ drowsy Stupor/coma Stupor/coma \n",
      "        \n",
      "NB: Effective serum osmolality: 2 [measured Nat (mEq/L) + Glucose (mmol/L); Anion Gap: (Na*) \n",
      "-[Cl + HCO3 (mEq/L)] \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI 35 Protocol for management of adult person with DKA or HHS\n",
      "\n",
      "Chunk 324: \n",
      "Initial Evaluation \n",
      "* Check blood glucose/capillary glucose, serum/urine ketones: to confirm \n",
      "hyperglycemia and ketonemia/ketonuria\n",
      "\n",
      "Chunk 325: \n",
      "* Obtain blood for metabolic profile\n",
      "\n",
      "Chunk 326: \n",
      "* Start IV fluids: As per protocol\n",
      "\n",
      "Chunk 327: \n",
      "IV Fluid Protocol \n",
      "WATT Ey \n",
      "Phen \n",
      "  \n",
      "Severe hypovolemia Mild dehydration Cardiogenic shock \n",
      "Administer 0.9% NaCl Corrected serum Na Hemodynamic monitor \n",
      "1.0 L/ hr Use of pressors \n",
      "Serum Na high / Serum Na normal Serum Na low \n",
      "0.45% NaCl (250-500 ml/hr)As per hydration status 0.9% NaCl (250 -500 ml/hr) \n",
      "| As per hydration status \n",
      "When serum glucose is 11.1 mmol/L (DKA) or 16.7 mmol/L (HHS), change to 5% dextrose \n",
      "with 0.45% NaCl at 150-250 ml/hr \n",
      "N.B.: Corrected Na for hyperglycemia= measured Na + [1.6 (Glucose in mg/dl— 100) / 100] \n",
      "  \n",
      "36 ll Diabetes Care: BADAS Guideline 2019 Potassium & bicarbonate \n",
      "eee ia) \n",
      "Establish adequate renal function \n",
      "(urine output around 50 ml/hr) \n",
      "  \n",
      "K+<3.3 mEq/L K+ = 3.3- 5.2mEq/L Kt>5.2mEq/L \n",
      "4 4 4 \n",
      "Hold insulin and Administer 20-30 Administer 20-30 mEqKineach — Do not give K*, check K* every \n",
      "mEq/hr K* until Kt>3.3 mEq/L litre of IV fluids\n",
      "\n",
      "Chunk 328: 2 hourly\n",
      "\n",
      "Chunk 329: \n",
      "Target K*= 4-5 mEq/L \n",
      "Bicarbonate \n",
      "pH 26.9 pH <6.9 \n",
      "No HCOs 100 mmol in 400 ml H20 + 20 mEq \n",
      "KCL, infuse for 2 hours \n",
      "Repeat every 2 hours until pH = \n",
      "7.Monitor K every 2 hrs \n",
      "Insulin protocol \n",
      "PE Lara atte mre ace eh egal bY) \n",
      "0.1 U/kg\n",
      "\n",
      "Chunk 330: B.Wt\n",
      "\n",
      "Chunk 331: as IV bolus 0.14 U/kg\n",
      "\n",
      "Chunk 332: B.Wt./hr as IV continuous insulin infusion \n",
      "g \n",
      "0.1 U/kg\n",
      "\n",
      "Chunk 333: B.Wt/hr IV continuous insulin \n",
      "If serum glucose does not fall by at least 10% in first hour, give 0.14 U/kg as IV bolus, then continue \n",
      "J previous treatment\n",
      "\n",
      "Chunk 334: y \n",
      "DKA HHS \n",
      "When serum glucose reaches 11.1 mmol/L, reduce When serum glucose reaches 16.7 mmol/L, \n",
      "infusion rate to 0.02-0.05 U/kg/hr IV\n",
      "\n",
      "Chunk 335: Target BG is in reduce infusion rate to 0.02-0.05 U/kg/hr IV\n",
      "\n",
      "Chunk 336: \n",
      "between 8.33-11.1 mmol/L until resolution of DKA\n",
      "\n",
      "Chunk 337: Target BG is in between 11.1- 16.7 mmol/L until \n",
      "patient is mentally alert\n",
      "\n",
      "Chunk 338: \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HE) 37 Other evaluations \n",
      "Serum electrolyte, BUN, venous pH, creatinine and glucose should be \n",
      "checked 2 hourly until resolution of the crisis\n",
      "\n",
      "Chunk 339: \n",
      "After resolution of DKA/HHS and person is able to eat, SC multidose insulin \n",
      "should be initiated\n",
      "\n",
      "Chunk 340: Subcutaneous insulin should be started at least 1-2 hour \n",
      "before stopping IV insulin\n",
      "\n",
      "Chunk 341: \n",
      "Precipitating cause should be addressed\n",
      "\n",
      "Chunk 342: \n",
      "Criteria for improvement of DKA \n",
      "Ay FF YN \n",
      "No dehydration \n",
      "No vomiting \n",
      "Able to take food \n",
      "No ketone in urine \n",
      "Anion gap normal \n",
      "Patient is well oriented, hemodynamically stable \n",
      "References \n",
      "1\n",
      "\n",
      "Chunk 343: American Diabetes Association’s Standards of Medical Care in Diabetes-2019\n",
      "\n",
      "Chunk 344: \n",
      "Diabetes Care 2018; 42(Suppl\n",
      "\n",
      "Chunk 345: 1):S1-S194\n",
      "\n",
      "Chunk 346: \n",
      "Bangladesh Endocrine Society Insulin guideline 2018\n",
      "\n",
      "Chunk 347: http://bes-org.net/ \n",
      "wp-content/ uploads/2019/03/Insulin%20Guideline.pdf \n",
      "Diabetes Mellitus\n",
      "\n",
      "Chunk 348: Diabetic Association of Bangladesh\n",
      "\n",
      "Chunk 349: 5th ed 2018\n",
      "\n",
      "Chunk 350: \n",
      "Kitabchi AE, UmpierrezGE, MilesJM, Fisher JN\n",
      "\n",
      "Chunk 351: Hyperglycemic crises in adult \n",
      "patients with diabetes\n",
      "\n",
      "Chunk 352: Diabetes Care 2009:32(7):1335-1343\n",
      "\n",
      "Chunk 353: \n",
      "https://www.aacc.org/community/aacc-academy/publications/scientific-shorts/ \n",
      "2013/correcting-serum-or-plasma-sodium-for-hyperglycemia-should-labs-repo \n",
      "rt-a-corrected-sodium \n",
      "  \n",
      "38 {IN Diabetes Care: BADAS Guideline 2019 Chapter 5 \n",
      "Chronic Complications of Diabetes Mellitus \n",
      "Chronic complications of diabetes encompass a wide spectrum of microvascular \n",
      "(nephropathy, retinopathy and neuropathy) and macrovascular (coronary artery \n",
      "disease, cerebrovascular disease and peripheral vascular disease) disorders\n",
      "\n",
      "Chunk 354: \n",
      "5.1 Diabetic nephropathy \n",
      "It is a specific form of micro-angiopathy of kidney which is characterized by \n",
      "* Persistent loss of albumin in urine (albuminuria) \n",
      "* Progressive renal insufficiency (declining eGFR) with or without hypertension \n",
      "Albuminuria \n",
      "Albumin-to-creatinine ratio (ACR) is the preferred method to detect elevated \n",
      "protein in urine\n",
      "\n",
      "Chunk 355: The recommended method to evaluate albuminuria is to measure \n",
      "urinary ACR in a spot urine sample (preferably morning fasting sample before \n",
      "exercise)\n",
      "\n",
      "Chunk 356: \n",
      "ACR is calculated by dividing albumin concentration in milligrams by creatinine \n",
      "concentration in grams\n",
      "\n",
      "Chunk 357: \n",
      "* — Normal: ACR <30 mg/g, normal to mildly increased\n",
      "\n",
      "Chunk 358: \n",
      "* Microalbuminuria: ACR 30-300 mg/g, moderately increased albuminuria. \n",
      "* Macroalbuminuria: ACR >300 mg/g, severely increased albuminuria\n",
      "\n",
      "Chunk 359: \n",
      "Table: Albuminuria categories in CKD\n",
      "\n",
      "Chunk 360: \n",
      "Albuminuria categories in CKD \n",
      "  \n",
      "Category ACR(mg/g) Terms \n",
      "Al <30 Normal to mildly increased \n",
      "A2 30-300 Moderately increased* \n",
      "A3 >300 Severely increased** \n",
      "*Relative to young adult level\n",
      "\n",
      "Chunk 361: ACR 30-300 mg/g for >3 months indicates CKD\n",
      "\n",
      "Chunk 362: \n",
      "**Including nephrotic syndrome (albumin excretion ACR > 2220 mg/g) \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI) 39 Stages of CKD by eGFR \n",
      "  \n",
      "Stages Description eGFR (ml/minute/1.73m7) \n",
      "1 Renal damage + normal or raised GFR 290 \n",
      "2 Renal damage + mildly decreased GFR 60 to 89 \n",
      "3 Moderately decreased GFR 30 to 59 \n",
      "4 Severely decreased GFR 15 to 29 \n",
      "5 Kidney failure <15 or on dialysis \n",
      "Screening and follow up \n",
      "* Full clinical check-up during each visit, specially blood pressure, pedal edema \n",
      "etc\n",
      "\n",
      "Chunk 363: \n",
      "* Urinary albumin excretion (UAE) and eGFR/CCr estimation\n",
      "\n",
      "Chunk 364: Two of three \n",
      "samples of UAE should be abnormal in 3-6 months\n",
      "\n",
      "Chunk 365: \n",
      "* Blood urea, creatinine, total protein, serum albumin, electrolytes, uric acid, \n",
      "Ca++, PO, estimation\n",
      "\n",
      "Chunk 366: \n",
      "* Serum creatinine and eGFR should be measured at least annually\n",
      "\n",
      "Chunk 367: Otherwise \n",
      "screening and follow-up with only urine albumin will miss >20% of progressive \n",
      "renal disease\n",
      "\n",
      "Chunk 368: \n",
      "* Monitoring of other urinary complications eg UTI (including asymptomatic), \n",
      "bladder dysfunction (autonomic bladder) etc\n",
      "\n",
      "Chunk 369: \n",
      "* Monitoring by sonography - kidney size, progressive increase in echogenicity \n",
      "of cortex\n",
      "\n",
      "Chunk 370: \n",
      "* Renal biopsy - is indicated in nephropathy in absence of retinopathy, heavy \n",
      "proteinuria, rapid unexplained deterioration of renal function etc\n",
      "\n",
      "Chunk 371: \n",
      "* Consultation from nephrologist at appropriate time\n",
      "\n",
      "Chunk 372: \n",
      "Treatment \n",
      "* Good glycemic control reduces incidence of diabetic nephropathy and delays \n",
      "its progression\n",
      "\n",
      "Chunk 373: \n",
      "* Control of hypertension is very important because uncontrolled hypertension \n",
      "causes rapid progression of diabetic nephropathy\n",
      "\n",
      "Chunk 374: Nephropathy itself makes \n",
      "hypertension refractory to anti-hypertensive drugs, thus necessitates intensive \n",
      "and combination regimens\n",
      "\n",
      "Chunk 375: Target of BP is <130/80 mm of Hg\n",
      "\n",
      "Chunk 376: \n",
      "* ACE inhibitors and ARBs are drugs of first choice to reduce or revert \n",
      "nephropathy\n",
      "\n",
      "Chunk 377: But these two drugs must not be combined\n",
      "\n",
      "Chunk 378: Check electrolytes \n",
      "and creatinine 2 weeks after starting\n",
      "\n",
      "Chunk 379: \n",
      "  \n",
      "40 l§N Diabetes Care: BADAS Guideline 2019 Protein intake up to 0.8 gm/kg/day of ideal body weight may be appropriate in \n",
      "advanced kidney disease, but not in early nephropathy\n",
      "\n",
      "Chunk 380: \n",
      "Correct high phosphate, uric acid\n",
      "\n",
      "Chunk 381: \n",
      "Fluid and electrolyte balance should be maintained\n",
      "\n",
      "Chunk 382: \n",
      "Iron supplementation often fails to correct anemia in renal failure\n",
      "\n",
      "Chunk 383: Iron along \n",
      "with erythropoietin provide optimum response\n",
      "\n",
      "Chunk 384: \n",
      "Treat infection, care urinary flow\n",
      "\n",
      "Chunk 385: \n",
      "Check HBsAg and anti-HCV and if negative vaccination against HBV is required\n",
      "\n",
      "Chunk 386: \n",
      "Renal replacement therapy: Should start earlier (eGFR 15 ml/min unlike 10 \n",
      "ml/min in non-diabetic) because most patients with ESRD have severe organ \n",
      "involvement and fluid overload which are often difficult to treat\n",
      "\n",
      "Chunk 387: A-V fistula \n",
      "should be done at appropriate time\n",
      "\n",
      "Chunk 388: \n",
      "Renal replacement therapy includes dialysis and renal transplantation\n",
      "\n",
      "Chunk 389: \n",
      "Dialysis comprises hemodialysis and peritoneal dialysis (intermittent or \n",
      "continuous ambulatory peritoneal dialysis)\n",
      "\n",
      "Chunk 390: \n",
      "Renal transplantation comprises only kidney transplantation and dual \n",
      "transplantation of pancreas with kidney\n",
      "\n",
      "Chunk 391: \n",
      "Referral criteria \n",
      "Patients should be referred to nephrologist if they have: \n",
      "An eGFR<30 mL/min/1.73 m2 \n",
      "Uncertainty about the etiology of kidney disease \n",
      "Difficult management issues \n",
      "Rapidly progressing kidney disease \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI! 41 Decision making path \n",
      "Diabetic person \n",
      "Kidney function tests \n",
      "O atdiagnosis and then once a year in type 2 diabetes \n",
      "0 yearly at or after 5 years (or earlier) of diagnosis in type1 \n",
      "diabetes \n",
      "Screening tests \n",
      "Urinary albumin and serum creatinine \n",
      "Evidence of nephropathy \n",
      "(with classification) \n",
      "1\n",
      "\n",
      "Chunk 392: Establish and maintain HbA1c <7% \n",
      "2\n",
      "\n",
      "Chunk 393: Treat hypertension and maintain BP <130/80 mm of Hg \n",
      "3\n",
      "\n",
      "Chunk 394: Look for other micro-angiopathies \n",
      "Referral to nephrologist \n",
      "if the CKD is in stage 4 or rapidly declining renal function \n",
      "  \n",
      "42 ‘88 Diabetes Care: BADAS Guideline 2019 5.2 Diabetic retinopathy \n",
      "Classification of diabetic retinopathy \n",
      "  \n",
      "Names of diabetic retinopathy Characteristic lesions \n",
      "Early non-proliferative diabetic retinopathy Microaneurysm, dot & blot hemorrhage, hard \n",
      "(NPDR) exudate\n",
      "\n",
      "Chunk 395: \n",
      "Moderate to severe non-proliferative diabetic | Cotton wool spots/soft exudate, venous beads & \n",
      "retinopathy (NPDR) loops, intraretinal microvascular abnormalities \n",
      "(IRMA) \n",
      "Neovascularization of disc (NVD), Proliferative diabetic retinopathy (PDR) \n",
      "Neovascularization elsewhere (NVE), vitreous \n",
      "hemorrhage, tractional retinal hemorrhage\n",
      "\n",
      "Chunk 396: \n",
      "Maculopathy Edema, exudate or hemorrhage in and around \n",
      "macula\n",
      "\n",
      "Chunk 397: \n",
      "Screening and follow-up \n",
      "* Person with type 1 diabetes: an initial dilated, comprehensive eye examination \n",
      "by an ophthalmologist or optometrist within 5 years after of diagnosis and \n",
      "then annually\n",
      "\n",
      "Chunk 398: If retinopathy is progressing or sight-threatening, then \n",
      "examinations should be done frequently\n",
      "\n",
      "Chunk 399: \n",
      "* Person with type 2 diabetes: an initial dilated, comprehensive eye examination \n",
      "by an ophthalmologist or optometrist at the time of the diabetes diagnosis and \n",
      "then annually\n",
      "\n",
      "Chunk 400: If retinopathy is progressing or sight-threatening, then \n",
      "examinations should be done frequently\n",
      "\n",
      "Chunk 401: \n",
      "* Women with preexisting type 1 or type 2 diabetes: if planning pregnancy, \n",
      "should have screening for retinopathy before pregnancy\n",
      "\n",
      "Chunk 402: If pregnant, should \n",
      "have eye examination every trimester\n",
      "\n",
      "Chunk 403: \n",
      "* Retinal Photography is not a substitute for a comprehensive eye examination\n",
      "\n",
      "Chunk 404: \n",
      "¢ Referred to ophthalmologist when required\n",
      "\n",
      "Chunk 405: \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI) 43 Decision making path \n",
      "Diabetic person \n",
      "Eye examination \n",
      "O atdiagnosis and then once a year in type 2 diabetes \n",
      "Os »yearly at or after 5 years (or earlier) of diagnosis in type 1 diabetes \n",
      "(when no retinopathy is documented) \n",
      "Ophthalmoscopy of dilated eye \n",
      "with fundus photo when needed \n",
      "Evidence of retinopathy \n",
      "(with classification) \n",
      "1\n",
      "\n",
      "Chunk 406: Establish and maintain HbA1c <7% \n",
      "2\n",
      "\n",
      "Chunk 407: Treat hypertension and maintain BP <130/80 mm of Hg \n",
      "3\n",
      "\n",
      "Chunk 408: Look for other micro-angiopathies \n",
      "Referral to ophthalmologist \n",
      "if the retinopathy is beyond early NPDR \n",
      "  \n",
      "44 ‘lI Diabetes Care: BADAS Guideline 2019 5.3 Diabetic neuropathy \n",
      "Screening \n",
      "* Assessment \n",
      "* Starting at diagnosis of type 2 diabetes \n",
      "* 5years after the diagnosis of type 1 diabetes \n",
      "¢ Atleast annually thereafter \n",
      "* Assessment methods \n",
      "* Symptoms \n",
      "¢ Assessment of either temperature or pinprick sensation (small fiber \n",
      "function) and vibration sensation using a 128-Hz tuning fork (for \n",
      "large-fiber function)\n",
      "\n",
      "Chunk 409: \n",
      "* To identify feet at risk for ulceration and amputation: 10-g monofilament \n",
      "testing\n",
      "\n",
      "Chunk 410: \n",
      "* Symptoms and signs of autonomic neuropathy should be assessed\n",
      "\n",
      "Chunk 411: \n",
      "Treatment \n",
      "* Optimize glycemic control\n",
      "\n",
      "Chunk 412: \n",
      "* Pregabalin, duloxetine, or gabapentin are recommended as_ initial \n",
      "pharmacologic treatments for neuropathic pain\n",
      "\n",
      "Chunk 413: \n",
      "Referral criteria \n",
      "° Difficult to treat cases \n",
      "5.4 Diabetic foot \n",
      "* Comprehensive foot evaluation should be done at least annually to identify \n",
      "risk factors for ulcers and amputations\n",
      "\n",
      "Chunk 414: \n",
      "* — Patients with sensory loss or prior ulceration or amputation should have their \n",
      "feet examined at every visit\n",
      "\n",
      "Chunk 415: \n",
      "History \n",
      "* Prior history of ulceration, amputation, charcot foot, angioplasty or vascular \n",
      "surgery, cigarette smoking, retinopathy\n",
      "\n",
      "Chunk 416: \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI) 45 ¢ Current symptoms of neuropathy (pain, burning, numbness) and vascular disease \n",
      "(leg fatigue, claudication)\n",
      "\n",
      "Chunk 417: \n",
      "Examination \n",
      "« — Inspection of the skin \n",
      "* Assessment of foot deformities \n",
      "* neurological assessment: 10-g monofilament testing with at least one other \n",
      "assessment: pinprick, temperature, vibration \n",
      "* Vascular assessment: pulses in the legs and feet\n",
      "\n",
      "Chunk 418: With symptoms of claudication or \n",
      "decreased or absent pedal pulses: ankle-brachial index, further vascular \n",
      "assessment as appropriate eg, doppler study \n",
      "Management \n",
      "¢ A multidisciplinary approach is recommended eg endocrinologist, vascular \n",
      "surgeon, orthopedic surgeon, neurologist, diabetes educator, foot care nurse, \n",
      "podiatrist etc\n",
      "\n",
      "Chunk 419: \n",
      "* Provide general preventive foot self-care education to all patients with diabetes\n",
      "\n",
      "Chunk 420: \n",
      "* Specialized therapeutic footwear is recommended for high-risk patients with \n",
      "diabetes including those with severe neuropathy, foot deformities, or history of \n",
      "amputation\n",
      "\n",
      "Chunk 421: \n",
      "Refer to foot care specialists \n",
      "¢ history of prior lower-extremity complications \n",
      "* — loss of protective sensation \n",
      "* — structural abnormalities \n",
      "¢ peripheral arterial disease \n",
      "5.5 Cardiovascular diseases \n",
      "Screening \n",
      "¢ Screening for coronary artery disease in the presence of any \n",
      "* Atypical cardiac symptoms (e.g., unexplained dyspnea, chest discomfort) \n",
      "* Signs or symptoms of vascular disease including carotid bruits, transient \n",
      "ischemic attack, stroke, claudication, or peripheral arterial disease \n",
      "« Electrocardiogram abnormalities (e.g.,Q waves)\n",
      "\n",
      "Chunk 422: \n",
      "  \n",
      "46 ‘lB Diabetes Care: BADAS Guideline 2019 Treatment \n",
      "¢ With known atherosclerotic cardiovascular disease: \n",
      "¢ ACE inhibitor or angiotensin receptor blocker\n",
      "\n",
      "Chunk 423: \n",
      "* In patients with prior myocardial infarction, b-blockers should be continued \n",
      "for at least 2 years after the event\n",
      "\n",
      "Chunk 424: \n",
      "* In patients with type 2 diabetes with stable congestive heart failure, metformin \n",
      "may be used if estimated glomerular filtration rate remains >30 mL/min but \n",
      "should be avoided in unstable or hospitalized patients with congestive heart \n",
      "failure with hypoxia\n",
      "\n",
      "Chunk 425: \n",
      "* Among persons with type 2 diabetes who have established atherosclerotic \n",
      "cardiovascular disease, sodium-glucose cotransporter 2 inhibitors or \n",
      "glucagon-like peptide 1 receptor agonists are recommended as part of the \n",
      "antihyperglycemic regimen\n",
      "\n",
      "Chunk 426: \n",
      "* Among persons with atherosclerotic cardiovascular disease at high risk of heart \n",
      "failure or in whom heart failure coexists, sodium—glucose cotransporter 2 \n",
      "inhibitors are preferred\n",
      "\n",
      "Chunk 427: \n",
      "5.6\n",
      "\n",
      "Chunk 428: Hypertension \n",
      "Classification of blood pressure \n",
      "  \n",
      "BP category Systolic BP Diastolic BP \n",
      "Normal <120 mmHg and <80 mmHg \n",
      "Elevated 120-129 mmHg and <80 mmHg \n",
      "Hypertension: Stage 1 130-139 mmHg or 80-89 mmHg \n",
      "Hypertension: Stage 2 2140 mmHg or 290 mmHg \n",
      "Screening, follow-up and treatment target \n",
      "¢ Blood pressure should be measured at every routine clinical visit\n",
      "\n",
      "Chunk 429: \n",
      "* Person with diabetes and hypertension at higher cardiovascular risk (existing \n",
      "ASCVD or 10-year ASCVD risk >15%): blood pressure target is <130/80 mmHg. \n",
      "¢ Person with diabetes and hypertension at lower risk for cardiovascular disease \n",
      "(10-year ASCVD risk <15%): blood pressure target is <140/90 mmHg\n",
      "\n",
      "Chunk 430: \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI) 47 Hypertension treatment protocol \n",
      "Initial BP<160/100 mmHg \n",
      "| | \n",
      "Start one agent \n",
      "4 \n",
      "Albuminuria \n",
      "| \n",
      "t 1 \n",
      "Start one drug: Start: \n",
      " ACEi ¢ ACEi or ARB \n",
      "« ARB \n",
      "- CCB \n",
      "+ Diuretic \n",
      "4 \n",
      "Assess BP control and adverse effects \n",
      "Treatment tolerated and \n",
      "Lifestyle management \n",
      "Initial BP>160/100 mmHg \n",
      "1 4 \n",
      "Start two agents \n",
      "4 \n",
      "Albuminuria \n",
      "| \n",
      "+ 7 \n",
      "Start drug from Start: \n",
      "2 of 3 options: « ACEi or ARB \n",
      "« ACEi or ARB and \n",
      "-CCB « CCB or Diuretic \n",
      "« Diuretic \n",
      "| | \n",
      "Not meeting target Adverse effects \n",
      "target achieved \n",
      "Add agent from Consider change to \n",
      "Continue therapy complementary drug class: alternative medication: \n",
      "+ ACEi or ARB * ACEI or ARB \n",
      "-CCB ° CCB \n",
      "Not meeting target on ~ Diuretic * Diuretic \n",
      "two agents | | Adverse | \n",
      "effects \n",
      "Assess BP Control and Adverse Effects \n",
      "l \n",
      "Treatment tolerated Not meeting target or adverse effects \n",
      "and target achieved using a drug from each of three classes \n",
      "Continue therapy Consider addition of mineralocorticoid receptor antagonist; \n",
      "  \n",
      "=z mek ocTere 1 MUNA Ryd el RUM MICH e (USL 8 \n",
      "48 EE Diabetes Care: BADAS Guideline 2019 5.7 Dyslipidemia \n",
      "Screening and monitoring of lipid profile \n",
      "* At the time of diabetes diagnosis, if not taking statins or other lipid-lowering \n",
      "therapy \n",
      "* Ataninitial medical evaluation \n",
      "*  Atevery 5 years, if under the age of 40 years \n",
      "* More frequently if indicated \n",
      "¢ At initiation of statins or other lipid lowering therapy \n",
      "¢ 4-12 weeks after initiation or a change in dose, and annually thereafter \n",
      "Target \n",
      "It is set to protect from cardiovascular risks, that depends on: \n",
      "¢ DMwhich is considered as CAD risk equivalent \n",
      "¢ Presence of cardiovascular disease \n",
      "* Presence of ASCVD risk factors which include LDL cholesterol >100 mg/dL (2.6 \n",
      "mmol/L), high blood pressure, smoking, chronic kidney disease, albuminuria and \n",
      "family history of premature ASCVD \n",
      "Targets of blood lipids in person with diabetes \n",
      "  \n",
      "Be <8 30 \n",
      "LDL <70-100 mg/dl \n",
      "Triglyceride <150 mg/dl \n",
      "HDL >40 mg/dl (male), >50 mg/dl (female) \n",
      "Treatment \n",
      "¢ — Lifestyle modification: \n",
      "* Weight loss if indicated \n",
      "* Reduction of saturated and trans fats \n",
      "* Increase of dietary omega-3 fatty acids, viscous fiber, and plant \n",
      "stanols/sterols intake \n",
      "« — Increased physical activity \n",
      "* Pharmacological therapy: \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HE) 49 Pharmacological therapy based on age, ASCVD or ASCVD risk factors \n",
      "Age | ASCVD or 10-tear ASCVD risk >20% Along with lifestyle modification, \n",
      "  \n",
      "Recommended pharmacological therapy \n",
      "<40 No None or moderate intensity statin may be \n",
      "considered based on risk-benefit profile or \n",
      "presence of ASCVD risk\n",
      "\n",
      "Chunk 431: \n",
      "<40 Yes High intensity statin; if LDL =>70 mg/dl despite \n",
      "of therapy consider combining with ezetimibe\n",
      "\n",
      "Chunk 432: \n",
      "240 No Moderate intensity statin or high intensity \n",
      "statin may be considered based on risk-benefit \n",
      "profile or presence of ASCVD risk\n",
      "\n",
      "Chunk 433: \n",
      "240 Yes High intensity statin; if LDL >70 mg/dl despite \n",
      "of therapy, consider combining with ezetimibe\n",
      "\n",
      "Chunk 434: \n",
      "    \n",
      "NB: Intensity of statin therapy may need to be adjusted according to individual \n",
      "patient response to medication (eg side effects, tolerability, LDL cholesterol \n",
      "levels, etc)\n",
      "\n",
      "Chunk 435: \n",
      "Statin therapy is contraindicated during pregnancy\n",
      "\n",
      "Chunk 436: \n",
      "5.8 Use of antiplatelet agents \n",
      "Aspirin therapy (75-150 mg/day) as a secondary prevention strategy in those \n",
      "with diabetes and a history of atherosclerotic cardiovascular disease\n",
      "\n",
      "Chunk 437: \n",
      "Patients with atherosclerotic cardiovascular disease and documented aspirin \n",
      "allergy, clopidogrel (75 mg/day) should be used\n",
      "\n",
      "Chunk 438: \n",
      "Dual antiplatelet therapy is reasonable for a year after an acute coronary \n",
      "syndrome and may have benefits beyond this period\n",
      "\n",
      "Chunk 439: \n",
      "References \n",
      "1\n",
      "\n",
      "Chunk 440: American Diabetes Association’s Standards of Medical Care in Diabetes—2019\n",
      "\n",
      "Chunk 441: \n",
      "Diabetes Care 2018;42(Suppl\n",
      "\n",
      "Chunk 442: 1):S1-S194\n",
      "\n",
      "Chunk 443: \n",
      "Diabetes Mellitus\n",
      "\n",
      "Chunk 444: Diabetic Association of Bangladesh\n",
      "\n",
      "Chunk 445: 5th ed 2018\n",
      "\n",
      "Chunk 446: \n",
      "https://www.kidney.org/kidneydisease/siemens_hcp_acr \n",
      "https://www.heart.org/-/media/data-import/downloadables/hypertension-guideline- \n",
      "highlights-flyer-ucm_497841 .pdf \n",
      "  \n",
      "50 {IH Diabetes Care: BADAS Guideline 2019 Chapter 6 \n",
      "Special Situations in Diabetes Mellitus \n",
      "6.1 Diabetes in pregnancy \n",
      "Gestational diabetes mellitus (GDM) is caused by placental hormones, namely beta \n",
      "HCG, human placental lactogen, estrogen, progesterone etc\n",
      "\n",
      "Chunk 447: antagonizing the \n",
      "action of insulin\n",
      "\n",
      "Chunk 448: \n",
      "Global prevalence of GDM is16.2% of live births in population of 20-49 years\n",
      "\n",
      "Chunk 449: \n",
      "Following factors are to be considered as the risk factors of developing GDM: \n",
      "BMI =23 kg/m2 (based upon ethnicity) \n",
      "Age 2=25 years \n",
      "First degree relative with diabetes \n",
      "History of delivery of baby >9lb or LGA (large for gestational age) or bad \n",
      "obstetric history \n",
      "Previous history of GDM, A1C =5.7%, IGT or IFG \n",
      "Physical inactivity \n",
      "Family origin with high prevalence of diabetes as in South Asians \n",
      "HTN or therapy for HTN, HDL <35 mg/dl and or TG >250 mg/dl, PCOS, \n",
      "Acanthosis negricans, history of CVD\n",
      "\n",
      "Chunk 450: \n",
      "Screening \n",
      "All pregnant women of our country should be routinely screened for GDM as \n",
      "our population falls under high risk group\n",
      "\n",
      "Chunk 451: As a screening test, use of GCT \n",
      "(glucose challenge test) is not necessary\n",
      "\n",
      "Chunk 452: One step 75g 2h OGTT should be \n",
      "used for screening and diagnosis of GDM\n",
      "\n",
      "Chunk 453: \n",
      "At first antenatal visit a diagnostic OGTT plus risk factor assessment should be \n",
      "done for all\n",
      "\n",
      "Chunk 454: During 24th to 28th weeks, 2nd OGTT is to be done for those who \n",
      "are normal in initial OGTT\n",
      "\n",
      "Chunk 455: This OGTT is mandatory\n",
      "\n",
      "Chunk 456: During 34th to 36th weeks, \n",
      "repeat OGTT may be done for the women with positive risk factors plus \n",
      "previous normal OGTT\n",
      "\n",
      "Chunk 457: This OGTT is optional\n",
      "\n",
      "Chunk 458: \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HHI! 51 Management \n",
      "Medical nutrition therapy (MNT) \n",
      "* MNT Should be started soon after diagnosis of GDM reviewed in each trimester\n",
      "\n",
      "Chunk 459: \n",
      "* MNT should be aimed to achieve normoglycemia, provide adequate maternal \n",
      "weight gain, provide adequate fetal growth, prevent ketosis and to achieve \n",
      "other general aims of MNT\n",
      "\n",
      "Chunk 460: \n",
      "* Weight loss with hypocaloric diet is generally not recommended to avoid \n",
      "ketosis and nutritional deficiency\n",
      "\n",
      "Chunk 461: \n",
      "* Calorie intake should be according to pre-pregnancy body weight \n",
      "Pre-pregnancy weight | During first trimester (kcal/kg/day) | During 2nd and 3rd trimester \n",
      "(BMI in Kg/m2) eID TE yy) \n",
      "<18.5 \n",
      "18.5 to 22.9 \n",
      "23 to 27.4 \n",
      ">27.5 \n",
      "35 40 \n",
      "30 35 \n",
      "25 30 \n",
      "30 -33% calorie restriction \n",
      "¢ Ideal weight gain during pregnancy should be as per following table\n",
      "\n",
      "Chunk 462: \n",
      "Recommended weight gain during pregnancy is based on pre-pregnancy BMI \n",
      "Singleton pregnancy \n",
      "<18.5 \n",
      "18.5-24.9 \n",
      "25.0-29.9 \n",
      "230.0 \n",
      "Twin pregnancy \n",
      "<18.5 \n",
      "18.5-24.9 \n",
      "25.0-29.9 \n",
      "230.0 \n",
      "28-40 (12.5-18.0) \n",
      "25-35 (11.5-16.0) \n",
      "15-25 (7.0-11.5) \n",
      "11-20 (5-9.0) \n",
      "No recommendation \n",
      "37-54 (16.8-24.5) \n",
      "31-50 (14.1-22.7) \n",
      "25-42 (11.4-19.1) \n",
      "  \n",
      "52 IE Diabetes Care: BADAS Guideline 2019 Meal pattern \n",
      "Three meals and 3 snacks should be taken including one snack at bed time\n",
      "\n",
      "Chunk 463: This \n",
      "approach can be adopted where help of nutritionist service is not available\n",
      "\n",
      "Chunk 464: \n",
      "Recommended overall total caloric distribution \n",
      "Carbohydrate: 33-40% with low glycemic index \n",
      "Protein: ~ 20% \n",
      "Fat: < 40%, saturated fat <7% and transfat<1% \n",
      "Plate model can be practiced \n",
      "Simple sugars should be avoided\n",
      "\n",
      "Chunk 465: Food containing complex carbohydrate \n",
      "intake is recommended \n",
      "High dietary fibre and whole grain containing foods should be encouraged\n",
      "\n",
      "Chunk 466: \n",
      "Non-calorie sweeteners (aspartame) may be used safely \n",
      "Lean protein, oily fish and vegetable consumption should be increased \n",
      "Recommended daily requirement of iron- 30 mg, calcium- 1000 mg & folate- \n",
      "0.6 mg \n",
      "Over-nutrition during pregnancy should be discouraged \n",
      "Physical activity \n",
      "Women with GDM should be encouraged to be as active as possible throughout \n",
      "the day.if there is no medical or obstetric contraindication following exercise plan \n",
      "can be adopted: \n",
      "Moderate activity of 30 minutes/day in 15¢ trimester is recommended\n",
      "\n",
      "Chunk 467: Walking \n",
      "can be continued till term at a pace that is comfortable\n",
      "\n",
      "Chunk 468: \n",
      "Advising intermittent exercise program such as 10 minutes three times a day \n",
      "preferably after a gap of one hour post prandial is another option\n",
      "\n",
      "Chunk 469: \n",
      "While doing exercise excessive abdominal muscular contracture should be \n",
      "avoided and should be modified by obvious safety issue \n",
      "Upper limb exercise is preferred during 2d and 3° trimester\n",
      "\n",
      "Chunk 470: Aerobic exercise \n",
      "is preferred, Walking, cycling and swimming are a few recommended exercises \n",
      "which can be practiced until term if there are no obstetric complications which \n",
      "require bed rest\n",
      "\n",
      "Chunk 471: \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI 53 Pharmacological management \n",
      "During first and third trimester \n",
      "Treatment in 15t an 3\" Trimester \n",
      "GDM plasma glucose targets and treatment protocol by SAFES \n",
      "Plasma Glucose values Treatment Changeof Treatment \n",
      "at onset treatmentif reviewed & \n",
      "targetnot continued \n",
      "  \n",
      "achieved in \n",
      "FPG 292 mg/dl to 109 mg/dl NPT 1 week NPT+PT \n",
      "(25.1 mmol/L) (6.0 mmol/L) \n",
      "and/or \n",
      "2h PPG 2120mg/dl to <140mg/dl NPT 1 week NPT+PT \n",
      "(26.7 mmol/L) (7.8 mmol/L) \n",
      "FPG 2110mg/dl to <126 mg/dl NPT 3 days NPT+PT \n",
      "(26.1 mmol/L) (7.0 mmol/L) \n",
      "and/or \n",
      "2h PPG 2140mg/dl_ to <200 mg/dl NPT 3 days NPT+PT \n",
      "(27.8 mmol/L) (11.1 mmol/L) \n",
      "FPG 2126 mg/dl NPT+PT x NPT+PT \n",
      "(27.0 mmol/L} \n",
      "and/or \n",
      "2h PPG 2200 mg/dl \n",
      "(211.1mmol/L) NPT+PT x NPT+PT \n",
      "NPT: Non-pharmacological treatment, PT: Pharmacological treatment \n",
      "  \n",
      "54 (§N Diabetes Care: BADAS Guideline 2019 Treatment in 2™ trimester \n",
      "GDM plasma glucose targets and treatment protocol by SAFES \n",
      "  \n",
      "Plasma Glucose values Treatment Change of treatment Treatment \n",
      "at onset if target not reviewed \n",
      "achieved in & continued \n",
      "FPG 292 to 109 NPT 2 week/1 week NPT+PT \n",
      "mg/dl mg/dl Uncomplicated/ \n",
      "(25.1 (6.0 complicated \n",
      "mmol/L) mmol/L) \n",
      "and/or \n",
      "2hPPG 2120 to <140 NPT 2 week/1 week NPT+PT \n",
      "mg/dl mg/dl Uncomplicated/ \n",
      "(26.7 (7.8 complicated \n",
      "mmol/L) mmol/L) \n",
      "FPG >110 to <126 NPT 1 week NPT+PT \n",
      "mg/dl mg/dl \n",
      "(26.1 (7.0) \n",
      "mmol/L) mmol/L) \n",
      "and/or \n",
      "2hPPG 2140 to <200 NPT 1 week NPT+PT \n",
      "mg/dl mg/dl \n",
      "(27.8 (11.1 \n",
      "mmol/L) mmol/L) \n",
      "FPG 2=126 mg/dl NPT+PT x NPT+PT \n",
      "(27.0 mmol/L) \n",
      "and/or \n",
      "2h PPG 2200 mg/dl \n",
      "(211.1mmol/L) NPT+PT x NPT+PT \n",
      "NPT: Non-pharmacological treatment, PT: Pharmacological treatment \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI 55 Recommended insulins \n",
      "* Recombinant human short acting insulin, recombinant human intermediate \n",
      "acting insulin are recommended for use during pregnancy\n",
      "\n",
      "Chunk 472: Among short \n",
      "acting analogue Aspart and Lispro are safe\n",
      "\n",
      "Chunk 473: Among long acting analogue use of \n",
      "detemir is recommended\n",
      "\n",
      "Chunk 474: Use of Glulisine, Glargine and Degludec is not \n",
      "recommended\n",
      "\n",
      "Chunk 475: \n",
      "* Required initial dose is 0.2 to 0.5 U/kg body weight\n",
      "\n",
      "Chunk 476: Obese women may need \n",
      "higher dose\n",
      "\n",
      "Chunk 477: Treatment should be graded to reach the targets\n",
      "\n",
      "Chunk 478: \n",
      "Recommended approach to start insulin \n",
      "Step 1:In case of high fasting blood glucose (FPG), it should be controlled with \n",
      "priority over that of high post meal blood sugar\n",
      "\n",
      "Chunk 479: An intermediate acting human \n",
      "insulin or basal analogue insulin (recommended for use in pregnancy) with a dose \n",
      "of 0.2U/kg at bed time may be a starting dose\n",
      "\n",
      "Chunk 480: Then titrated to reach the target of \n",
      "fasting blood glucose\n",
      "\n",
      "Chunk 481: \n",
      "Step 2: Raised post meal blood glucose should be controlled by bolus insulin \n",
      "-either by regular / short acting human insulin or by short/ ultra acting analogue \n",
      "with meal(s) (recommended for use in pregnancy) and titrated as frequently to \n",
      "reach the post-meal targets\n",
      "\n",
      "Chunk 482: \n",
      "* Only bolus insulin may be needed in some cases of GDM when FPG is well \n",
      "controlled with non-Pharmacological therapy\n",
      "\n",
      "Chunk 483: \n",
      "* Premixed insulin can be considered on individual basis where patients are \n",
      "unwilling to or unable to take basal bolus regimen\n",
      "\n",
      "Chunk 484: \n",
      "Combined use of human insulin with analogue insulin is not recommended\n",
      "\n",
      "Chunk 485: \n",
      "Recommended OAD: Use of sulphonylurea during GDM is not recommended .Use \n",
      "of Metformin is discouraged\n",
      "\n",
      "Chunk 486: \n",
      "Post-partum management \n",
      "* Mothers who were on low dose insulin (<0.5units/kg/day) can stop and \n",
      "monitor glucose levels\n",
      "\n",
      "Chunk 487: Mothers who were on insulin >1units/kg/day may \n",
      "reduce the dose to 50% and while those on 0.5-1units need individualized \n",
      "clinical decision\n",
      "\n",
      "Chunk 488: \n",
      "* All mothers with history of gestational diabetes should be counseled about \n",
      "screening for GDM during every subsequent pregnancy\n",
      "\n",
      "Chunk 489: \n",
      "* Empowering health care professionals (gynecologists, mid-wives, lady health \n",
      "visitors, pediatricians, nurses, diabetes educators) by providing sanitized \n",
      "standard literature and continuing education by conducting training are \n",
      "crucial\n",
      "\n",
      "Chunk 490: In all levels a shared decision making with obstetric team should be \n",
      "considered when necessary\n",
      "\n",
      "Chunk 491: \n",
      "  \n",
      "56 ‘ll Diabetes Care: BADAS Guideline 2019 After delivery at least 1 fasting and 1 after a meal PG before discharge should \n",
      "be measured in GDM patients who were managed by MNT and FPG and after \n",
      "meals PG should be monitored for at least 24 hours who were managed with \n",
      "insulin\n",
      "\n",
      "Chunk 492: If blood glucose remains elevated, continued monitoring is warranted\n",
      "\n",
      "Chunk 493: \n",
      "Possibility of type 2 diabetes should be considered\n",
      "\n",
      "Chunk 494: If immediate post-delivery \n",
      "(1-3 days), BG is suggestive of diabetes, then should be confirmed by FPG (27 \n",
      "mmol/l) or post-prandial BG(=11.1mmol/I)\n",
      "\n",
      "Chunk 495: \n",
      "As some case of GDM may represent pre-existing undiagnosed type 2 diabetes \n",
      "and 50% women with GDM may develop type 2 diabetes within 5 to 10 years, \n",
      "women with GDM(not requiring insulin after delivery) should be screened for \n",
      "diabetes 6 weeks post-partum (linked to child immunization) with 75g 2h \n",
      "OGTT using non-pregnant OGTT criteria\n",
      "\n",
      "Chunk 496: \n",
      "If BG is normal, reassessment should be done annually with 75g 2h OGTT or \n",
      "A1C\n",
      "\n",
      "Chunk 497: If prediabetes, reassessment should be done 6 monthly and should be put \n",
      "on MNT or metformin should be followed by standard protocol\n",
      "\n",
      "Chunk 498: \n",
      "Low dose estrogen-progesterone can be offered for contraception\n",
      "\n",
      "Chunk 499: \n",
      "Progesterone only preparation increases risk of vascular complications\n",
      "\n",
      "Chunk 500: \n",
      "Screening for all components of metabolic syndrome should be offered\n",
      "\n",
      "Chunk 501: \n",
      "Throughout the period of breast feeding all types of insulins and metformin \n",
      "can be safely used in lactating women\n",
      "\n",
      "Chunk 502: Women with preprgnancy diabetes \n",
      "who are breastfeeding should continue to avoid any drugs for the treatment of \n",
      "diabetes complications that were discontinued for safety reasons in the \n",
      "pre-conception period\n",
      "\n",
      "Chunk 503: \n",
      "6.2 Diabetes in children \n",
      "Diabetes mellitus in childhood and adolescence is most often type 1 diabetes\n",
      "\n",
      "Chunk 504: \n",
      "But they have the chance of developing other specific types of diabetes\n",
      "\n",
      "Chunk 505: \n",
      "Now-a-days type 2 diabetes is developing in the young at a very high rate\n",
      "\n",
      "Chunk 506: \n",
      "Diagnostic and management issues in this group of population are a bit \n",
      "different from that of adult\n",
      "\n",
      "Chunk 507: \n",
      "Type 2 diabetes mellitus in children is relatively less common than in adult\n",
      "\n",
      "Chunk 508: But \n",
      "nowadays it is being reported more frequently and is associated with rising \n",
      "rate of obesity among the children\n",
      "\n",
      "Chunk 509: \n",
      "Type 2 diabetes was once seen as a disease of adults\n",
      "\n",
      "Chunk 510: Today, this type of diabetes \n",
      "is growing at alarming rates in children and adolescents\n",
      "\n",
      "Chunk 511: Over a 20-year period, \n",
      "type 2 diabetes has doubled in children in Japan, so that it is now more common \n",
      "than type 1\n",
      "\n",
      "Chunk 512: \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HE) 57 type 2 diabetes in children is becoming a global public health issue with \n",
      "potentially serious outcomes\n",
      "\n",
      "Chunk 513: \n",
      "* Asthe trend of type 2 diabetes is increasing at present it has become important \n",
      "to screen the children for this type of diabetes\n",
      "\n",
      "Chunk 514: \n",
      "Toe Mm lela em miele \n",
      "All types DM Children with symptoms of diabetes \n",
      "Type2 DM Children with risk factors of diabetes: \n",
      "O Over-weight (BMI >85th percentile for age & sex) \n",
      "O Family history of type 2 diabetes \n",
      "O Mother was diabetic/GDM during the child's gestation \n",
      "O Some ethnic groups \n",
      "O Features of insulin resistance \n",
      "@ Acanthosis nigricans \n",
      "Hypertension \n",
      "Dyslipidemia \n",
      "Polycystic ovary syndrome \n",
      "Low birth weight \n",
      "O Children with obesity and one or more risk factors should be screened at the age of 10 \n",
      "years or at onset of puberty\n",
      "\n",
      "Chunk 515: If normal, then screening should be done in every 3 years\n",
      "\n",
      "Chunk 516: \n",
      "© Diabetes in children and adolescents, specially type 1, usually presents with classical \n",
      "symptoms\n",
      "\n",
      "Chunk 517: It can easily be diagnosed by RPG\n",
      "\n",
      "Chunk 518: OGTT is seldom required; it should not be \n",
      "performed if diabetes can be diagnosed by RPG or FPG, as excessive hyperglycemia can \n",
      "result\n",
      "\n",
      "Chunk 519: \n",
      "Principles of diabetes management in childhood \n",
      "Management of the diabetes in children needs special skill in this field\n",
      "\n",
      "Chunk 520: Treatment \n",
      "modalities do not differ much from those of adults\n",
      "\n",
      "Chunk 521: However, they mostly need \n",
      "insulin because they are either of type 1 diabetes or of other types with severe \n",
      "insulin deficiency\n",
      "\n",
      "Chunk 522: \n",
      "Targets of diabetes management in the young (based on ISPAD guideline) \n",
      "  \n",
      "58 (\\l§§ Diabetes Care: BADAS Guideline 2019 Glycemic levels: plasma glucose (mmol/L); HbA1c (%) \n",
      "FPG/Pre-meal Post-meal Bed time HbA1c \n",
      "5.0-8.0 5.0-10.0 6.7-10.0 <7.5 \n",
      "No hypoglycemia \n",
      "Target of growth Within +/- 2.5 SD of growth chart \n",
      "Drug treatment of type 1 diabetes only insulin\n",
      "\n",
      "Chunk 523: \n",
      "Drug treatment of type 2 diabetes \n",
      "Age group Option for drug \n",
      "<10 years of age Insulin only \n",
      "10-18 years Insulin and/or metformin \n",
      ">18 years Insulin and/or metformin, and/or other agents, eg\n",
      "\n",
      "Chunk 524: \n",
      "sulphonylureas, thiazolidinediones etc\n",
      "\n",
      "Chunk 525: \n",
      "Medical nutrition therapy (MNT) \n",
      "* A meal plan is based on the individual's usual food intake, insulin therapy, \n",
      "exercise patterns etc\n",
      "\n",
      "Chunk 526: \n",
      "* Timing and amount of food will depend on type of insulin, physical activity, \n",
      "lifestyle and results of blood glucose monitoring\n",
      "\n",
      "Chunk 527: \n",
      "* All children with diabetes should be referred to a dietitian for counseling at \n",
      "diagnosis of diabetes and also subsequently if they have problem with their diet \n",
      "adjustment\n",
      "\n",
      "Chunk 528: \n",
      "¢ Age-specific calorie calculating charts are available for measuring diet allowance\n",
      "\n",
      "Chunk 529: \n",
      "Diabetes education \n",
      "« Diabetes education needs to be a continuous process and repeated for it to be \n",
      "effective\n",
      "\n",
      "Chunk 530: \n",
      "« They are to be trained to develop skill in all aspects of diabetes, especially \n",
      "insulin injection technique, dietary practice, home monitoring of blood glucose \n",
      "etc\n",
      "\n",
      "Chunk 531: Providing emotional support is also very important\n",
      "\n",
      "Chunk 532: \n",
      "+ — Infants and toddlers: They are totally dependent on parents and care providers \n",
      "for injections, food and monitoring\n",
      "\n",
      "Chunk 533: Need to be educated on prevention, \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI) 59 recognition and management of acute complications, especially \n",
      "hypoglycemia, because it is very common complication in this age group\n",
      "\n",
      "Chunk 534: \n",
      "School going children to be trained on Insulin injections and blood glucose \n",
      "monitoring,recognizing hypoglycemic symptoms and understanding self \n",
      "management, adapt to school programs, school meals, exercise and sports\n",
      "\n",
      "Chunk 535: \n",
      "Teacher/school authority should be involved in this learning process and \n",
      "parents are advised on the gradual development of the child's independence\n",
      "\n",
      "Chunk 536: \n",
      "Adolescents: Independent, responsible self-management appropriate to the \n",
      "level of maturity and understanding should be promoted\n",
      "\n",
      "Chunk 537: Strategies to manage \n",
      "transition to adulthood and progressive hand-over of responsibility are to be \n",
      "developed\n",
      "\n",
      "Chunk 538: \n",
      "Sports and exercise \n",
      "Children with type 1 diabetes with good blood glucose control can do all levels \n",
      "of exercise, including leisure activities, recreational sports, and competitive \n",
      "professional performance\n",
      "\n",
      "Chunk 539: Exercise is more important for young type 2 diabetic, \n",
      "especially who are obese\n",
      "\n",
      "Chunk 540: The emphasis must be on adjusting the therapeutic \n",
      "regimen with the level of exercise and diet, and avoiding hypoglycemia\n",
      "\n",
      "Chunk 541: \n",
      "Children between 3-5 years of age may take part in free play, walking, running \n",
      "etc\n",
      "\n",
      "Chunk 542: \n",
      "Children between 6-9 years of age may start learning to play team sports such \n",
      "as football, cricket etc\n",
      "\n",
      "Chunk 543: \n",
      "Children above 10 years of age and adolescents may be able to take part in all \n",
      "complex sports, like basketball, football, tennis, hockey etc\n",
      "\n",
      "Chunk 544: \n",
      "In the case of adolescents, hormonal changes can contribute to the difficulty in \n",
      "controlling blood glucose levels\n",
      "\n",
      "Chunk 545: Extra care is required for exercise in this age \n",
      "group\n",
      "\n",
      "Chunk 546: \n",
      "Hypertension in the young \n",
      "Hypertension in childhood is defined as systolic or diastolic blood pressure >95th \n",
      "percentile for age, sex and height. 'High-normal’ blood pressure is defined as \n",
      "systolic or diastolic blood pressure >90th but <95th percentile for age, sex and \n",
      "height\n",
      "\n",
      "Chunk 547: Elevated blood pressure should be confirmed on 3 separate days\n",
      "\n",
      "Chunk 548: \n",
      "Treatment of high-normal blood pressure is given through lifestyle measures\n",
      "\n",
      "Chunk 549: If \n",
      "target blood pressure is not reached within 3-6 months, phamacologic treatment \n",
      "should be initiated\n",
      "\n",
      "Chunk 550: Drug treatment should be started as soon as hypertension is \n",
      "confirmed\n",
      "\n",
      "Chunk 551: ACE inhibitor is the preferred agent\n",
      "\n",
      "Chunk 552: The goal of treatment is a blood \n",
      "pressure consistently <90th percentile for age, sex and height, whichever is lower\n",
      "\n",
      "Chunk 553: \n",
      "  \n",
      "60 (I Diabetes Care: BADAS Guideline 2019 Dyslipidemia in the young \n",
      "Fasting lipid profile should be performed in children soon after diagnosis of \n",
      "diabetes (after diabetes control)\n",
      "\n",
      "Chunk 554: If lipids are abnormal, annual monitoring is \n",
      "recommended\n",
      "\n",
      "Chunk 555: If LDL cholesterol values are within the accepted risk levels (<100 \n",
      "mg/dl), a lipid profile should be repeated every 3-5 years\n",
      "\n",
      "Chunk 556: \n",
      "Initial therapy includes blood glucose control and MNT\n",
      "\n",
      "Chunk 557: After the age of 10 years, \n",
      "statin is recommended in patients who do not reach target (who have LDL \n",
      "cholesteorl >160 mg/dl or >130 mg/dl with a cardiovascular risk factor) with \n",
      "lifestyle changes\n",
      "\n",
      "Chunk 558: The goal of therapy is an LDL cholesterol value <100 mg/dl\n",
      "\n",
      "Chunk 559: \n",
      "6.3 Diabetes in elderly \n",
      "People over 60 years of age form about 15% of total population globally\n",
      "\n",
      "Chunk 560: Among \n",
      "total diabetics of the world, 60-year group constitutes about 35%. And among total \n",
      "population over 65 years of age, 25% are diabetics\n",
      "\n",
      "Chunk 561: So they are putting a great \n",
      "impact on general as well as in diabetic populations\n",
      "\n",
      "Chunk 562: \n",
      "Older people may present in any of the following states \n",
      "Apparently good Intermediate Poor \n",
      "health health health \n",
      "Life expectancy More Intermediate Less \n",
      "Physical/mental More Intermediate Less \n",
      "fitness \n",
      "Independence More Intermediate Less \n",
      "Management Less relaxed Intermediate More relaxed \n",
      "strategy \n",
      "Management of diabetes in elderly \n",
      "Treatment goal \n",
      "Category FPG (mmol/L) HbA1c (%) \n",
      "Good 7.2 <7.5 \n",
      "Intermediate 8.3 <8.0 \n",
      "Poor 10.0 <8.5 \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 EE 61 Lifestyle modification \n",
      "MNT: Adequate fluid is to be ensured to avoid dehydration\n",
      "\n",
      "Chunk 563: Malnutrition or \n",
      "weight loss should be taken care\n",
      "\n",
      "Chunk 564: Tube feeding or parenteral nutrition may be \n",
      "needed in some\n",
      "\n",
      "Chunk 565: \n",
      "Physical activity: Older people are encouraged to be active as condition allows, \n",
      "from regular exercise to simple home-based mobility\n",
      "\n",
      "Chunk 566: Risk assessment should \n",
      "be done before recommending activity\n",
      "\n",
      "Chunk 567: Risk of injury with fall and \n",
      "hypoglycemia is to be considered\n",
      "\n",
      "Chunk 568: \n",
      "Pharmacotherapy \n",
      "‘Start low, go slow' is applicable to most medications\n",
      "\n",
      "Chunk 569: \n",
      "Agents which preferentially lower postprandial hyperglycemia may be more \n",
      "effective in achieving glycemic goals without increasing the risk of fasting \n",
      "hypoglycemia\n",
      "\n",
      "Chunk 570: \n",
      "Metformin is first-line therapy, but it should be used cautiously in people over \n",
      "80 years of age\n",
      "\n",
      "Chunk 571: Metformin may cause unintended weight loss and higher \n",
      "gastrointestinal side-effects, \n",
      "DPP-4 inhibitor/GLP-1 agonist may also be considered\n",
      "\n",
      "Chunk 572: \n",
      "Glibenclamide and Glimeiride has the highest risk of hypoglycemia, so should \n",
      "be avoided ; gliclazide has the lowest\n",
      "\n",
      "Chunk 573: \n",
      "Glinides and AGI may be considered in postprandial hyperglycemia\n",
      "\n",
      "Chunk 574: Glinides \n",
      "are also useful in erratic eating habits\n",
      "\n",
      "Chunk 575: \n",
      "Insulin may provide anabolic benefit in frail ones\n",
      "\n",
      "Chunk 576: Long acting insulin analogue \n",
      "is safe and efficacious in older people\n",
      "\n",
      "Chunk 577: Rapid/short acting insulin targets \n",
      "post-prandial blood glucose better\n",
      "\n",
      "Chunk 578: Visual, motor and cognitive impairments \n",
      "may hamper insulin injection\n",
      "\n",
      "Chunk 579: Insulin pen devices can simplify administration\n",
      "\n",
      "Chunk 580: \n",
      "Complex regimens should be avoided to reduce errors\n",
      "\n",
      "Chunk 581: \n",
      "Acute emergencies in elderly \n",
      "Hypoglycemia and sick day management plan should be strengthened\n",
      "\n",
      "Chunk 582: Older \n",
      "people are more prone to hypoglycemia\n",
      "\n",
      "Chunk 583: Blood glucose <6.0 mmol/L is to be \n",
      "avoided\n",
      "\n",
      "Chunk 584: HbA1c <7.0% should be taken as warning of possible overtreatment\n",
      "\n",
      "Chunk 585: \n",
      "Causes of ‘hypoglycemia’ in the elderly people: \n",
      "Polypharmacy \n",
      "Erratic meals, unusual activity \n",
      "Renal, hepatic impairment \n",
      "Malabsorption, swallowing problems \n",
      "  \n",
      "62 {I Diabetes Care: BADAS Guideline 2019 * Defective counterregulatory system, antecedent/unaware hypoglycemia \n",
      "* Cognitive impairment, less expression of symptoms, hampered self- \n",
      "management \n",
      "Like hypoglycemia, timely recognition and management of hyperglycemic \n",
      "emergencies (DKA, HHS) in older people must be ensured\n",
      "\n",
      "Chunk 586: \n",
      "Comorbidities \n",
      "Several comorbid conditions are usually present in older people along with \n",
      "complications of diabetes\n",
      "\n",
      "Chunk 587: These may be cognitive impairment, falls, pain, arthritis, \n",
      "fractures, hearing impairment, functional disability, urinary incontinence, obesity, \n",
      "stroke, CHF, periodontal disease, cancer, depression, hypertension, dyslipidemia etc\n",
      "\n",
      "Chunk 588: \n",
      "All these should be addressed as much as possible\n",
      "\n",
      "Chunk 589: \n",
      "6.4 Diabetes and surgery \n",
      "Pre-operative assessment \n",
      "* Pre-operative assessment must be done in close consultation with the \n",
      "physician, surgeon and anesthetist\n",
      "\n",
      "Chunk 590: \n",
      "* It should include assessment of any diabetic complications or associated \n",
      "conditions, which may increase surgical risk, eg cardiac autonomic neuropathy\n",
      "\n",
      "Chunk 591: \n",
      "« Drug and dose adjustment depend on drug regime and type of insulin\n",
      "\n",
      "Chunk 592: \n",
      "Day prior to surgery \n",
      "¢ Biguanides should be stopped 24 hours prior to, or on the day of surgery\n",
      "\n",
      "Chunk 593: \n",
      "* If operation in the early morning usual or lower doses of other antidiabetic \n",
      "medications are continued upto previous evening\n",
      "\n",
      "Chunk 594: \n",
      "* For major surgeries, the patient may be kept nil per oral (NPO) over-night prior \n",
      "to surgery; in patients with gastroparesis, the duration of NPO should be \n",
      "around 10-12 hours\n",
      "\n",
      "Chunk 595: \n",
      "Day of surgery \n",
      "¢ Anti-diabetic medications are held on the morning of the operation\n",
      "\n",
      "Chunk 596: \n",
      "* Surgery should be scheduled as early as possible in the morning\n",
      "\n",
      "Chunk 597: \n",
      "« In all major surgeries glucose-insulin infusion should be started\n",
      "\n",
      "Chunk 598: The unit of \n",
      "insulin to be added to 5 or 10% dextrose or dextrose saline needs to be \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI 63 individualized and adjusted as per the results of the glucometer readings\n",
      "\n",
      "Chunk 599: \n",
      "Blood glucose should be monitored 1 to 2 hourly; it should be in the range of \n",
      "6.0-10.0 mmol/L or lower if feasible\n",
      "\n",
      "Chunk 600: Glucose-insulin-potassium infusion may \n",
      "be considered according to situations\n",
      "\n",
      "Chunk 601: Best option I/V insulin syringe pump can \n",
      "be practised in long surgical procedure\n",
      "\n",
      "Chunk 602: \n",
      "* During minor surgery glucose-insulin infusion may sometimes be required in \n",
      "uncontrolled diabetes, but not in stable state\n",
      "\n",
      "Chunk 603: \n",
      "During operation \n",
      "* The choice of the anaesthetic agent is best left to the anaesthetist; there is no \n",
      "preferred choice of anaesthetic agent for diabetics\n",
      "\n",
      "Chunk 604: \n",
      "* Cardiovascular status should be closely monitored during surgery\n",
      "\n",
      "Chunk 605: \n",
      "* The glucose-insulin administration is continued where it is required; it is \n",
      "guided by blood glucose monitoring\n",
      "\n",
      "Chunk 606: \n",
      "¢ In longer duration operations subcutaneous correction dose insulin may be \n",
      "required according to blood glucose levels\n",
      "\n",
      "Chunk 607: \n",
      "Post-operative care \n",
      "¢ The glucose-insulin administration is continued (where required) till the \n",
      "patient is able to take oral food\n",
      "\n",
      "Chunk 608: \n",
      "* At this time, if the blood glucose is not under fair control, rapid acting insulin \n",
      "can be given in small doses (as correction dose) subcutaneously, if fasting is \n",
      "high long acting basal insulin may be required\n",
      "\n",
      "Chunk 609: \n",
      "* Once patient is back on his routine diet and is stable, he can be managed with \n",
      "the regimen he was on prior to surgery\n",
      "\n",
      "Chunk 610: \n",
      "For minor surgery in well controlled diabetes \n",
      "* Patient on short acting secretagogues and/or insulin should omit breakfast \n",
      "and the morning dose\n",
      "\n",
      "Chunk 611: The drug(s) should be restarted once patient is back on \n",
      "routine diet after operation\n",
      "\n",
      "Chunk 612: \n",
      "* Patient on long acting secretagogues may be tried replace with shorter acting \n",
      "secretagogues at least 7 days prior to surgery\n",
      "\n",
      "Chunk 613: \n",
      "*  Per-operative glucose-insulin drip is usually not required\n",
      "\n",
      "Chunk 614: \n",
      "For major surgery (requiring over-night NPO) \n",
      "* Diabetes should be controlled by insulin\n",
      "\n",
      "Chunk 615: Per-operative glucose-insulin drip is \n",
      "essential\n",
      "\n",
      "Chunk 616: \n",
      "  \n",
      "64 ‘INE Diabetes Care: BADAS Guideline 2019 In the post-operative period, once diet is resumed, patients should be shifted to \n",
      "short or rapid acting insulin\n",
      "\n",
      "Chunk 617: Restarting of the patent's previous regimen can be \n",
      "done once the patient is fully stable\n",
      "\n",
      "Chunk 618: \n",
      "For poorly controlled diabetes (elective surgery) \n",
      "Insulin is used to control diabetes in all types of operation \n",
      "Hospitalization of the patient at least 3 days before major surgery \n",
      "Per-operative glucose-insulin drip is required, especially in major surgery \n",
      "For emergency surgery \n",
      "Insulin infusion is started and frequent monitoring of blood glucose is done when \n",
      "operation is performed in patients with blood glucose crossing 14.0 mmol/L\n",
      "\n",
      "Chunk 619: \n",
      "Electrolytes, acid base status and urinary ketone levels are checked\n",
      "\n",
      "Chunk 620: \n",
      "If feasible surgery is delayed till blood glucose comes below 20 mmol/L and \n",
      "ketonuria disappears\n",
      "\n",
      "Chunk 621: If delaying is not possible, operation with intensive \n",
      "management of diabetic state is to be done\n",
      "\n",
      "Chunk 622: \n",
      "It is important to emphasize that with optimal care, surgery in a diabetic is as \n",
      "safe in a person without diabetes\n",
      "\n",
      "Chunk 623: \n",
      "6.5 Diabetes and sick day \n",
      "Period of illnesses eg fever, vomiting or diarrhoea, often cause hyperglycemia and \n",
      "ketosis, and sometimes hypoglycemia\n",
      "\n",
      "Chunk 624: To prevent these, certain management \n",
      "principles are followed\n",
      "\n",
      "Chunk 625: These are: \n",
      "The person needs to test his/her blood for glucose and ketone\n",
      "\n",
      "Chunk 626: If it is not \n",
      "possible, testing urine for glucose and ketone is very important\n",
      "\n",
      "Chunk 627: \n",
      "Fluid balance needs to be maintained; so sufficient intake is necessary\n",
      "\n",
      "Chunk 628: If the \n",
      "blood glucose is low, sweetened fluids, eg fruit juice is to be given to avoid \n",
      "hypoglycaemia\n",
      "\n",
      "Chunk 629: If blood glucose is elevated, low calorie soft drinks, soup or \n",
      "broth may be given\n",
      "\n",
      "Chunk 630: \n",
      "The anti-diabetic agents should never be stopped altogether; dose may need \n",
      "to be reduced\n",
      "\n",
      "Chunk 631: \n",
      "If the person is on insulin, intermediate or long acting insulin is continued; the \n",
      "dose may need to be reduced\n",
      "\n",
      "Chunk 632: Shorter acting insulin should be adjusted \n",
      "according to blood glucose values and food intake\n",
      "\n",
      "Chunk 633: \n",
      "If the person is on OAD the dose is to be readjusted; sometimes the longer \n",
      "acting OADs may need to be replaced by shorter acting ones or insulin\n",
      "\n",
      "Chunk 634: \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI 65 These principles are to be followed until the blood glucose is <12 mmol/L and \n",
      "ketone diminishes or disappears\n",
      "\n",
      "Chunk 635: \n",
      "In situations with fever, the infective focus should be treated\n",
      "\n",
      "Chunk 636: Treatment for \n",
      "vomiting/diarrhoea may also be required simultaneously\n",
      "\n",
      "Chunk 637: \n",
      "Special attention \n",
      "Following conditions require special attention and necessitate hospitalization: \n",
      "Vomiting or diarrhoea persists for longer than 6 hours \n",
      "Sick for 2 days and not getting better \n",
      "Blood glucose remains above 14 mmol/L \n",
      "Moderate ketonuria persists despite treatment \n",
      "Very young individual \n",
      "Abdominal pain \n",
      "Hyperventilation \n",
      "Co-existing serious diseases \n",
      "6.6 Ramadan fasting \n",
      "* Pre Ramadan education is the cornerstone of safe Ramadan fasting\n",
      "\n",
      "Chunk 638: \n",
      "* Patients and their family members or friends, healthcare professionals who \n",
      "manage or support them, should be educated\n",
      "\n",
      "Chunk 639: \n",
      "* Educational program should be started around 3 months before Ramadan\n",
      "\n",
      "Chunk 640: \n",
      "Ramadan focused structured education program should include \n",
      "information on risk stratification, diet and exercise, food intake, drugs \n",
      "adjustment, blood glucose monitoring (during day & night), recognition of \n",
      "hypoglycemia and other complications and when to breakfast. \n",
      "* Studies from home and abroad clearly demonstrated the benefit of \n",
      "Ramadan focus education program in terms of glycemic control, weight loss \n",
      "and reduced hypoglycemia risk\n",
      "\n",
      "Chunk 641: \n",
      "  \n",
      "66 (IN Diabetes Care: BADAS Guideline 2019 Modification of OAD during Ramadan \n",
      "Name of drug \n",
      "  \n",
      "Metformin \n",
      "Sulfonylurea \n",
      "Meglitinides \n",
      "Acarbose \n",
      "Thiazolidinediones \n",
      "DPP-4 inhibitors \n",
      "SGLT2 inhibitors \n",
      "Modification during Ramadan \n",
      "Daily total dose remains unchanged \n",
      "Once daily dose should be taken at Iftar \n",
      "For twice daily dose, should be taken at Iftar and Suhoor \n",
      "For thrice daily dose, morning dose should be taken at \n",
      "Suhoor and combined after noon and evening dose at Iftar \n",
      "Prolonged release preparation should be taken at Iftar \n",
      "Switch to newer Sulfonylurea (Gliclazide, Glimepiride) \n",
      "wherever possible \n",
      "Glibenclamide should be avoided \n",
      "For once daily dose, the total dose should be taken at Iftar \n",
      "Dose may be reduced in patients with good glycemic \n",
      "control \n",
      "For twice daily dose, full pre-Ramadan breakfast dose \n",
      "should be taken at Iftar and 50% of the dinner dose should \n",
      "be taken in Suhoor \n",
      "Thrice daily dosing may be reduced/ redistributed to 2 \n",
      "doses taken with iftar and Suhoor \n",
      "No dose modification\n",
      "\n",
      "Chunk 642: Pre-Ramadan morning dose is given \n",
      "at Iftar, lunch dose at dinner (if taken), and evening dose at \n",
      "Suhoor \n",
      "No dose modification\n",
      "\n",
      "Chunk 643: Can be taken at Iftar or Suhoor \n",
      "No dose modification\n",
      "\n",
      "Chunk 644: Can be taken at Iftar or Suhoor \n",
      "No dose modification \n",
      "Should be taken with iftar \n",
      "Extra water should be ingested during non-fasting periods \n",
      "Should not be used in the elderly, patients with renal \n",
      "impairment, hypotensive individuals or those taking \n",
      "diuretics \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HE) 67 Changes to insulin regimen during Ramadan \n",
      "A) Basal insulin (Detemir, Glargine, Degludec or NPH) \n",
      "Detemir, Glargine, Deglutec \n",
      "[Usually at bedtime and \n",
      "single dose] \n",
      "NPH [single or twice dose] \n",
      "B) Rapid/short acting insulin: \n",
      "The same dose and time as pre-Ramadan if blood sugar \n",
      "(in SMBG) is high \n",
      "May be reduced if fasting blood sugar is within target \n",
      "If Single-same breakfast dose should be taken at Iftar if \n",
      "BG is high, Reduce 15-30% if BG is within target \n",
      "For twice daily-same dose of breakfast at Iftar if BG is \n",
      "high, reduce 15-30% if BG within target \n",
      "  \n",
      "Once, twice or thrice daily \n",
      "Bolus [(analogue-Lispro, Glulisine, Aspart)/regular] \n",
      "The same pre-Ramadan breakfast dose should be taken \n",
      "at Iftar \n",
      "The lunch dose will be shifted to dinner dose in full \n",
      "during Ramadan if full dinner is taken \n",
      "Reduce pre-Ramadan dinner dose by 20-50% for Suhoor \n",
      "in Ramadan \n",
      "C) Premix (analogue-30/70, 50/50; conventional 30/70, 50/50, 25/75):May be \n",
      "  \n",
      "eye eae eer am OCLC) \n",
      "Single dose \n",
      "Twice daily [breakfast & \n",
      "dinner] \n",
      "Once daily dose- same dose at Iftar \n",
      "Twice daily doses- the pre-Ramadan breakfast dose will \n",
      "be same for Iftar dose \n",
      "Pre-Ramadan dinner dose may be reduced by 20-50% \n",
      "for Suhoor (depending on prolonged fasting, carb \n",
      "content) and glycemic control \n",
      "  \n",
      "68 II Diabetes Care: BADAS Guideline 2019 SMBG \n",
      "Good to do: Pre Suhoor — before taking meal, early morning- 2 hrs after Suhoor, \n",
      "around 10 am, mid-day - 11 am to 2 pm, pre Iftar meal, 2 hrs after Iftar and at any \n",
      "time when there are symptoms of hypoglycemia / hyperglycemia or feeling unwell\n",
      "\n",
      "Chunk 645: \n",
      "Must to do : Before Iftar, 2 hour after Iftar, Mid-day \n",
      "Frequency of SMBG should be daily for first 3 days, every 3rd day from next week \n",
      "onwards and every alternateday in the last week\n",
      "\n",
      "Chunk 646: \n",
      "6.7 Hajj and travel \n",
      "It could be estimated that Muslims with diabetes performing Hajj may exceed \n",
      "220000 per year\n",
      "\n",
      "Chunk 647: During Hajj duty, there may be major medical challenges for \n",
      "Muslims with diabetes and their healthcare providers\n",
      "\n",
      "Chunk 648: Risk stratification, medication \n",
      "adjustments, proper clinical assessment, and education before doing the Hajj are \n",
      "crucial\n",
      "\n",
      "Chunk 649: \n",
      "Changes during Hajj days \n",
      "During the Hajj, diet, amount of fluid intake and physical activity may be altered \n",
      "significantly\n",
      "\n",
      "Chunk 650: The health risks for pilgrims with diabetes include hypoglycemia, \n",
      "dehydration, foot injuries and infection, hyperglycemia (diabetic ketoacidosis and \n",
      "hyperosmolar state), heat exhaustion and heat stroke, infections (such as chest \n",
      "infection, foot infection and diarrhea), and cardiac events due to increased physical \n",
      "exertion\n",
      "\n",
      "Chunk 651: \n",
      "General recommendations \n",
      "Before travel \n",
      "* To consult physician 1-2 months before the Hajj for good control of diabetes \n",
      "mellitus and associated morbidities and attend a medical education session \n",
      "* To inform the camp manager and/or physician about your disease and \n",
      "medications \n",
      "* To prepare a checklist of mandatory requirements \n",
      "* To get adequate knowledge of SMBG and adjustment of medication as \n",
      "necessary \n",
      "* To complete recommended vaccinations, including influenza and \n",
      "pneumococcal vaccines \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 BE) 69 Prepare enough medications, cool pack to store insulin, glucometers \n",
      "It is preferable to pack diabetes medications in carry-on bags, not in the \n",
      "checked luggage.This will protect the medicines from temperature changes in \n",
      "luggage stored in cargoes, which may affect the potency of insulin and other \n",
      "medications \n",
      "To choose shoes, sandals, and flip-flops with appropriate shapes and sizes \n",
      "(wide-front shoe to avoid extra pressure on the feet and the toes during long \n",
      "walking)\n",
      "\n",
      "Chunk 652: Use soaks while barefoot walking is required \n",
      "Hajj events are prohibited to perform during menstruation so postponding \n",
      "menstruation during this period is advised\n",
      "\n",
      "Chunk 653: Use of medicines for this should be \n",
      "planned earlier with consultation of physician \n",
      "Those with severe non-proliferative and proliferative retinopathy should \n",
      "consult their ophthalmologist before deciding to go to the Hajj \n",
      "During travel and Hajj \n",
      "To carry some carbohydrates to be used during hypoglycemia \n",
      "Try to adhere to a healthy balanced diet containing adequate, but not excess, \n",
      "carbohydrates, with appropriate protein and fiber but minimal \n",
      "(monounsaturated) fat \n",
      "To drink plenty of water daily and carry enough water stored \n",
      "If using insulin, before Ihram to check blood glucose using glucometer and urine \n",
      "ketone using dipstick (for type 1)\n",
      "\n",
      "Chunk 654: If needed, a small dose of insulin to cover for \n",
      "hyperglycemia and/or small mealto avoid hypoglycemia should be kept always \n",
      "If using insulin before and during long walking, decrease the dose of short and \n",
      "intermediate insulin about 20% or more depending on the distance and effort\n",
      "\n",
      "Chunk 655: \n",
      "For patients on sulfonylurea drugs, this adjustment of daily dose (up to 50% \n",
      "decrease in the corresponding drug doseof previous dose) can be applied \n",
      "Before Tawaf (circumambulation around Ka’bah) and Saay (walking between \n",
      "Safa and Marwah), consume some additional carbohydrates (Complex \n",
      "carbohydrate is preferred) if the blood sugar within target \n",
      "To consult your medical team promptlyin case of fever, diarrhea, vomiting or any \n",
      "acute medical condition instead of delaying \n",
      "Always have an umbrella and try to stay in shaded areas \n",
      "Wetting the head and body with water many times during the day is another \n",
      "way to keep the body cool \n",
      "Check feet daily before going to bed\n",
      "\n",
      "Chunk 656: To inspect feet daily for lesions such as \n",
      "blisters and bleeding between toes\n",
      "\n",
      "Chunk 657: Using a mirror will help to inspect the \n",
      "bottom of the foot and the heel\n",
      "\n",
      "Chunk 658: If unable to do it, you may seek the help of a \n",
      "relative or a friend \n",
      "  \n",
      "70 (IN Diabetes Care: BADAS Guideline 2019 To use socks or stocking that fit well in the shoe \n",
      "Use shoes with flat outside sole \n",
      "To use leather shoes with good space for the toes\n",
      "\n",
      "Chunk 659: Athletic and/or running \n",
      "shoes are good choices for walking\n",
      "\n",
      "Chunk 660: Brand-new shoes are not preferred, as new \n",
      "shoes may rub unduly on the feet \n",
      "To avoid soaking feet in hot water \n",
      "Seek immediate help if you notice any new lesion or swelling of the feet, \n",
      "redness and pain \n",
      "Medication adjustment \n",
      "Metformin, alpha-glucosidase inhibitors, thiazolidinediones, dipeptidyl \n",
      "peptidase-4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor \n",
      "agonists and SGLT-2 inhibitors require no dose adjustment \n",
      "The risk of hypoglycemia with sulfonylurea is usually more in the elderly with \n",
      "diabetes and those with renal impairment and medical illnesses\n",
      "\n",
      "Chunk 661: Sulfonylureas \n",
      "should be avoided or used with caution\n",
      "\n",
      "Chunk 662: Also the dose may be adjusted before \n",
      "doing the Hajj physical activity, and newer generations are preferred\n",
      "\n",
      "Chunk 663: \n",
      "Insulin treatment is usually linked to increased risk of hypoglycemia, especially \n",
      "during the Hajj and its prolonged walking\n",
      "\n",
      "Chunk 664: Proper adjustment of insulin doses is \n",
      "required during the Hajj in patients with type 1 and type 2 diabetes\n",
      "\n",
      "Chunk 665: The \n",
      "combination of basal (glargine, detemir or degludec) and rapid-acting insulin \n",
      "analogs (lispro, aspart and glulisine) proved to be superior to human insulin \n",
      "formulations (isophane insulin (NPH) and regular) during the Hajj as this \n",
      "regimen may reduce the risk of hypoglycemia\n",
      "\n",
      "Chunk 666: \n",
      "Insulin pump therapy has been shown effective in optimizing glycemic control \n",
      "and in reducing the risk of hypoglycemia in patients with type 1 diabetes, so it \n",
      "could be a good choice during the Hajj\n",
      "\n",
      "Chunk 667: In addition, insulin pump allows more \n",
      "flexibility around meal times, as well as lowers the basal dose, minimizing the \n",
      "risk of developing hypoglycemia as a result of exercise (Hajj walking)\n",
      "\n",
      "Chunk 668: \n",
      "References \n",
      "Diabetes Mellitus, Distance Learning Program, 5th edition, BADAS, 2018 \n",
      "GDM SAFES (South Asian Federation of Endocrine Societies) Recommendations and \n",
      "Action Plan, 2017 \n",
      "Standards of Medical care in Diabetes, ADA (American Diabetes Association), 2019 \n",
      "Diabetes and Ramadan: Practical Guidelines, IDF (International Diabetes Federation), \n",
      "2016 \n",
      "Mahmoud Ibrahim, et al\n",
      "\n",
      "Chunk 669: Recommendations for management of diabetes and its \n",
      "complications during Hajj (Muslim pilgrimage)\n",
      "\n",
      "Chunk 670: BMJ Open Diabetes Res Care\n",
      "\n",
      "Chunk 671: 2018; 6 (1): \n",
      "e000574\n",
      "\n",
      "Chunk 672: \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI! 71 Chapter 7 \n",
      "Prevention of Diabetes Mellitus \n",
      "Types of prevention of diabetes mellitus \n",
      "1\n",
      "\n",
      "Chunk 673: Primordial prevention \n",
      "2\n",
      "\n",
      "Chunk 674: Primary prevention: Refers to avoiding the onset of the disease (diabetes) \n",
      "3\n",
      "\n",
      "Chunk 675: Secondary prevention: Means early detection of diabetes and prompt initia- \n",
      "tion of treatment to prevent complications of diabetes \n",
      "4\n",
      "\n",
      "Chunk 676: Tertiary prevention: Aims to delay and/or prevent further progression of the \n",
      "diabetic complications \n",
      "Primary prevention \n",
      "Type 2 diabetes is the commonest form of diabetes\n",
      "\n",
      "Chunk 677: Although a heterogeneous \n",
      "disorder, progression from insulin insensitivity to pre-diabetes, then to diabetes is \n",
      "now well understood\n",
      "\n",
      "Chunk 678: \n",
      "The risk factors for type 2 diabetes are: a) aging, b) family history of type 2 diabetes, \n",
      "c) over-weight/obesity, d) physical inactivity e) pregnancy, f) intra-uterine and early \n",
      "childhood malnutrition g) stress and h) smoking\n",
      "\n",
      "Chunk 679: Except age and family history all \n",
      "others are amenable to modification\n",
      "\n",
      "Chunk 680: Many of these risk factors are common for \n",
      "other non-communicable diseases (NCDs)\n",
      "\n",
      "Chunk 681: \n",
      "Diabetes prevention programmes focus on lifestyle modification, specifically \n",
      "modest weight loss and increased physical activity\n",
      "\n",
      "Chunk 682: \n",
      "Primary prevention can be achieved through two basic approaches: \n",
      "A\n",
      "\n",
      "Chunk 683: Population approach \n",
      "1.Creation of mass awareness \n",
      "* — Incorporation of basic information in school text book curriculums \n",
      "* Use of mass media, eg\n",
      "\n",
      "Chunk 684: newspapers, radio, television etc \n",
      "« Use of social organizations, as religious institutes, voluntary organizations \n",
      "2\n",
      "\n",
      "Chunk 685: Care of risk factors \n",
      "* Creation of facilities for performing physical activities, like sports, gyms etc \n",
      "* Promotion of healthy eating habits, like campaign against ‘fast food culture \n",
      "  \n",
      "72 ‘88 Diabetes Care: BADAS Guideline 2019 B\n",
      "\n",
      "Chunk 686: High-risk group approach \n",
      "This approach of primary prevention can be achieved by Identification and \n",
      "screening of people at risk and intervention \n",
      "Individuals at high risk of type 2 diabetes mellitus \n",
      "  \n",
      "* BMI above normal (223 kg/m2) \n",
      "e Age2=40 years \n",
      "* 1st degree relative with diabetes \n",
      "¢ Habitual physical inactivity \n",
      "¢ Waist-hip ratio above normal \n",
      "¢ History of GDM or delivery of baby >9 lbs \n",
      "e Previously identified as IFG/IGT \n",
      "¢ Hypertension \n",
      "¢ Dyslipidemia- HDL-c <35 mg/dl, TG >250 mg/dl \n",
      "¢ Some ethnicties \n",
      "¢ PCOS, acanthosis nigricans etc \n",
      "Intervention for Primary prevention: It is done by ensuring weight management, \n",
      "regular physical activity, medical nutrition therapy and even by using drugs (like \n",
      "metformin) to modify the risk factors\n",
      "\n",
      "Chunk 687: Metformin may be used in persons with \n",
      "prediabetes, with BMI 35 kg/m2, age <60 years and prior GDM\n",
      "\n",
      "Chunk 688: \n",
      "Secondary and tertiary prevention \n",
      "It includes good glycemic control, strict control of blood pressure, proper care of \n",
      "eye and foot\n",
      "\n",
      "Chunk 689: This will prevent further deterioration of organ function and target \n",
      "organ damage\n",
      "\n",
      "Chunk 690: \n",
      "References \n",
      "* Prevention of diabetes mellitus, WHO (World Health Organization) Technical Report \n",
      "Series 844, 1994, \n",
      "Development Programme for the Prevention & Care of Diabetes in Finland, Finnish \n",
      "Diabetes Association, 2001\n",
      "\n",
      "Chunk 691: \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HE\n",
      "\n",
      "Chunk 692: 73 Appendix \n",
      "Injection technique \n",
      "Injections are given into the deep subcutaneous tissue at 45-90° angle by \n",
      "two-finger pinch of skin\n",
      "\n",
      "Chunk 693: The pinch is recommended to ensure a strict \n",
      "subcutaneous injection; avoiding intramuscular injection\n",
      "\n",
      "Chunk 694: Injections can be given \n",
      "perpendicularly without lifting a skin fold when needles are smaller and there is \n",
      "enough subcutaneous fat\n",
      "\n",
      "Chunk 695: Needles should be inserted fully, otherwise there is a risk \n",
      "of intradermal injections\n",
      "\n",
      "Chunk 696: A wait of 15 seconds after pushing the plunger helps to \n",
      "ensure complete expulsion of insulin through the needle, especially in pens\n",
      "\n",
      "Chunk 697: \n",
      "Cleaning or disinfection of skin is advisable, but may not be necessary unless \n",
      "hygiene is a real problem\n",
      "\n",
      "Chunk 698: \n",
      "Vials (also the pen devices) of cloudy insulin must always be gently rolled (not \n",
      "shaken) 10-20 times, to mix the insulin suspension\n",
      "\n",
      "Chunk 699: When a mixture of two insulins \n",
      "drawn up (eg regular insulinare mixed with NPH), the regular insulin is to be drawn \n",
      "up into the syringe before the intermediate acting one\n",
      "\n",
      "Chunk 700: The mixture must be \n",
      "administered immediately\n",
      "\n",
      "Chunk 701: \n",
      "Injection sites \n",
      "Abdomen (the preferred site when faster and uniform absorption is required and it \n",
      "may be less affected by muscle activity or exercise)\n",
      "\n",
      "Chunk 702: Lateral aspect of thigh (the \n",
      "preferred site for slower absorption of longer acting insulin)\n",
      "\n",
      "Chunk 703: Lateral aspect of arm \n",
      "(assistance is required for injection)\n",
      "\n",
      "Chunk 704: The lateral upper quadrant of the buttocks \n",
      "(used less often)\n",
      "\n",
      "Chunk 705: Rotation of injection sites are important within the same area of \n",
      "injection\n",
      "\n",
      "Chunk 706: \n",
      "Insulin storage \n",
      "Insulin must never be frozen\n",
      "\n",
      "Chunk 707: Direct sunlight or warming (eg in hot climates) \n",
      "damages insulin\n",
      "\n",
      "Chunk 708: Insulin should not be used if there is change in appearance \n",
      "(clumping, frosting, precipitation,or discoloration)\n",
      "\n",
      "Chunk 709: Unused insulin should be stored \n",
      "in a refrigerator(4-8° C) to retain its potency up to expiry date\n",
      "\n",
      "Chunk 710: When in use, the \n",
      "insulin may be kept in room temperature (if not too hot) for one month after \n",
      "opening without much loss of efficacy\n",
      "\n",
      "Chunk 711: But it retains its potency much better if kept \n",
      "in refrigerator\n",
      "\n",
      "Chunk 712: In hot climates where refrigeration is not available, cooling jars, \n",
      "earthenware pitcher or cool wet cloth around the insulin will help to preserve \n",
      "insulin activity\n",
      "\n",
      "Chunk 713: \n",
      "  \n",
      "74 (88 Diabetes Care: BADAS Guideline 2019 Case history \n",
      "Case-01 \n",
      "Mr Ahmed, 50 years, schoolteacher, has undergone OGTT\n",
      "\n",
      "Chunk 714: His report shows F-5.7 \n",
      "mmol/L, 2HAG-7.2 mmol/L\n",
      "\n",
      "Chunk 715: He has family history of diabetes\n",
      "\n",
      "Chunk 716: His height is 170 cm \n",
      "and weight is 86 kg\n",
      "\n",
      "Chunk 717: Today his BP is 130/80 mmHg\n",
      "\n",
      "Chunk 718: What is his diagnosis and what \n",
      "is the advice for him? \n",
      "Case-02 \n",
      "Mr Rozario, 48 years, banker, has undergone annual checkup revealing RBS of 8.6 \n",
      "mmol/L\n",
      "\n",
      "Chunk 719: His physician advised OGTT, which revealed F-6.4 mmol/L, 2HAG-9.7 \n",
      "mmol/L\n",
      "\n",
      "Chunk 720: His height is 172cm, weight 70 kg\n",
      "\n",
      "Chunk 721: He is hypertensive for 5 years, What is \n",
      "the treatment and follow up plan for him? \n",
      "Case-03 \n",
      "Mrs Sen 52 years, housewife, reported to a physician with general weakness and \n",
      "tiredness\n",
      "\n",
      "Chunk 722: She was advised OGTT which shows F-6.9 mmol/L, 2HAG-15.8 mmol/L\n",
      "\n",
      "Chunk 723: \n",
      "Today her BP is150/90 mmHg, BMI is 26kg/m2 and her other investigation reports \n",
      "are unremarkable\n",
      "\n",
      "Chunk 724: What will be treatment plan for her? \n",
      "Case-04 \n",
      "Mr Barua, 60 years, retired service holder, is diabetic for 5 years\n",
      "\n",
      "Chunk 725: He is on Tab \n",
      "Metformin (500 mg) three times daily for last 2 years\n",
      "\n",
      "Chunk 726: Now he reported with \n",
      "following investigations: F-9.2 mmol/L, 2 HABF-19.6 mmol/L, HbA1c-9.2%, ALT-42 \n",
      "U/L, S\n",
      "\n",
      "Chunk 727: creatinine-0.9mg/dl\n",
      "\n",
      "Chunk 728: His BMI is 28kg/m2\n",
      "\n",
      "Chunk 729: He is very much compliant with his \n",
      "lifestyle advice\n",
      "\n",
      "Chunk 730: What will be the treatment option for him? \n",
      "Case-05 \n",
      "Mr Alamgir, 45 years old, school teacher, is diabetic for 6 years\n",
      "\n",
      "Chunk 731: As a diabetic his \n",
      "lifestyle is well adjusted\n",
      "\n",
      "Chunk 732: He is on Tab Glimepiride 3 mg daily and Tab Metformin 850 \n",
      "mg three times daily\n",
      "\n",
      "Chunk 733: His recent HbAtc is 10.1% and FBS is 13.4 mmol/L, S\n",
      "\n",
      "Chunk 734: \n",
      "creatinine-1.2 mg/dl, ALT-30U/L; his height is 178 cm, weight-70 kg\n",
      "\n",
      "Chunk 735: What will be \n",
      "the treatment plan for him? \n",
      "Case-06 \n",
      "Mrs\n",
      "\n",
      "Chunk 736: Khaleda, 52 years, housewife, diabetic for 6 years, hypertensive for 4 years\n",
      "\n",
      "Chunk 737: She \n",
      "also has dyslipidemia\n",
      "\n",
      "Chunk 738: She is gaining weight for last few years\n",
      "\n",
      "Chunk 739: At present her BMI is \n",
      "Diabetes Care: BADAS Guideline 2019 BEI 75 34.2 kg/m2\n",
      "\n",
      "Chunk 740: Her BP is 150/95 mmHg\n",
      "\n",
      "Chunk 741: She is on Inj\n",
      "\n",
      "Chunk 742: Premix insulin 46+0 +24, Tab \n",
      "Vildagliptin plus metformin (50/500 mg) 1+0+1\n",
      "\n",
      "Chunk 743: At present her blood sugar is \n",
      "F-10.2 mmol/L and 2HABF-16.4 mmol/L and HbA1c- 9.2%\n",
      "\n",
      "Chunk 744: What change she needs \n",
      "in her treatment to achieve glycemic target? \n",
      "Case-07 \n",
      "Mr Latif, 55 years, businessman, is diagnosed as diabetic for last 10 days\n",
      "\n",
      "Chunk 745: His \n",
      "investigations revealed: S .creatinine-1.8 mg/dl, GFR-53.2 ml/min/1.73m2, S\n",
      "\n",
      "Chunk 746: \n",
      "chol-245 mg/dl, HDL-32 mg/dl, LDL-123 mg/dl, TG-214 mg/dl and ALT-70 U/L\n",
      "\n",
      "Chunk 747: He is \n",
      "now on Inj\n",
      "\n",
      "Chunk 748: Premix insulin-32+0+24, Tab Metformin 500 mg thrice daily, Tab \n",
      "Linagliptin 5 mg once daily\n",
      "\n",
      "Chunk 749: He is hypertensive for three years and his BP is well in \n",
      "target with Tab Losartan 50 mg 0+0+1\n",
      "\n",
      "Chunk 750: What will be the choice of antidiabetic drug \n",
      "for him? \n",
      "Case-08 \n",
      "Mrs Rahima, 65 years, housewife, reported to emergency department with sudden \n",
      "severe chest pain and on evaluation she had single vessel CAD and required PCI\n",
      "\n",
      "Chunk 751: \n",
      "She is diabetic for 5 yrs\n",
      "\n",
      "Chunk 752: She is on Tab Gliclazide 120 mg/day and Tab Metformin 2 \n",
      "gm daily\n",
      "\n",
      "Chunk 753: Her HbAic is 7.4%, FBS-8.8 mmol/L, LDL-120mg/dl, ALT-38U/L, S\n",
      "\n",
      "Chunk 754: \n",
      "creatinine-1.2mg/dl\n",
      "\n",
      "Chunk 755: BMI is 28.2 kg/m2 and BP is 160/90 mmHg\n",
      "\n",
      "Chunk 756: She is hypertensive \n",
      "for 3 years and on Tab Amlodipine 5mg/day\n",
      "\n",
      "Chunk 757: What will be the treatment plan for \n",
      "her considering her comorbidities? \n",
      "Case-09 \n",
      "Mrs Ruma Sen, a 62-year-old housewife, is living in Dhaka\n",
      "\n",
      "Chunk 758: She is over-weight (BMI \n",
      "24 Kg/m2)\n",
      "\n",
      "Chunk 759: She has presented with increased thirst, urination, and marked general \n",
      "weakness for one month\n",
      "\n",
      "Chunk 760: There is nothing remarkable on physical examination\n",
      "\n",
      "Chunk 761: \n",
      "Her OGTT was done 5 days back; report shows: FBG- 11.6 mmol/L; 2 hr post-glucose \n",
      "value- 21.1 mmol/L; HbA1c- 9.8%\n",
      "\n",
      "Chunk 762: There is nothing remarkable on other laboratory \n",
      "tests\n",
      "\n",
      "Chunk 763: What will be the treatment plan for her? \n",
      "Case-10 \n",
      "Mr Akbar Ali,a 45-year-old businessman, is living in Dhaka\n",
      "\n",
      "Chunk 764: His BMI is 25.3 Kg/m2.He \n",
      "has presented with general weakness for last 2 months\n",
      "\n",
      "Chunk 765: There is nothing \n",
      "remarkable on physical examination\n",
      "\n",
      "Chunk 766: His OGTT was done 3 days back; report shows: \n",
      "FBG- 16.2 mmol/L; 2 hr post-glucose value- 24.1 mmol/L; HbA1c- 14.5%\n",
      "\n",
      "Chunk 767: There is \n",
      "nothing remarkable on other laboratory tests\n",
      "\n",
      "Chunk 768: What will be the management \n",
      "stratigy plan for him? \n",
      "  \n",
      "76 ‘158 Diabetes Care: BADAS Guideline 2019 Abbreviation \n",
      "ACR \n",
      "AGI \n",
      "ALA \n",
      "ALT \n",
      "ASCVD \n",
      "BG \n",
      "BMI \n",
      "BP \n",
      "BUN \n",
      "CAD \n",
      "CGM \n",
      "CHF \n",
      "CKD \n",
      "CVD \n",
      "eGFR \n",
      "EPA \n",
      "DHA \n",
      "DM \n",
      "ESRD \n",
      "GAD \n",
      "hCG \n",
      "HbAic \n",
      "HDL \n",
      "HNF \n",
      "IHD \n",
      "ISPAD \n",
      "LAD \n",
      "LDL \n",
      "MDI \n",
      "MNT \n",
      "MODY \n",
      "NAFLD \n",
      "NPH \n",
      "PCI \n",
      "PCOS \n",
      "RBC \n",
      "SMBG \n",
      "TG \n",
      "UTI \n",
      "Albumin-to-creatinine ratio \n",
      "Alpha-glucosidase inhibitors \n",
      "a-Linolenic acid \n",
      "Alanine aminotransferase \n",
      "Atherosclerotic cardiovascular disease \n",
      "Blood glucose \n",
      "Body mass index \n",
      "Blood pressure \n",
      "Blood urea nitrogen \n",
      "Coronary artery disease \n",
      "Continuous glucose monitoring \n",
      "Congestive heart failure \n",
      "Chronic kidney disease \n",
      "Cardiovascular disease \n",
      "estimated glomerular filtration rate \n",
      "Eicosapentaenoic acid \n",
      "ocosahexaenoic acid \n",
      "Diabetes Mellitus \n",
      "End-stage renal disease \n",
      "Glutamic acid decarboxylase \n",
      "Human chorionic gonadotropin \n",
      "Hemoglobin A1c \n",
      "High-density lipoproteins \n",
      "Hepatocyte nuclear factors \n",
      "Ischemic heart disease \n",
      "International Society for Pediatric and Adolescent Diabetes \n",
      "Left anterior descending artery \n",
      "Low-density lipoproteins \n",
      "Multiple dose injection \n",
      "Medical nutrition therapy \n",
      "Maturity onset diabetes of the young \n",
      "Non-alcoholic fatty liver disease \n",
      "Neutral protamine Hagedorn \n",
      "Percutaneous coronary intervention \n",
      "Polycystic ovary syndrome \n",
      "Red blood cells \n",
      "Self-monitoring of blood glucose \n",
      "Triglycerides \n",
      "Urinary tract infection \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 Bll 77 AS Guideline 2019 \n",
      "  \n",
      "  \n",
      "Unrestricted Educational Grant from Novo Nordisk (Pvt) Limited\n",
      "\n"
     ]
    }
   ],
   "source": [
    "from sentence_transformers import SentenceTransformer\n",
    "import numpy as np\n",
    "\n",
    "# Load a pre-trained model for semantic text similarity\n",
    "model = SentenceTransformer(\"sentence-transformers/paraphrase-MiniLM-L6-v2\")\n",
    "\n",
    "# Function to split the document into sentences or parts\n",
    "def split_document_into_sentences(all_text):\n",
    "    # Splitting text into sentences (you could use other text-splitting strategies)\n",
    "    sentences = all_text.split(\". \")\n",
    "    return sentences\n",
    "\n",
    "# Function to perform semantic chunking\n",
    "def semantic_chunking(all_text, chunk_size=3, similarity_threshold=0.8):\n",
    "    sentences = split_document_into_sentences(all_text)\n",
    "\n",
    "    # Get embeddings for all sentences in the document\n",
    "    sentence_embeddings = model.encode(sentences)\n",
    "    \n",
    "    # Initialize a list to store chunks\n",
    "    chunks = []\n",
    "    current_chunk = []\n",
    "\n",
    "    for i, embedding in enumerate(sentence_embeddings):\n",
    "        if not current_chunk:\n",
    "            current_chunk.append(sentences[i])\n",
    "        else:\n",
    "            # Calculate the similarity between the last sentence of the current chunk and the next sentence\n",
    "            last_embedding = model.encode([current_chunk[-1]])  # Embedding of the last sentence in the chunk\n",
    "            similarity = np.dot(embedding, last_embedding[0]) / (np.linalg.norm(embedding) * np.linalg.norm(last_embedding[0]))\n",
    "\n",
    "            # If the similarity is above a threshold, add it to the current chunk\n",
    "            if similarity > similarity_threshold:\n",
    "                current_chunk.append(sentences[i])\n",
    "            else:\n",
    "                # Start a new chunk\n",
    "                chunks.append(\". \".join(current_chunk))\n",
    "                current_chunk = [sentences[i]]\n",
    "\n",
    "    # Add the last chunk\n",
    "    if current_chunk:\n",
    "        chunks.append(\". \".join(current_chunk))\n",
    "\n",
    "    return chunks\n",
    "\n",
    "\n",
    "\n",
    "# Perform semantic chunking\n",
    "chunks = semantic_chunking(all_text)\n",
    "\n",
    "# Output the chunks\n",
    "for i, chunk in enumerate(chunks):\n",
    "    print(f\"Chunk {i+1}: {chunk}\\n\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "id": "0c43c028-073a-4962-8daf-6445fde05cbf",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "First chunk: DIABETES CARE \n",
      "BADAS Guideline 2019 \n",
      "          \n",
      "  \n",
      "   \n",
      "  \n",
      "   P|) \n",
      "DAS GUELINE ON Man \n",
      "DELIT IGEMEN \n",
      "  \n",
      "A Joint Initiative of \n",
      "Diabetic Association of Bangladesh \n",
      "NCDC Program, Directorate General of Health Services DIABETES CARE \n",
      "BADAS Guideline 2019 \n",
      "  \n",
      "A Joint Initiative of \n",
      "Diabetic Association of Bangladesh \n",
      "NCDC Program, Directorate General of Health Services \n",
      "  \n",
      "Diabetes Care: BADAS Guideline 2019 HEI! 1 DIABETES CARE: BADAS GUIDELINE 2019 \n",
      "Convener: Prof A K Azad Khan \n",
      "Chairman: Prof Hajera Mahtab \n",
      "Members of the steering committee \n",
      "Prof Dr AHM Enayet Hossain \n",
      "Prof Akhtar Hussain \n",
      "Prof Zafar Anmed Latif \n",
      "Prof Tofail Ahmed \n",
      "Prof Laique Ahmed Khan \n",
      "Prof Nazrul Islam Siddiqui \n",
      "Prof Md Hafizur Rahman \n",
      "Prof Abdus Saleque Mollah \n",
      "Prof Md Farid Uddin \n",
      "Prof M A Jalil Ansary \n",
      "Prof Dr MA Samad \n",
      "Prof SM Ashrafuzzaman \n",
      "Prof MA Hasnat \n",
      "Dr Kazi Ali Hassan \n",
      "Dr Abdul Mannan Sarker \n",
      "Members of the Task Force \n",
      "Prof Md Faruque Pathan \n",
      "Dr Tareen Ahmed \n",
      "Dr Md Feroz Amin \n",
      "Dr Faria Afsana \n",
      "Dr Bishwajit Bhowmik \n",
      "Dr Nazmul Kabir Qureshi \n",
      "Dr Indrajit Prasad \n",
      "Dr Tanjina Hossain \n",
      "Dr Shahjada Selim \n",
      "Dr M Saifuddin \n",
      "Dr Tasnima Siddiquee \n",
      "Dr Abdul Alim \n",
      "Published \n",
      "November 2019 \n",
      "Correspondence \n",
      "Diabetic Association of Bangladesh \n",
      "122 Kazi Nazrul Islam Avenue, Dhaka 1000, Bangladesh \n",
      "Design and layout \n",
      "Liason Office,122 Kazi Nazrul Islam avenue, Shabag, Dhaka \n",
      "Printing \n",
      "BADAS-RVTC Printing Press \n",
      "477 Medical Road, Jurain, Dhaka 1204, Bangladesh \n",
      "  \n",
      "Unrestricted Educational Grant from Novo Nordisk (Pvt) Limited \n",
      "  \n",
      "2 \\l§8 Diabetes Care: BADAS Guideline 2019 President \n",
      "  \n",
      "Diabetic Association of Bangladesh \n",
      "Message \n",
      "It gives me immense pleasure to know that BADAS is publishing country’s first \n",
      "diabetes care guideline\n",
      "Second chunk: | express my heartfelt thanks to all the members of the \n",
      "taskforce team and expert committee for putting their effort to develop the guide- \n",
      "line\n",
      "Total number of chunks: 768\n"
     ]
    }
   ],
   "source": [
    "print(\"First chunk:\", chunks[0])\n",
    "print(\"Second chunk:\", chunks[1])\n",
    "\n",
    "# Get the number of chunks\n",
    "num_chunks = len(chunks)\n",
    "print(f\"Total number of chunks: {num_chunks}\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
